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SUMMARY
Background: Cough often lasts for over one year and is associated with airway 
inflammation. The effect o f inhaled corticosteroids on symptom severity and 
inflammatory mediator levels in these patients is unknown. The main objective o f the 
thesis was to determine whether inhaled corticosteroids reduce cough severity and 
sputum mediator concentrations in patients with chronic persistent cough. We also 
endeavoured to find non-invasive markers o f inflammation that would predict 
corticosteroid responsiveness.
The secondary aims o f the thesis were to evaluate the role o f neurotrophins in chronic 
cough, quality o f life in cough and the effect o f specific treatment, extrathoracic 
airway hyperreactivity and the value o f clinical history in predicting the final 
diagnosis of cough.
Methods: We performed a double-blind, randomised, placebo-controlled, crossover 
study with inhaled fluticasone 500 meg twice daily and placebo for 14 days in 8 8  
patients with cough for over one year, with normal chest radiography and spirometry. 
Outcome measures were a daily cough visual analogue scale (VAS) and induced 
sputum concentrations o f eosinophilic cationic protein (ECP), myeloperoxidase 
(MPO), leukotriene B4  (LTB4 ), leukotrienes C4/D4/E4 (cys-LT), prostaglandin E2 
(PGE2), interleukin- 8  (IL-8 ) and tumor necrosis factor-alpha (TNF-a). Sputum cell 
counts, exhaled nitric oxide (eNO) and carbon monoxide (CO) were performed at all
Neurotrophins were measured at baseline in serum and induced sputum by enzyme 
immumoassay. St. George’s Respiratory Questionnaire (SGRQ) and the Hospital 
Anxiety and Depression Scale (HADS) were utilised to assess quality o f life before 
and after specific treatment o f cough. Extrathoracic airway hyperreactivity (EAHR) 
was measured using methacholine challenge with flow volume testing and recording a 
25% drop in MIF5 0 . Symptoms asked in history at the baseline visit were analysed for 
their predictive value o f the final diagnosis of cough.
Results: There was a significant improvement in the cough visual analogue scale 
following inhaled fluticasone compared to placebo [mean difference (95%CI) 1.0(0.4, 
1.5), p<0.001].
There was evidence o f airway inflammation in chronic persistent cough, with 
increased induced sputum cell counts, exhaled nitric oxide and inflammatory 
mediators (LTB4 , cys-LT, PGE2 , ECP, IL- 8  and TNF-a). LTB4 , cys-LT and PGE2 
were elevated in all causes o f cough. IL-8 , MPO and TNF-a levels were elevated in 
bronchiectasis alone.
Sputum ECP, eNO and CO fell significantly following inhaled fluticasone. There was 
no change in sputum cell counts and other mediator concentrations. Exhaled nitric 
oxide was the best predictor o f corticosteroid responsiveness in cough. This was 
followed by sputum eosinophil%, total IgE levels, sputum ECP and sputum cys- 
leukotriene levels.
There was no significant difference either in the levels o f serum or sputum 
neurotrophins in chronic cough subjects compared to controls or between the 
commonest causes of cough: post-nasal drip syndrome (PNDS), gastro-oesophageal 
reflux disease (GORD), asthma and bronchiectasis. The median (inter-quartile range) 
for sputum NGF (pg/ml) was 516 (296-772) in healthy controls and 580 (312-880) in 
subjects with chronic cough (p=0.284). There was no correlation between 
neurotrophin levels and sputum cell counts. Sputum NGF levels correlated with 
duration o f cough (r=0.34, p=0.002).
In the quality o f life study, we found a marked impairment in all SGRQ domains and 
a significant improvement following specific treatment of cough. These findings were 
independent o f the cause o f cough. Clinical levels o f anxiety and depression were not 
a feature o f chronic cough, but there was a significant improvement in the scores after 
treatment.
Extrathoracic airway hyperreactivity was present in only 14% of subjects and was 
unrelated to any particular aetiology of cough. Airway inflammatory cells in induced 
sputum and mediator levels were similar in the group with EAHR compared to the 
group without, other than an increase in sputum LTB4  levels. There was a marked 
predominance o f females noted in the group with EAHR (11/12).
In the fifth experiment, the value o f symptoms in making a final diagnosis was 
assessed. The diagnostic pattern was similar to other cough studies with PNDS [n=30, 
34%], GORD [18, 20%], asthma [13, 15%], bronchiectasis [9, 10%] and eosinophilic 
bronchitis [5, 6 %] being the commonest causes. In 10 subjects (11%) the cough was
termed idiopathic. General cough questions regarding the positional or diurnal 
variation in cough did not lead to any specific diagnosis. Positive predictive value of 
symptoms in diagnosing a specific cause o f cough was low. However, we found that 
specific history for GORD had a 100% negative predictive value and for 
bronchiectasis, history o f a dry cough had a 100% NPV. For asthma, the NPV of 
clinical history was 8 6 %. Certain specific triggers like cat/dog dander and grass 
pollen had > 90 % specificity for asthma. Questions for PNDS had the lowest positive 
or negative predictive value and improving the specificity o f questions with scoring 
systems for rhino-sinusitis did not improve this outcome.
Conclusion: Cough severity and sputum ECP levels are modestly reduced by inhaled 
corticosteroids in patients with chronic cough persisting for over one year. LTB4 , 
cys-LT, PGE2 , IL-8 , MPO and TNF-a levels are unaltered by this therapy. This raises 
the possibility that drugs targeted to reduce the effects o f these mediators may be of 
benefit in chronic persistent cough.
Measured levels o f neurotrophins in serum and NGF in induced sputum were not 
elevated compared to controls. This implies that either neurotrophins are not 
responsible for the neurogenic inflammation in cough or that different methods of 
evaluating them, possibly at receptor level are required.
Extrathoracic airway hyperreactivity is not a common feature of chronic persistent 
cough and does not seem to add any clinically useful addition to the management o f 
chronic cough.
Clinical history provided some useful questions with high negative predictive values 
for GORD and bronchiectasis, which will require evaluation in prospective cough 
studies.
The presence o f airway inflammation and inflammatory mediators in all causes o f 
cough presents future therapeutic targets in the management o f chronic persistent 
cough.
CHAPTER 1
INTRODUCTION AND REVIEW OF LITERATURE
1.1 EPIDEMIOLOGY AND CAUSES OF CHRONIC COUGH
1.1.1 Definition and incidence of chronic cough
Cough is the commonest reason for patients to seek medical attention (1). At any given time, 
approximately 20% of the UK population have a troublesome cough and an indication of the 
size of the problem is the self-prescription of over the counter anti-tussives, estimated at 75 
million doses per annum in the UK (2, 3). Sales of anti-tussives have been estimated to be 
over $600 million in the USA (4).
Cough is an explosive expiration which provides a means of clearing the tracheo-bronchial 
tree of secretions and foreign bodies. It also serves as a warning of severe lung disease and 
allows investigations to be performed in a timely manner. However, a chronic persistent 
cough is associated with several complications and severely disrupts quality of life.
Based on duration, two categories of cough are commonly described: acute, lasting less than 
three weeks; or chronic, lasting three weeks or more (5). This was based on the fact that most 
acute coughs are due to infections, which should resolve within three weeks. However some 
severe infections can persist longer and a cut-off period of eight weeks is now preferred (6 ).
Patients with persistent chronic cough account for 10-38% of the practice of a chest specialist 
(7-9) and recurrent cough has been reported in 22% of the general population (10).
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1.1.2 Physiology of cough
A cough is an explosive burst of high velocity expiratory airflow, which clears secretions. 
Coughing maybe initiated voluntarily or as a reflex.
The cough reflex has 5 components (11).
i. the cough receptors
ii. the afferent nerves
iii. a poorly defined medullary cough centre
iv. efferent nerves
V. effector muscles
Cough receptors
Receptors for cough belong to the general group of rapidly adapting irritant receptors (12). 
They have been demonstrated to exist in the lower airways and pharynx, and it is inferred that 
they must exist in other sites as mechanical stimulation of the external auditory canal, 
eardrums, paranasal sinuses, diaphragm, pleura, pericardium and stomach have all been 
reported to cause cough (5).
A variety of stimuli can initiate a cough reflex, possibly accounting for the multiplicity of 
causes of cough. Inflammation itself could stimulate the cough reflex. Mechanical receptors 
are sensitive to touch and displacement. They are found mainly in the larynx, trachea and 
carina and reduce in number more distally along the tracheo-bronchial tree (5). Chemical 
receptors are concentrated in the larynx and bronchi and are primarily sensitive to noxious 
gases and fumes (5). Changes in temperature can stimulate the cough response as well (5).
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1.1.3 Causes and Complications of chronic cough
Cough can be caused be a variety of disorders, some of which are listed in table 1.1.1 (13) 
described by Madison, Irwin and colleagues. Some additional causes are listed in table 1.1.2. 
Acute cough is usually caused by infections, but can often be the only presenting symptom of 
more severe illnesses such as pulmonary embolism or aspiration.
Pathogenic triad o f chronic cough
Amongst non-smokers, who are not being treated with ACE inhibitors, the cause of cough is 
usually post-nasal drip syndrome (PNDS), gastro-oesophageal reflux disease (GORD) or 
asthma; singly or in combination (figure 1.1.1). This has been termed the pathogenic triad o f  
chronic cough (14). Although chronic bronchitis is a very common cause of cough, smokers 
tend to accept their cough and present infrequently for assessment of their cough.
Complications o f  Cough
The act of coughing can be associated with several complications, which can range from mild 
to severe and can severely impair the quality of life of sufferers (table 1.1.3).
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Table 1.1.1: Causes of cough [adapted from Madison et al (13)\
Anatomic location Causes
Extrathoracic
central nervous system 
head and neck
Gilles de la Tourette’s disease 
common cold
ear conditions 
elongated uvula 
enlarged, infected tonsils 
laryngeal disorders 
nasal polyps
neurilemmoma of vagus nerve 
osteophytes of cervical spine 
palatine artery aneurysm 
rhinitis/sinusitis 
rhinolith
syngamus laryngeus infection (nematode infection) 
thyroiditis
asthma
bronchial carcinoid 
bronchiectasis 
bronchogenic carcinoma 
broncholith 
chronic bronchitis 
foreign bodies 
endobronchial sarcoidosis 
endobronchial tuberculosis 
exposed endobronchial suture 
inhaled medications 
relapsing polychondritis 
Sjogren’s syndrome
tracheobronchitis (bacterial, viral or fungal) 
pertussis 
ulcerative colitis 
wegener’s granulomatosis
connective tissue disorders that involve the lung 
extrinsic allergic alveolitis 
idiopathic pulmonary fibrosis 
infectious pneumonias 
pulmonary vascular disorders
Intrathoracic
Airways Aspiration
Parenchyma of the lung carcinoma-metastatic
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Anatomic location Causes
Mediastinum
Cardiovascular
Upper gastrointestinal
Pleural space
Diaphragm
bronchogenic cyst 
hodgkin’s disease 
intrathoracic goitre 
neural tumours 
thymoma 
teratoma
aberrant innominate artery 
aortic aneurysm 
enlarged left atrium 
left ventricular failure 
mitral stenosis
pericardial stimulation by transvenous
pacemaker
pulmonary embolism
treatment with angiotensin-converting enzyme
inhibitors
vascular ring
oesophageal cyst 
gastro-oesophageal reflux disease 
pharyngeal swallowing disorders 
tracheobronchial fistula
effusion
pneumothorax
thoracentesis
stimulation by transvenous pacemaker
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Table 1.1.2 Additional causes of cough (Studies and Case Reports)
Cause of Cough Reference
Abacavir as treatment for HIV (15)
Aberrant right subclavian artery syndrome (16)
Bronchomalacia (17)
Chronic bronchitis in pigeon fanciers (18)
Coeliac disease (19)
Exposure to fungus Humicola fuscoatra at home (20)
Holmes Adie Syndrome (21)
Holmes Adie Syndrome with Thrl24Met mutation in
peripheral myelin protein zero (MPZ gene) (22)
Impacted cerumen in the ear, hair lying against tympanic membrane (23)
Occupational Causes
Cough in hot pepper workers (chilli peppers) (24)
Latex-induced eosinophilic bronchitis (25)
Tropical pulmonary eosinophilia (26)
Working on a mushroom farm (67% of workers reported cough) (27)
World Trade Centre Cough (fire-fighters after September 11, 2001) (28)
Cough in glass bottle workers (29)
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Figure 1.1.1: Commonest causes of chronic cough in specialist clinics
□  PNDS DG ORD □  Asthma
Irwin 1990 Brightling Smyrnios Poe 1989 
1999 1995
□  Others
McGarvey
1998
Sources: Irwin 1990 (8), Brightling 1999 (30), Smyrnios 1995 (31), Poe 1989 (32) and 
McGarvey 1998 (33).
Table 1.1.3: Complications of cough [adaptedfrom Irwin et al (5)]
Cardiovascular
Neurologic
Gastro-intestinal
Genitourinary
Musculoskeletal
Respiratory
Miscellaneous
Arterial hypotension 
Loss of consciousness
Rupture of subconjunctival, nasal and anal veins 
Dislodgement of intravascular catheters 
Bradyarrhythmias, tachyarrhythmias
Cough syncope 
Headache
Cerebral air embolism 
CSF fluid rhinorrhoea 
Acute cervical radiculopathy 
Malfunctioning ventriculoatrial shunts 
Seizures
Stroke due to vertebral artery dissection
Gastro-oesophageal reflux events 
Hydrothorax in peritoneal dialysis 
Splenic rupture 
Inguinal hernia
Urinary incontinence
Rupture of rectus abdominus muscles 
Rib fractures
Pulmonary interstitial emphysema, with risk of 
pneumomediastinum, pneumoperitoneum, subcutaneous 
emphysema, pneumothorax 
Laryngeal/tracheobronchial trauma 
Exacerbation of asthma 
Intercostal lung herniation
Petechiae and purpurae 
Disruption of surgical wounds 
Self-consciousness, hoarseness, dizziness
Decrease in quality of life
Difficulties in present diagnosis and treatment modalities
Although the causes of cough have been well studied, in the clinic setting it is often very 
difficult to arrive at a specific diagnosis.
Several algorithms have been developed for investigating the cause of chronic cough, 
involving a series of investigations and/or trials of empirical treatments (8 , 33, 34). However, 
despite these attempts, in a significant proportion of patients (12-31%), the specific cause of 
the cough is not established (32, 33, 35).
Hence our current diagnostic and treatment modalities are inadequate, causing prolongation of 
the suffering of patients with chronic cough.
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1.2 AIRWAY INFLAMMATION IN CHRONIC COUGH
1.2.1 Is airway inflammation present in chronic cough?
Patients with chronic cough have increased sensitivity to a variety of inhaled tussive stimuli 
including capsaicin and solutions with low chloride concentrations (36). Airway inflammation 
may contribute to the pathophysiology of cough as asthmatic subjects with cough and patients 
with cough following a viral infection also demonstrate a heightened response to inhaled 
capsaicin (37, 38).
Chronic cough is a multi-factorial condition. Airway inflammation could be a common 
unifying feature in all causes of cough. In cough due to asthma, rhino-sinusitis, gastro- 
oesophageal reflux disease and angiotensin-converting enzyme (ACE) inhibitors, 
inflammation of the airways has been demonstrated (39-42).
Studies utilising bronchial biopsies and broncho-alveolar lavage have shown increased 
number and activity of airway inflammatory cells (41, 43), suggesting an important role for 
airways inflammation in the pathophysiology of chronic cough.
Various studies in specific sub-groups of cough have shown the presence of elevated 
mediators of inflammation, such as interleukin-8 , tumour necrosis factor-a (39), cysteinyl 
leukotrienes and eosinophilic cationic protein (44). Recently, Birring et al demonstrated 
elevated levels of mast cell derived mediators in chronic cough, where the main groups of 
subjects were cough variant asthma, eosinophilic bronchitis and idiopathic cough (45).
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Inflammation of the airways does appear to be a significant finding in chronic cough. The 
pattern of inflammation has varied in different studies.
1.2.2 Eosinophilic inflammation
Airway inflammation with eosinophils is a characteristic feature of asthma. Eosinophilic 
inflammation has been described as the predominant cellular pattern in several cough studies. 
Carney and colleagues demonstrated high levels of eosinophils in induced sputum in 50% 
subjects with chronic cough compared to 19% in controls (46). In a comparative study, Niimi 
et al found the serum ECP level and percentage of eosinophils in bronchoalveolar lavage fluid 
and biopsy specimens in cough subjects were elevated, similar to patients with classic asthma 
associated with wheeze (40). In contrast, Hsu et al reported sputum eosinophilia in 28% of 
patients with chronic cough, (7/25 subjects); (of whom 5/7 responded to oral prednisolone) 
compared to 92% of asthmatics (47).
Gibson and colleagues first described the presence of eosinophils in induced sputum samples 
of subjects with cough and no evidence of asthma. They suggested the terminology 
‘eosinophilic bronchitis’ (48) for this group of corticosteroid responsive subjects with cough. 
More recently, Fujimura and colleagues have proposed a corticosteroid sensitive disease 
entity known as ‘atopic cough’ which is associated with eosinophilic tracheo-bronchitis and 
atopy, without bronchial hyperreactivity (49).
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The spectrum of diseases with eosinophilic inflammation of the airways has now broadened to 
include cough variant asthma, atopic cough, eosinophilic bronchitis, allergic rhinitis and 
COPD (50).
1.2.3 Neutrophilic inflammation
In contrast to the above studies reporting predominant eosinophilia, Jatakanon and colleagues 
found a two-fold increase in neutrophils in induced sputum in cough subjects compared to 
controls, when they studied subjects with non-asthmatic cough (51). This was associated with 
an increase in cytokines associated with neutrophil chemotaxis (IL- 8  and TNF-a) and was in 
agreement with the study on non-asthmatic cough subjects by Pizzichini et al reporting that 
59% of subjects had neutrophil elevation in sputum with increased IL- 8  levels (52). A 
generalised neutrophilia in cough subjects was noted in a study from Japan (53), but response 
to asthma medications was seen only in those with evidence of eosinophilia.
A direct effect of acid in GOR or inhaled sino-nasal fluid in PNDS could induce neutrophilic 
inflammation in the airways. Corren et al demonstrated in an animal model that sinusitis can 
cause hyperreactivity of the lower airways by post-nasal dripping of cells or cell products into 
the lower airways (54). It has been speculated that the act of repeated coughing may 
contribute to inflammation (51). Epithelial damage induced by coughing may induce the 
release of inflammatory cytokines such as IL- 8  and TNF-a, which are elevated in chronic 
cough (51). Both IL- 8  and TNF-alpha can cause neutrophilia (55, 56).
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Moodley and colleagues considered the possibility that hypertonic saline itself was causing 
neutrophilia in induced sputum and compared samples of bronchial lavage fluid collected at 
different sites in the airways in healthy individuals. Their conclusion was that the relatively 
high neutrophil count in sputum arose from the proximal airways and was not a response to 
hypertonic saline (57).
1.2.4 Role of mast cells and lymphocytes
There has been recent interest in the role of mast cells and lymphocytes in cough (45, 58, 59). 
Broncho-alveolar lavage in chronic non-productive cough subjects demonstrated an increase 
in eosinophils along with mast cells (41). Gibson et al studied bronchial brushings in chronic 
cough and found intraepithelial mast cells were elevated in subjects with inhaled 
corticosteroid responsive cough (60). Mast cell derived mediators, such as PGD2 and 
histamine were increased in all causes of cough (45), suggesting a role for mast cells in the 
complex inflammation associated with cough. Lymphocytes were found to be elevated 
specifically in subjects with idiopathic cough (45, 59) with a possibility raised that idiopathic 
cough was related to auto-immune diseases.
1.2.5 Can coughing cause airway inflammation?
It is possible that inflammation itself may perpetuate cough by enhancing the cough reflex 
through the release of inflammatory mediators and cytokines. But can coughing exacerbate 
the inflammation, setting up a vicious cycle of events?
There is no real evidence at present to answer this question. During the procedure of sputum 
induction, changes in sputum composition were detectable after 24 hours (61). There maybe
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an influx of neutrophils into the airways (61), although it does not appear to be rapid as no 
increase is detectable over 30 minutes of sputum induction (61) nor is a prolonged effect 
likely as the sputum neutrophil count is repeatable after one or two weeks (62).
1.2.6 Effect of anti-inflammatory treatment in cough
Corticosteroids, oral and inhaled, can reduce cough when associated with eosinophilic 
inflammation, especially in conditions such as cough variant asthma, eosinophilic bronchitis 
and atopic cough. The role of corticosteroids as general anti-inflammatory agents in all causes 
of cough remains to be determined.
Leukotriene antagonists maybe useful in certain cases of cough variant asthma, even when 
resistant to corticosteroids (63). Newer, and more specific anti-inflammatory agents are being 
assessed, for example, a Th2 cytokine inhibitor, suplatast tosilate, used in 20 patients with 
cough variant asthma in a double blind, randomised placebo-controlled study reduced the 
initially elevated sputum ECP and eosinophils in induced sputum compared to placebo (64).
Conclusion
Chronic cough is associated with airway inflammation. The predominant cell type could be 
eosinophils, neutrophils, lymphocytes or mast cells. The type of airway inflammatory cell 
predominant in an individual patient presenting with chronic cough, may help to predict the 
response to corticosteroids (60), as occurs in patients with asthma (65) and COPD (6 6 ).
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Information on cellular patterns in different causes of cough is limited. Their role in predicting 
corticosteroid responsiveness in patients with chronic cough due to all common causes has not 
been elucidated.
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1.3 NON-INVASVIVE TESTS TO ASSESS AIRWAY INFLAMMATION AND 
CORTICOSTEROID RESPONSIVENESS
Bronchoscopy with biopsy and lavage is the ‘gold standard’ to assess inflammation in the 
airways in conditions such as asthma and COPD. However, it is an invasive technique 
associated with risks. Less invasive techniques, such as induced sputum and measurement of 
markers in exhaled air have been evaluated in several respiratory conditions, including 
chronic cough.
1.3.1 Induced sputum
Sputum has been a useful tool to evaluate many respiratory diseases. The difficulty in 
obtaining spontaneous samples lead to the development of techniques to stimulate the 
production of sputum. Ultrasonically nebulised hypertonic saline successfully induces sputum 
from normal as well as asthmatic subjects (67) with cellular and biochemical content similar 
to spontaneously produced samples (62). The advantages of induced sputum are that it is non- 
invasive, simple (62), safe (6 8 ) and responsive (69).
Methodology
Different approaches to sputum induction have been described in the literature, with fixed or 
increasing concentrations of hypertonic saline over varying time periods (70, 71). Although 
sputum cell counts do not appear to be affected by the tonicity of saline used (72), cellular and 
biochemical composition may change over the induction period (61) and it would be 
appropriate to standardise the duration of the procedure. The technique has evolved over
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several years and can now provide meaningful information about inflammation of the lower
| airways (67).
!
i
Role as a non-invasive marker o f  inflammation
The use of induced sputum to assess inflammation of the airways has lead to an improved
understanding of the different phenotypes of asthma and COPD. Sputum eosinophil count can
i
| be used to predict the response to oral prednisolone in these conditions (6 6 , 73). Severe
asthma appears to be more commonly associated with a neutrophil predominance (74).
Role in cough
Induced sputum has been utilised as a tool to study the presence of inflammation in chronic
[
cough (46, 51). Lack of sputum eosinophils predicted lack of responsiveness to corticosteroids 
in subjects with non-asthmatic chronic cough (52). Gibson and colleagues demonstrated that 
there was evidence of sputum eosinophilia in patients with chronic cough without variable 
obstruction and airway hyperreactivity typical of asthma (75, 76) and called this ‘eosinophilic 
bronchitis’. This condition has now been diagnosed in up to 15% of cases of chronic cough in 
specialist centres (30) and induced sputum is now recommended as an additional test in the 
algorithm of cough management (6 ).
1.3.2: Exhaled nitric oxide
|
I
!
Nitric oxide (NO), previously known as endothelium derived relaxant factor (EDRF), is a 
highly reactive molecule formed from L-arginine by the action of the stereo-specific enzyme
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nitric oxide synthase (NOS). At least three forms of NOS exist; two are constitutive and are 
activated by a rise in intracellular calcium ions, producing small amounts of NO involved in 
local regulatory functions and cell signalling. The final form of NO synthase known as iNOS 
or inducible nitric oxide synthase, is expressed following induction by inflammatory 
cytokines and endotoxin and produces large amounts of NO after activation.
The anatomical and cellular source of nitric oxide in the airways is unclear. Although majority 
of exhaled NO in normal subjects probably originates in the upper airways (77, 78), NO can 
be detected in the lower airways via bronchoscopic sampling in normal individuals (79, 80). 
Nitric oxide can be measured in exhaled air by the process of chemiluminescence, with 
detection of NO as a result of its photochemical reaction with ozone. The quantity of light is 
proportional to the concentration of NO in the exhaled gas. Most recent analysers are able to 
detect to < 1 part per billion.
The guidelines produced by the European Respiratory Task Force cover several technical 
factors to be considered during measurement (81). Slow expiration against a resistance 
elevates the soft palate and produces levels of exhaled NO identical to those samples directly 
from the lower airways at bronchoscopy (79, 80).
Role as a non-invasive marker o f  inflammation
Values of exhaled nitric oxide can be elevated in asthma (77, 79, 82) and viral respiratory 
infections (83). In asthma, exhaled NO has been advocated as a non-invasive marker of 
airway inflammation (84-86).
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Exhaled NO levels decrease with corticosteroid treatment in asthma (87, 8 8 ) and in 
bronchiectasis (89), possibly because glucocorticoids suppress airway inflammation and 
prevent induction of iNOS (90).
Role in cough
Exhaled nitric oxide has been suggested as a method of differentiating ‘asthmatic’ from ‘non­
asthmatic’ cough with a positive and negative predictive value of 60 and 93% respectively 
(91). In this study by Chatkin and colleagues all subjects with a positive methacholine 
challenge test were diagnosed to have an asthmatic cough, which is usually accurate in 
approximately 8 8 % of cases (33). Most investigators would diagnose an asthmatic cough on 
the basis of a positive methacholine test with response to specific asthma treatment (5, 6 ). 
Exhaled NO levels were elevated in subjects with eosinophilic bronchitis (92). In 
bronchiectasis, Kharitonov and colleagues reported high levels of eNO (89), but this was not 
supported by Ho et al (93).
Further work on the value of exhaled NO in diagnosing of the cause of cough and predicting 
corticosteroid responsiveness is indicated.
1.3.3 Carbon monoxide
Carbon monoxide (CO), a gas detectable in exhaled air, is produced from three major sources: 
enzymatic degradation of heme, non-heme related release (lipid peroxidation, bacterial) and
19
exogenous CO. Approximately 85% of CO in the body is from degradation of haemoglobin 
by the enzyme heme oxygenase (HO) and approximately 15% from degradation of 
myoglobin, catalase, NO synthase and cytochromes (94). HO exists in 3 isoforms - HO-1,2 
and 3. HO-1 is a stress protein which can be induced by a variety of stimuli including pro- 
inflammatory cytokines, bacterial toxins and nitric oxide.
Exhaled CO is easily performed and usually detectable in all subjects. Measurements are 
reproducible and ambient air concentrations (0 - 2  ppm) do not have much effect on readings 
(95).
Role in inflammation and as non-invasive marker o f  inflammation
Levels of exhaled CO are elevated in asthma, upper respiratory tract infections, lower 
respiratory tract infections, seasonal allergic rhinitis and cystic fibrosis (95-99). Treatment 
with inhaled or oral corticosteroid has been shown to reduce exhaled CO in asthmatics (96, 
100). Exhaled CO is related to the severity of asthma (101) and has been advocated as a non- 
invasive marker of airway inflammation (101-103).
Carbon monoxide levels are elevated in bronchiectasis (104). The value of this measurement 
in all causes of chronic cough and as a predictor of response to inhaled corticosteroid has not 
been evaluated.
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1.3.4 Nasal nitric oxide
Elevated nasal nitric oxide can be measured in allergic and perennial rhinitis (105, 106) which 
is reduced by treatment with nasal glucocorticoids (105). Differences of nasal NO in subjects 
with rhinitis compared to normals are not very high and this reduces the value of nasal NO as 
a non-invasive test for monitoring rhinitis (107).
1.3.5 Exhaled breath condensate
Exhaled breath condensate is a new technique to measure inflammatory parameters in subjects 
with asthma and COPD (108, 109). Recently, Niimi and colleagues demonstrated reduced pH 
in exhaled breath of patients with chronic cough ( 1 1 0 ) suggesting that endogenous acidity 
could contribute to heightened cough reflex sensitivity. Reduced pH in exhaled breath 
condensate has been associated with neutrophilic airway inflammation (111). Hydrogen 
peroxide levels were elevated in bronchiectasis ( 1 1 2 ) and correlated with disease severity. 
There have been no reports on measurement of inflammatory mediators in breath condensate 
of patients with chronic cough.
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1.4 MEDIATORS INVOLVED IN CHRONIC COUGH
1.4.1 Inflammatory mediators in airway inflammation
Inflammation of the airways appears to be controlled and perpetuated through large extra­
cellular signalling peptide mediators (113). These cytokines can be pro-inflammatory or anti­
inflammatory. Various papers have shown that inflammatory mediators can be measured in 
the induced sputum cell-free supernatant repeatably (44, 62, 114). Induced sputum mediator 
levels, such as ECP and eicosanoids, can be higher than levels in broncho-alveolar lavage 
fluid (115, 116). There is a complex interaction between inflammatory cells and mediators 
released, which serves to perpetuate airway inflammation.
1.4.2 Specific mediators possibly involved in chronic cough
a. Leukotrienes (B4 and cysteinyl leukotrienes)
Leukotrienes have been known of since the 1930’s when they were collectively termed as 
slow-reacting substance of anaphylaxis (SRS-A). They were purified and individually 
characterized in the 1980’s. Leukotrienes are formed during the breakdown of arachidonic 
acid by the enzyme 5-lipoxygenase (5-LO) and consist of LTA4 , LTB4 , LTC4 , LTD4  and 
LTE4 . These mediators are produced by various cell types, especially mast cells and 
eosinophils as well as basophils, macrophages and monocytes (117). They are elevated in 
patients with asthma (118) and in nasal secretions of subjects with symptomatic rhinitis (119).
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Cysteinyl leukotrienes
Leukotrienes C4, D4 and E4 each contain a cysteine residue, hence the name cysteinyl 
leukotrienes. Cysteinyl-leukotrienes can cause bronchoconstriction (120), increase vascular 
permeability ( 1 2 1 ), increase mucous production ( 1 2 2 ) and may directly increase eosinophilic 
airway inflammation.
Leukotriene B4
Leukotriene B4 does not have a cysteine residue. Its biological activity includes a 
chemoattractant stimulus for inflammatory cells, bringing them from the circulation into the 
focus of inflammation (117). LTB4 exerts its strongest chemoattractant effect on neutrophils 
(123), but it can also attract eosinophils and monocytes (124). It is released by activated mast 
cells and macrophages.
In subjects with cough, cys-LT was increased in the sputum supernatant of subjects with 
eosinophilic bronchitis and cough variant asthma (44, 45). LTB4 levels have not been 
measured in chronic cough.
In patients with cough due to chronic bronchitis, the cys-LT receptor antagonist, pranlukast, 
had no significant effect (125). However, montelukast reduced cough in infants with reactive 
airway disease following respiratory syncytial virus (RSV) bronchiolitis (126).
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b. Prostaglandins
Prostaglandins are small lipid molecules that regulate several processes in the body including 
immune function (127). In response to inflammatory stimuli, membrane phospholipids 
liberate arachidonic acid by the action of phospholipase A2 . Arachidonic acid is converted to 
PGH2 by the cyclooxygenase enzymes COX-1 and COX-2 to a series of prostaglandins 
including PGI2, PGF2 a, PGD2 and PGE2 (127).
PGE2 is usually considered to have an anti-inflammatory role in asthma (128, 129) but is pro- 
inflammatory in periodontal disease (127). PGE2 could have a pro-inflammatory role in 
cough. Choudry et al (130) demonstrated that inhalation of PGE2 significantly increased the 
cough response to capsaicin in normal volunteers and increased the respiratory resistance after 
capsaicin. These effects were not seen with inhalation of bradykinin, histamine or citric acid. 
Their results suggested that the cough reflex is increased in the presence of PGE2 in the 
airways. Birring and colleagues demonstrated increased PGE2 levels in induced sputum in all 
groups of patients with cough (45).
Brightling et al reported high levels of PGD2 in induced sputum of subjects with eosinophilic 
bronchitis (44). Subsequently, Birring and colleagues demonstrated that PGD2 was elevated in 
all causes of cough (45).
c. Eosinophilic cationic protein (ECP)
Eosinophils in an activated state contain granule proteins, one of which is ECP. It is a potent 
tissue damaging protein. It can release histamine from mast cells. Its destructive effect on
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airway epithelium and surrounding tissues may expose underlying sensory nerves and cough 
receptors to various other environmental insults (41).
ECP levels are elevated in induced sputum of subjects with cough due to eosinophilic 
bronchitis (44, 131, 132). High levels of ECP in induced sputum have been measured in non- 
eosinophilic asthma (133) and in other non-eosinophilic conditions like COPD (134) and 
bronchiectasis (135); suggesting that neutrophils, as well as eosinophils, may contain ECP, as 
demonstrated by Sur et al (136).
d. Myeloperoxidase (MPO)
Neutrophils contain cytotoxic enzymes which help their role in host defence. One such 
cytotoxic system is provided by myeloperoxidase, a haemoprotein within azurophilic granules 
(137). Stimulation of neutrophils leads to rapid secretion of MPO which can be detected 
extracellularly.
Elevated levels of MPO in broncho-alveolar lavage has been demonstrated in asthma (138) 
and COPD and correlated with neutrophil numbers as well as IL- 8  (139). Levels in chronic 
cough have not been measured.
e. Interleukin-8 (IL-8)
Interleukin- 8  is a pro-inflammatory cytokine. It is a potent neutrophil chemoattractant and 
activator (140) released from a variety of inflammatory airway cells, including macrophages, 
eosinophils and epithelial cells (141-143). It may also have chemotactic activity for 
eosinophils (144, 145).
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In persistent asthma associated with neutrophilia in sputum, 11-8 levels were increased and 
correlated with neutrophils, ECP and MPO (133). IL- 8  appears to be marker of severe asthma 
(146).
Jatakanon and colleagues demonstrated that non-asthmatic cough was associated with sputum 
neutrophils and found elevated IL- 8  levels in induced sputum in these subjects (51). In 
patients with chronic cough reported by Birring and colleagues, sputum neutrophil count and 
IL- 8  were within normal limits (45). However, the predominance of subjects in their study 
had a final diagnosis of asthma, eosinophilic bronchitis and idiopathic cough.
f. Tumour necrosis factor-a (TNF-a)
TNF-a is a potent pro-inflammatory cytokine. It is a peptide, not constitutively present in the 
lungs, but secreted rapidly upon stimulation from macrophages, T and B cells, mast cells and 
epithelial cells. It stimulates a generalised immune reaction.
Elevated levels of TNF-a are found in the airways of asthmatics using broncho-alveolar 
lavage (147). Inhalation of TNF-a results in increased neutrophil counts in induced sputum of 
normal subjects and mild asthmatics (55, 148). Jatakanon et al studied induced sputum 
samples of subjects with non-asthmatic cough and found significantly increased levels of 
TNF-a which did not correlate with the neutrophil count (51).
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g. Other mediators
Histamine was elevated in induced sputum of certain sub-groups of cough (45). Bradykinin 
and related kinins are peptide hormones, formed in tissues and fluids during inflammation. It 
has been proposed that coughing during treatment with ACE inhibitors is linked to the action 
of kinins, since ACE is able to degrade kinins and the effects of ACE inhibitors are reduced 
by kinin antagonists (149).
1.4.3 Effect of corticosteroid on mediator levels
Corticosteroids are powerful anti-inflammatory agents. Serum ECP levels decline with 
inhaled corticosteroid treatment in asthmatics (150, 151).
The results for other mediators are less encouraging. Leukotriene levels did not respond to 
corticosteroid treatment and studies with ICS failed to detect any effect in urinary LTE4 
excretion (152). In vitro there was a 30% reduction of IL- 8  release from epithelium and 
smooth muscle with corticosteroid treatment (153) and in patients with persistent asthma, IL- 8  
levels were high despite the use of inhaled corticosteroids (133).
Fujimoto and colleagues studied the effect of glucocorticoids on inflammation in patients with 
COPD and measured ECP and IL- 8  in induced sputum (154). They found elevated levels of 
both at baseline, but after corticosteroids, only ECP showed a significant reduction.
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1.4.4 Are inflammatory mediators involved in chronic cough?
Airway inflammation has been demonstrated in several studies studying the pathophysiology 
of chronic cough with neutrophilic, eosinophilic or mast cell associated inflammation. 
Elevated mediator levels in induced sputum were present in patients with non-asthmatic dry 
cough (51) and eosinophilic bronchitis (155). Birring and colleagues recently demonstrated 
that mast cell derived mediators (histamine, PGD2) and PGE2 were elevated in all subjects 
studied with cough (45).
Cough response to capsaicin can be enhanced by substances released during inflammation 
such as prostaglandins and bradykinin (156, 157). Choudry et al demonstrated inhalation of 
prostaglandin E2 (PGE2) in humans enhanced the cough reflex (130).
It is also possible that chemical mediators affect the electrophysiological properties of the 
afferent nerve membrane without causing a generator potential and activating the nerve. They 
could modulate nerve excitability. An example of PGE2 and nerve modulation, described by 
Kollarik and Undem (158) is depicted in figure 1.4.1.
Summation of this information strongly suggests a pathogenic role for inflammatory 
mediators in chronic cough. The precise mediators involved in various causes of cough have 
not been confirmed and their response to anti-inflammatory agents remains to be investigated.
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Figure 1.4.1: Examples of the action of activator and modulator of nerve excitability in 
vagal afferent fibres of guinea pig trachea [Kollarik and Undem, (158).
Activation of airway nociceptive afferent afferent nerve fibre by bradykinin [activator] and 
the sensitising effect of prostaglandin E2 (PGE2 ); [modulator].
Upper trace: transient administration of bradykinin directly over the receptive field evoked a 
short delayed burst of action potential discharge.
Middle trace: The tissue was incubated with PGE2 that caused by itself no activation.
Lower trace: PGE2 enhanced response to subsequent challenge with bradykinin.
Vagal afferent fibre in guinea pig trachea 
(conduction velocity = 3.8 m/s)
10s
t bradykinin
1 min
10s
A
bradykinin
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1.5 NEUROTROPHINS AND COUGH
1.5.1 Biology of neurotrophins and their receptors:
Neurotrophins are a family of structurally related growth factors which include nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5 and 
the recently discovered neurotrophin- 6  (NT-6 ) (159). Their potency to regulate the 
development, differentiation, survival and function of distinct neuronal subsets is well 
established. They derived their name from the term ‘neuron’ related to nerves and ‘trophe’ 
meaning nutrient. Recently there is growing evidence for their involvement in the process of 
inflammation. T-cells, B-cells, macrophages and mast cells are sources of neurotrophic factors 
during the process of inflammation.
The biological effects of neurotrophins are mediated by binding either to high affinity 
(Kd-10'11) tyrosine kinase receptors (trkA, trkB, trkC) or the low affinity (Kd-1 O’9) pan- 
neurotrophin receptor (p75NTR). Substantial biological effects of neurotrophins are mediated 
through the high affinity tyrosine kinase receptors. TrkA is the high affinity receptor for NGF, 
trkB for BDNF and NT-4, and trkC for NT-3. Trk receptors and p75NTR are widely 
expressed in neurons of the peripheral and central nervous systems as well as on non-neuronal 
cells such as immune cells, muscle cells and epithelial cells (160).
Functions o f  neurotrophins in the mature immune system
Since NGF is the best characterised neurotrophin, most of the available data deals with this 
neurotrophin. The main functions of NGF (161) can be summarised as
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• Stimulation of rapid degranulation of mast cells and basophils
• Promotion of differentiation, activation and cytokine production of mast cells, 
granulocytes and macrophages
• Activation of eosinophils
• Promotion of proliferation of B- and T-cell subsets
• Enhances Th2cytokine production and IgE synthesis
• Induces differentiation of activated B-cells in Ig-secreting plasma cells
1.5.2 Neurotrophins and asthma
Work in mouse models of allergic inflammation has shown that neurotrophins alter sensory 
innervation, enhance neuropeptide production and induce airway hyper-responsiveness (162, 
163).
Patients with severe allergic bronchial asthma demonstrate high serum levels of NGF (164). 
Virchow and colleagues investigated the presence of NGF, BDNF and NT-3 in broncho- 
alveolar lavage after segmental allergen provocation in mild asthmatic patients (165) and 
found an increase in neurotrophins in allergen-exposed lung segments, but only during the 
late-phase response. Elevated NGF and BDNF levels have been demonstrated in serum of 
steroid-naive asthmatic (166) with a reduction in levels following inhaled corticosteroids.
NGF levels are also increased in other allergic conditions such as rhinoconjunctivitis and 
urticaria-angio-oedema (164). The role of NGF and BDNF in asthma is better established than 
that of NT-3 and NT-4 (167).
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Neurotrophins could participate in the pathogenesis of asthma in different ways:
• as nerve growth factors, including neuropeptide synthesis and neuronal hyper­
reactivity
• as cytokine-like factors influencing the allergic immune response and 
inflammation and
• as growth factors directly controlling smooth muscle function.
1.5.3 Neurogenic inflammation in cough
Tachykinins are a family of neuropeptides released on stimulation with mechanical, thermal, 
chemical (capsaicin, nicotine) or inflammatory stimuli (bradykinin, histamine, prostaglandins) 
(168). Substance P and neurokinin A are members the tachykinin family. These neuropeptides 
are transferred via axonal transport to pre-synaptic axon endings in the spinal cord and to 
peripheral nerve endings.
There are two principle cough receptors, rapidly adapting receptors (RAR’s) which are 
innervated by A fibres and unmyelinated C-fibres (169, 170). Tachykinins have been shown 
to be present in unmyelinated sensory fibres using immunohistochemical techniques (171, 
172). C-fibres antidromically release CGRP, SP and NKA when stimulated by irritants such 
as capsaicin (172, 173). Endobronchial biopsy specimens obtained from subjects with 
idiopathic cough showed an increase in airway calcitonin gene-related peptide (CGRP) and 
vasoactive intestinal peptide-immunoreactive nerves (174).
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Hope-Gill and colleagues studied the cough reflex in patients with idiopathic pulmonary 
fibrosis and healthy controls (175). They found that substance P and bradykinin induced 
cough and oral prednisolone significantly reduced the cough. In induced sputum, elevated 
levels of nerve growth factor and brain derived neurotrophic factor were present (175).
1.5.4 Possible role of neurotrophins in chronic cough
In pulmonary tissue, there is expression of NGF, BDNF and NT-3, as revealed by 
microdensitometric analysis of bands of immunoreactivity (176).
Neurotrophins are signalling molecules, locally upregulated in allergic inflammatory 
processes. Sensory C-fibres contain neuropeptides in their peripheral and central terminals. 
Inflammation within the airway wall sends signals to the distant cell body in the relevant 
sensory ganglia to induce the transcription on neuropeptide synthesizing enzymes. The 
mechanism of this is unknown, but a likely mechanism could involve the action of 
neurotrophins (158).
In inflammatory processes, increased synthesis of tachykinins leads to inflammatory 
hypersensitivity. These effects can be mediated by NGF (177-179).
NGF and BDNF cause increased capsaicin sensitivity in sensory neurons (160, 178). In vitro 
BDNF gene transcription directly regulates capsaicin sensitivity in vagal sensory afferents 
(180).
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Endogenous neuronal lipid mediator anandamide, which can be synthesised in the lung, is a 
ligand of cannabinoid (CB) and vanilloid receptors (VR). Anandamide when given by aerosol, 
can induce cough in conscious guinea pigs (181), possibly through activation of vanilloid 
(VR1) receptors. Recently, the vanilloid receptor, originally known as the capsaicin receptor, 
has been proposed as a receptor for cough in humans (182). It has been speculated that NGF 
affects airway nerves through the vanilloid receptor (VR1) in allergic asthma (183).
Taken together, this evidence suggests that neurotrophins may be involved in the 
inflammation in chronic cough.
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1.6 QUALITY OF LIFE IN CHRONIC PERSISTENT COUGH
Chronic cough is one of the commonest causes of presentation to a general practitioner. It is 
associated with considerable morbidity and social disability (10, 184, 185). The diagnosis and 
management of chronic cough is often difficult. Cough often persists for several years (33, 
35, 110) and patients are usually resigned to suffering with it. 23% of patients self-presenting 
to a cough clinic had been specifically told by their physician that they would have to learn to 
live with their cough (8 ).
1.6.1 Health related quality of life
Quality of life is an outcome related to a fundamental aim of health care (186). Health related 
quality of life measurement is a means of quantifying, in a standardised and objective manner, 
the impact of disease on patients’ daily life, health and wellbeing. It is a process that is similar 
to a highly structured clinical history, where the end product is an objective measurement that 
can be used for scientific purposes (187). Health status questionnaires address the 
emotional/psychological effects of an illness along with the physical effects. The majority of 
items in these questionnaires are concerned with practical aspects of disturbances to daily life 
and aim to summarise the wide effects of a disease into an overall score.
1.6.2 Cough specific quality of life assessment
Until recently, the quality of life of people with chronic cough had never been studied. French 
and colleagues used the Sickness Impact Profile (SIP) and Adverse Cough Outcome Survey 
(ACOS) developed by themselves and demonstrated, in a prospective study, that chronic
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cough was associated with adverse psychosocial and physical effects on the quality of life
(188). Some of the common complaints recorded are depicted in table 1.6.1.
French et al introduced a cough specific quality of life questionnaire (the CQLQ) in 2002
(189), followed by Birring and colleagues with the Leicester Cough Questionnaire (LCQ) in 
2003 (190). Both are recent additions to outcome measures in cough studies which could 
prove very useful, but will benefit with further validation in larger and varied populations.
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Table 1.6.1: Spectrum and frequency of cough-associated adverse occurrences before 
and after specific treatment to patients (n=28) cured of their coughs.
[Adapted from: French et al. Arch Intern Med 1998 (188)]
Frequency, %
Before treatment After treatment p
Adverse Occurrence
Needs reassurance nothing is serious 
Concerned something is wrong 
Frequent retching 
Exhaustion 
Others think something is wrong with me 
Embarrassment 
Self-consciousness 
Difficulty speaking on the phone 
Hoarseness
Had to change lifestyle 
Cannot sleep at night 
Can no longer sing in church 
Spouse cannot tolerate cough 
Wetting pants 
Dizziness
Excessive sweating
75 19 <0 . 0 0 1
6 8 1 1 <0 . 0 0 1
57 8 <0 . 0 0 1
61 15 <0 . 0 0 1
46 19 0.03
46 1 1 <0.004
46 14 0 . 0 1
43 2 2 0 . 0 1
46 15 0 . 0 1
36 1 1 0.03
43 15 0 . 0 2
29 8 <0.05
27 8 0.08
32 7 0 . 0 2
29 7 0.04
29 7 0.04
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1.6.3 Effect of treatment on quality of life
French and colleagues (188) studied 28 subjects before and after treatment of their cough and 
found a resolution of the deterioration in quality of life following successful treatment of the 
cough. The Sickness Impact profile (SIPS) scores significantly decreased towards normal and 
the ACOS items decreased from 8 . 6  to 1.9 (p<0.001). A substantial proportion of their 
patients’ health related dysfunction in the ACOS was explained by cough inducing concern of 
cancer, exhaustion, fear of AIDS or TB and hoarseness. Birring and colleagues used the LCQ 
to assess the effect of specific therapy in 9 subjects (190) and found a highly significant 
correlation for improvement in VAS scores and LCQ scores (p=0.007). The change in quality 
of life following specific treatment of cough has not been assessed in a large study.
1.6.4 Comparison of quality of life across different respiratory conditions
The cough specific questionnaires will be helpful in cough specific studies, but will not be 
useful to compare the quality of life across different respiratory conditions. Quality of life is 
widely used as an outcome measure in studies in asthma and COPD with respiratory disease 
specific questionnaires such as the St. George’s Respiratory Questionnaire (SGRQ) and in 
various medical disorders with the Hospital Anxiety and Depression scale. The SGRQ was 
designed so the scores would have an ‘absolute’ property and be independent of patient and 
study (191). It has 76 items divided into 3 sections: Symptoms, Activity and Impacts (which 
covers aspects concerned with social functioning and psychological disturbances resulting 
from airway disease) (191). A comparison of the effect of cough on quality of life compared 
with other medical conditions has not been done.
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Objective measures of cough such as portable cough counters of good quality will eventually 
be the best method to assess effect of therapy on cough. However, at present, subjective 
measures such as health related quality of life instruments are likely to be the ones that best 
reflect the cough severity integrating the cough frequency, intensity and its effect on daily life.
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1.7 BRONCHIAL AND EXTRATHORACIC AIRWAY HYPERREACTIVITY IN 
CHRONIC COUGH
1.7.1 Bronchial hyperreactivity (BHR) in chronic cough
Airway hyperresponsiveness or hyperreactivity is an increased ability of the airways to 
narrow after exposure to constrictor agonists. Airway hyperresponsiveness is believed to be 
affected by genetic as well as environmental factors (192, 193). The association of airway 
hyperresponsiveness and inflammation is controversial. Acute allergen exposure causes an 
increase of airway hyperresponsiveness that is consistently associated with an influx of 
inflammatory cells in the airways (194), which suggests a possible causal relation between 
airway inflammation and hyperresponsiveness (84, 195-197). Recently several studies have 
questioned this association. (198, 199). In chronic cough, Carney and colleagues found BHR 
in 23% subjects and sputum eosinophils in 50%, showing the dissociation between lower 
airway hyperreactivity and eosinophilic inflammation of the airways. Fujimura and colleagues 
found that capsaicin cough response was not related to airway hyperreactivity (2 0 0 ).
Methacholine, a direct stimulus of bronchoconstriction, is currently the gold standard for the 
assessment of bronchial hyper-reactivity (201, 202). The presence of bronchial hyperreactivity 
is used to diagnose cough variant asthma along with response to specific treatment. For a 
diagnosis of eosinophilic bronchitis, a negative challenge test is required along with 
eosinophils in sputum and response to corticosteroids. McGarvey and colleagues evaluated 
investigations in chronic cough and found the histamine challenge test had a positive
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predictive value of 8 8 % for asthma, implying that not all patients with cough and bronchial 
hyperresponsiveness have asthma (33) similar to work by Irwin et al (203). A negative 
methacholine challenge test is very useful in cough management to exclude the diagnosis of 
asthma (5, 6 ).
1.7.2 Extrathoracic airway hyperreactivity (EAHR) in chronic cough
Cough can be initiated anatomically by conditions that are outside the lower airways and 
hence measuring lower airway hyper-reactivity alone may not reveal the entire picture in 
cough. Asthma like symptoms, especially cough, could be associated with extrathoracic 
airway dysfunction.
Extrathoracic airway narrowing can be demonstrated during lung function testing using flow 
volume curves. Bucca and Rolla matched flow-volume loops with fibreoptic laryngoscopy 
during histamine challenge inhalation and found that the maximal mid-inspiratory flow 
(MIF50) best reflected changes in mid-inspiratory glottis area (204). They used this index to 
study patients with upper respiratory disorders and found extrathoracic airway hyper­
responsiveness in subjects with sinusitis, laryngitis and pharyngitis (204, 205). This was 
associated with damage to the epithelium and proliferation of submucosal fibres (206). It is 
unknown whether the hyperreactivity is a cause or effect of the nasal condition.
In patients with gastro-oesophageal reflux, those subjects with cough compared to those 
without, had a significantly lower PC25MIF50, indicative of extrathoracic airway
41
hyperreactivity (207). When patients with asthma like symptoms were studied, extrathoracic 
airway hyper-reactivity was found in 67% and was the sole abnormality in 27% (208). In 51% 
the diagnosis was considered as asthma. Patients presenting with cough alone had the highest 
probability of having extrathoracic airway responsiveness and the lowest probability of having 
bronchial responsiveness (208). MIF50 can be influenced by anxiety or defensive glottic 
closure and a positive test requires a decrease in a dose-dependent manner (208).
Carney and colleagues considered the possibility that upper airway hyperreactivity could be a 
unifying mechanism in cough, but found it present in only 12/30, 40% of subjects with 
chronic cough persistent for longer than 4 weeks (46). The mechanism of EAHR is unknown. 
It could be triggered by stimulation of pharyngo-laryngeal receptors (208), or simply a reflex 
narrowing of the glottis(209).
Extrathoracic airway hyperreactivity has not been studied in a large group of subjects with 
chronic persistent cough and its association with airway inflammation is unknown.
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1.8 SPECIFIC DIAGNOSIS OF THE AETIOLOGY OF COUGH
Chronic cough is a formidable challenge to the physician, both in diagnosis and therapy. Anti- 
tussive therapy is classified as specific therapy when aimed at the established or presumed 
diagnosis of cough and non-specific therapy when the goal is to suppress the cough reflex (5).
In patients with chronic cough who are non-smokers, not on ACE-inhibitor treatment and 
have a normal chest radiograph -  the commonest causes of cough are asthma, post-nasal drip 
syndrome and gastro-oesophageal reflux disease. Table 1.8.1 depicts the commonest causes of 
cough in patients investigated in specialist clinics (6 ).
1.8.1 Importance of establishing a specific diagnosis of the cough
In general respiratory clinics chronic cough is considered one of the most difficult cases to 
treat and success rates are low(7), however, specialised cough clinics report high success rates 
of therapy (8 , 9, 32). The chief cause of this difference is a failure to consider the potential 
origin of the cough as being outside the lower respiratory tract (2 1 0 ).
Morice and committee members of the ERS Task Force describe the key to successful 
management is to establish a diagnosis and then treat the specific cause of cough (6 ). Chronic 
cough can often be due to more than one condition and treatment failures often result when 
this fact is not appreciated. In multiple prospective studies, it has been shown that chronic 
cough may be due to multiple causes from 18-62% of the time (8 , 14, 31, 34).
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1.8.2 Role of clinical history
It was generally believed that a carefully taken history, with detailed questioning about the 
character and timing of the cough would help in diagnosing the cause of cough. Mello and 
colleagues set up a study to specifically answer this question and found that the variability of 
character, timing or complications of cough could not lead to a specific diagnosis (2 1 1 ).
Specific questions to achieve a diagnosis of cough have a poor positive predictive value [52% 
for PNDS, 56% for asthma and 40% for GORD] (33).
1.8.3 Role of investigations
Chest X-ray and spirometry are primary tests for patients presenting with cough to a clinic. 
Specialised tests for chronic cough in the absence of any abnormality in chest radiography and 
lung functions include bronchial provocation testing, oesophageal pH monitoring, CT scan or 
X-ray of sinuses, bronchoscopy and high resolution CT scan of the chest. It is common to 
consider a response to specific therapy as an essential requirement for a diagnosis of cough, 
hence the value of performing these tests is in question.
Methacholine/histamine challenge test should be positive along with a response to specific 
therapy for a primary diagnosis of asthma (5). McGarvey and colleagues found that histamine 
challenge testing had a positive predictive value (PPV) of 8 8 % for a diagnosis of CVA (33).
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24 hour pH monitoring has a high negative predictive value for GORD as a cause of cough. 
PPV in a study by McGarvey and colleagues was 6 8 %. Palombini et al demonstrated a PPV of 
84% and negative predictive value (NPV) of 100% (14).
PNDS is a general term for any cause of rhinitis or sinusitis causing cough. Clinical 
examination has a PPV of 63% (33), radiological tests are not particularly sensitive (33) and 
treatment with sedative anti-histamines not very specific (6 ). Hence it is more difficult to 
make a precise diagnosis of PNDS as a cause of cough. Sinus CT scans in one study showed a 
PPV of 80% and NPV of 100% for this condition (14).
Flexible bronchoscopy adds little to the diagnosis of the cause of chronic cough with normal 
radiography (212). High resolution CT scans are useful in the diagnosis of bronchiectasis and 
should be performed when the cough does not respond to treatment for common conditions.
1.8.4 Management of the patient with chronic cough
Final diagnosis or diagnoses of the cause of the cough are usually based on defined pre­
treatment criteria (5) and accepted only when the cough significantly improves or disappears 
with specific therapy (8 ).
The American College of Chest Physicians (5) published an algorithm to help the 
management of patients with chronic cough (Figure 1.8.1) and recently, the European 
Respiratory Task Force (6 ) have published their recommendations (Figure 1.8.2).
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Diagnosing the cause of cough and treating it effectively can involve several investigations 
that are expensive and long treatment durations to achieve a cure. Balancing the cost with 
time to treatment success is a major challenge (6 ). A cost-effective analysis revealed that 
empirical treatment is the cheapest option but performing all investigations reduced the time 
to response (213). An appropriate combination of clinical history, investigations and 
therapeutic trials will be required. The choice ultimately depends on a combination of 
experience, facilities and resources.
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Figure 1.8.1: Guidelines from the American College of Chest Physicians 
Management of Chronic Cough (5)
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CHAPTER 2
HYPOTHESES AND AIMS OF THE STUDY
HYPOTHESES OF THE STUDY
The hypotheses of the study were
• Inhaled corticosteroids are effective in reducing symptoms in chronic persistent cough 
compared with a placebo inhaler.
• Non-invasive tests of airway inflammation can predict steroid responsiveness in chronic 
cough.
• There is airway inflammation in chronic cough with increased levels of inflammatory 
mediators which decreases following inhaled corticosteroid treatment.
• The quality of life is reduced in subjects with chronic persistent cough and improves 
following specific treatment of the cough.
• Extrathoracic airway hyperreactivity is present in the majority of patients with cough
• Clinical history will be useful in making a final diagnosis in chronic cough.
AIMS OF THE STUDY
The aims of this study were:
• To determine the efficacy of inhaled corticosteroids in patients with chronic cough that 
has persisted for over one year
• To assess the effect of this treatment on induced sputum cell counts, exhaled nitric oxide 
and carbon monoxide levels
• To assess the role of non-invasive tests of airway inflammation (induced sputum cell 
counts and exhaled gases) as predictors of a successful response to inhaled corticosteroid 
treatment in chronic persistent cough
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•  To measure inflammatory mediators in chronic cough (leukotriene B4, cysteinyl 
leukotrienes C4D4E4, interleukin-8 , myeloperoxidase, eosinophilic cationic protein, 
prostaglandin E2 and tumour necrosis factor-a) and the effect of inhaled steroids on these 
mediators
• To assess the role of neurotrophins (nerve growth factor, neurotrophin-3, brain derived 
neurotrophic factor) in chronic cough
• To assess the quality of life before and after specific therapy in patients with chronic 
cough
• To study the factors associated with extrathoracic hyperreactivity in chronic cough
• To judge the role of a clinical history in diagnosing the specific cause of chronic cough.
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CHAPTER 3
GENERAL METHODS AND MEASUREMENTS
3.1: ETHICAL APPROVAL AND STUDY DESIGN
Ethical approval
The study was submitted to the Ethics Committee of the West Glasgow Hospital NHS Trust 
and full approval was received. The study was discussed in detail with all subjects and each 
patient signed an informed consent form prior to participating in the study.
Study design
All other treatment for cough was omitted during the course of the study. The subjects entered 
a double-blind, randomised, placebo-controlled, crossover study where they received a two- 
week course of treatment with either an inhaled steroid (fluticasone accuhaler 500 meg bd) or 
a matching placebo inhaler. This was followed by a two-week washout phase where no 
treatment was administered and then a further 2 weeks of the inhaler not used initially. A 
diary was maintained at home on a daily basis where the severity of the cough was charted for 
the entire period of six weeks.
There were five visits for the study to complete the randomised crossover trial with inhaled 
corticosteroids versus placebo. Thereafter subjects were treated for their cough clinically, with 
two monthly visits as required.
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Visit schedule and tests performed at each visit:
Visit 1: Written informed consent, eligibility check, clinical history and examination; chest 
radiograph, flow volume loops and reversibility to inhaled salbutamol, cough severity score as 
in the cough diary; blood tests for IgE, blood counts and neurotrophin mediator levels, sputum 
induction, exhaled CO, eNO, nasal NO, quality of life questionnaires, diary given to patients 
for peak expiratory flow measurements and cough severity scale.
Visit 2 (1 week later): Methacholine provocation test for bronchial and extrathoracic
hyperreactivity; checked the cough diary; commenced placebo controlled cross-over trial of 
inhaled steroids.
Visit 3 (after 2 weeks): Cough diary checked; induced sputum, eNO and CO repeated; the 
washout period was initiated.
Visit 4 (after 2 weeks): Cough diary checked; induced sputum, CO and eNO repeated; the 
crossover inhaler started.
Visit 5 (end of steroid trial): Induced sputum, CO and eNO repeated; the cough symptom 
scores assessed.
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Further follow-up
All subjects were offered trials of specific therapy for their cough depending on the likely 
clinical diagnosis as well as further investigations as indicated. Quality of life questionnaires 
were repeated at the end of the study.
3.2: SUBJECTS
Subjects with chronic cough (cough persisting longer than one year) were identified and 
recruited from general respiratory clinics of the hospital (Gartnavel General Hospital, 
Glasgow). Further patients were recruited through contact with local general practitioners and 
by advertisement in a local newspaper.
Inclusion criteria:
1. History of chronic cough for at least one year.
2. Never smoker or ex-smoker for at least one year.
3. No known chronic respiratory condition to account for the cough
4. Clinical examination of the respiratory system, chest radiograph and spirometry not 
indicative of any lung disease
5. No history suggestive of an upper respiratory tract infection in the preceding six weeks
6 . No treatment with oral or inhaled corticosteroids for at least three weeks prior to inclusion
7. Willing to sign the informed consent form.
Exclusion Criteria:
1. Pregnancy or lactation
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2. Age below 18 years
3. Patients receiving angiotensin-converting enzyme inhibitors.
3.3: LUNG FUNCTION MEASUREMENT
FLOW VOLUME LOOPS
Flow volume loops were performed in all subjects using an electronic pneumotachograph 
spirometer (Vitalograph-Compact, Vitalograph Ltd, Buckinghamshire, UK), which achieves 
standards set by the American Thoracic Society (214) and European Respiratory Society 
(215). The spirometer was calibrated regularly using a fixed volume syringe, with correction 
for ambient temperature, and serviced once a year by the company engineers.
The definition of a maximal flow volume curve is the graphical presentation of the flow 
versus volume signal recorded from a maximal forced expiration, starting from full 
inspiration, which is immediately followed by a maximal inspiration. Subjects were requested 
to wear a nose-clip and breathe in to full inspiration through the mouth. They were then asked 
to blow out forcefully through the mouth-piece to full expiration and then inhale to full 
inspiration once again through the mouth piece to complete the expiratory and inspiratory 
arms of the flow volume loop (216). Once the subject had learnt the technique, three 
recordings were made and the best of three measurements was recorded for forced expiratory 
volume in one second (FEVi), forced vital capacity (FVC), maximum mid-expiratory flow or 
forced expiratory flow (FEF 25-75 or MMEF) and maximum mid-inspiratory flow (MIF50).
Values were expressed as a percentage of predicted value, adjusted for age and height (217).
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For the forced inspiratory flow predicted values, normal ranges are available only for males of 
different ages. For females, predicted values used are age-grouped as the normal data has not 
been accumulated in any large study (information on enquiry to Vitalograph, UK). For this 
reason, only the actual MIF values have been used for analysis in this study and not % 
predicted values.
Reversibility of FEVi to salbutamol was assessed using 2.5 mg nebulised salbutamol and 
repeating the flow volume loop in 15 minutes. The change in FEVi was calculated as a 
percentage of the pre-bronchodilator value using the formula:
[(post-salbutamol FEVi -  pre-salbutamol FEVi ^  pre-salbutamol FEVi) X 100].
PEAK EXPIRATORY FLOW (PEF)
All patients were asked to maintain a peak flow diary (appendix 1) for a week to record their 
morning and night PEF. Patients were asked to stand or sit upright and blow forcefully into 
the Mini-Wright’s peak flow meter (Clement Clarke, Harlow, UK) and the best of three 
readings was recorded in the diary card. PEF was expressed as litres/minute. Percentage 
lability was calculated using the formula (218):
[(maximum PEF of the day -  minimum PEF of the day mean PEF) X 100]
Dividing by the mean value helps to normalise the amplitude for differences in body size 
(height, gender and age) and for the degree of baseline obstruction. The upper limit of peak 
flow lability is 19% for adults (219), hence a variability of 20% was considered positive in 
this study.
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3.4: BRONCHIAL PROVOCATION TESTS
BRONCHIAL HYPERRESPONSIVENESS (BHR)
Bronchial hyperresponsiveness was measured using the methacholine challenge test similar to 
the technique described by Cockcroft et al (220). Histamine or methacholine administered by 
nebulisation using incremental doubling doses with measurement of lung function at each 
dose allows a dose-response curve to be established and a threshold response can be 
identified. This allows quantification of the response, expressed as the provoking 
concentration (PC) of the bronchoconstrictor substance required to produce a given change in 
lung function and is calculated by linear interpolation.
We used methacholine (an acetylcholine analogue) as the challenging agent in concentrations 
of 1, 2, 4 and 8  mg methacholine diluted in phosphate buffered saline [acetyl-p methyl choline 
chloride; Sigma Chemical Company, Poole, Dorset, UK; made up in phosphate buffered 
saline to pH 7.4. by the Sterile Pharmacy, Western Infirmary]
Aerosols were generated using a Wright nebuliser and subjects inhaled this aerosol by normal 
tidal breathing via the mouth. The nebuliser contained 3 ml of nebulisate and was driven by a 
continuous airflow of 9 1/m from a compressed air source o f 50 lbs/inch (345 kPa), calibrated 
to deliver an output of 0.13 ml/min (2 2 1 , 2 2 2 )
A flow volume loop was measured as previously described. Subjects then inhaled phosphate 
buffered saline for two minutes with FEVi recorded at 30, 90 and 180 seconds following
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inhalation. The lowest post-saline value for FEV i was then used as the baseline from which 
subsequent falls are calculated. At five-minute intervals the subjects received two-minute 
nebulised inhalations of doubling doses of methacholine, starting at 1 mg/ml. Inhalations were 
continued until the FEVi fell by more than 20% and the PC2 0FEV1 was then calculated by 
linear interpolation (223). If any subject had bronchoconstriction, they received inhaled 
salbutamol at the end of the procedure to reverse this effect.
A fall in FEVi of ^ 20% at a methacholine concentration of < 8  mg/ml was accepted as 
bronchial hyperresponsiveness.
EXTRATHORACIC AIRWAY HYPERRESPONSIVENESS (EAHR)
This was an additional measurement during the methacholine challenge test to assess upper 
airway hyper-reactivity. The maximum mid-inspiratory flow (MIF50) was recorded during 
each of the flow volume loops performed for the methacholine challenge test. As MIF50 can 
be influenced by anxiety or defensive glottic closure, a positive test required a decrease in a 
dose-dependent manner.
Extra thoracic airway threshold was expressed as the methacholine concentration causing a 
25% drop in MIF50 (PC2 5MIF50) and the concentration of 8  mg/ml was expressed as the cut­
off to define extrathoracic airway hyperresponsiveness (207, 224).
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3.5: MEASUREMENT OF EXHALED NITRIC OXIDE, CARBON MONOXIDE AND 
NASAL NITRIC OXIDE
Exhaled nitric oxide was measured using a Logan Research Analyser (LR2000, Logan 
Research Ltd, Rochester, Kent, UK) which utilises the principle of chemiluminescence. The 
equipment has a detection range from < 1 to 5000 parts per billion (ppb), accuracy of ±2 ppb 
and a response time of < 2 seconds. The sampling rate was 250 ml/min. The measurements 
are repeatable within a coefficient of variation < 10%. The equipment was calibrated regularly 
against a standard gas mixture containing 96 ppb of nitric oxide (BOC Special Gases, Surrey 
Research Park, Guildford, UK). The equipment was fitted with bacteriological and system 
protection filters which were changed frequently to prevent contamination.
The technique was based on the recommendation of the European Respiratory Society Task 
Force (81). The measurement of exhaled NO was achieved by performing an exhalation 
manoeuvre (wearing a nose clip) from total lung capacity for 15 to 2 0  seconds with a constant 
flow (5 to 6  L/min) and exhalation pressure (3 ± 0.4 mmHg) [figure 3.5.1]. This closes the 
soft palate and prevents nasal contamination of the sample. The value corresponding to the 
plateau at the end of expiration was recorded. All readings were performed in triplicate and 
mean values were calculated.
Nitric oxide within the exhaled air reacts with ozone produced within the machine, with the 
production of nitrogen dioxide in an excited state. In returning to a stable base state, 
electromagnetic radiation with a wavelength of 600-3000 nm in released and detected by a
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photomultiplier tube. There is a direct relationship between nitric oxide concentration and 
radiation detected. A continuous reading is produced, with all parameters measured every 40 
milliseconds, and the concentration o f nitric oxide recorded when at a stable level in late 
expiration. Expired carbon dioxide and flow rates are monitored to ensure a satisfactory 
manoeuvre and that the reading is taken from exhaled alveolar air rather than dead space gas.
Figure 3.5.1: Procedure fo r  measurement o f  exhaled nitric oxide
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CARBON MONOXIDE
Exhaled carbon monoxide (CO) was measured simultaneously using a modified 
electrochemical cell with a device integrated into the chemiluminescence analyser described 
above for measurement of exhaled nitric oxide (CO option, LR2000, Logan Research Ltd., 
Rochester, Kent, UK). It was sensitive to CO from 0 to 50 parts per million (ppm), adapted for 
online recording of CO concentration and also equipped for measurement of exhaled volume, 
sample pressure, NO and CO2 . Subjects wore a nose clip and were asked to exhale from total 
lung capacity without breath holding into a Teflon tube at a constant flow of 5 L/min. A point 
measurement of CO at 75% of exhaled volume was used as a measure of lower respiratory 
tract CO. All readings were performed in triplicate and mean values were calculated. The 
methods used to measure exhaled NO and CO complied with the ERS Task Force guidelines.
3.6 NASAL NITRIC OXIDE
This was measured by the same machine used for eNO (LR2000, Logan Research Ltd., 
Rochester, Kent) with a teflon tube inserted into one of the nares during breath holding after a 
maximal inhalation. This manoeuvre achieved soft palate closure and allowed analysis of the 
local NO concentration with free flow of ambient air from one nostril to the other and 
subsequent direction into the analyser. Nasal NO was recorded as the plateau for NO 
concentration during this manoeuvre. All readings were performed in triplicate and mean 
values were calculated.
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3.7: INDUCED SPUTUM TESTING
Procedure of sputum induction:
Sputum was induced using a modification of the method of Pin et al (71). Subjects were pre­
treated with 2 0 0  jug salbutamol administered through a metered dose inhaler and large volume 
spacer device to minimise bronchoconstriction. Sputum was then induced using 3% 
hypertonic saline administered through a nebuliser (Sonix 2000, Medix Ltd, Harlow, 
Essex,UK) over a period of 20 minutes (nebuliser output 0.9 ml/min; mass median diameter 
5.5 micrometer) [figure 3.7.1]. Subjects were encouraged to expectorate into a sterile 
container at any time during the procedure. Spirometry was performed every 5 minutes to 
confirm there was no adverse effect on lung functions. If FEVi fell by 20% or more, or if 
troublesome symptoms occurred, the nebulisation was stopped. The sample was transferred to 
the laboratory on ice as soon as possible, and in all cases in < 2  hours.
|
|
I
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Figure 3.7. / : Procedure o f sputum induction
Processing of sputum samples
T he procedure o f  processing sputum samples was similar to that described by Popov et al 
(225). In the laboratory, the whole sample o f sputum and saliva was transferred to a petri dish 
and the macroscopic characteristics recorded. Sputum plugs from samples were selected out, 
if necessary using an inverted microscope, to minimise salivary contamination. The selected 
portion was weighed and treated with 4 times the volume o f fresh dithiothreitol (DTT) 
(‘Sputolysin’, Calbiochem-Novabiochem (UK) Ltd, Nottingham, UK) in a balanced salt 
solution (Sputolysin 10%; Calbiochem-Novabiochem (UK) Ltd, Nottingham, UK) diluted to
0.1% with distilled water.
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The sample was briefly vortexed (15s) and agitated on a bench rocker for 15minutes. A 
further 4 times the initial volume of dulbeccos phosphate buffered saline was added to give a 
final concentration of 0.05% DTT. The sample was filtered through a 50micron nytex mesh 
(R. Cadoch & Sons, London, UK) to remove residual clumps and a total cell count was done 
using a Neubauer haemocytometer and a trypan blue exclusion test for cell viability were 
carried out. An aliquot was removed and a lx l0 6 cells/ml suspension prepared to make two 
cytospin slides using a Shandon III cytocentrifuge (Shandon, Cheshire, UK) at 450 rpm for 6  
minutes.
The slides were air dried and stained with Giemsa stain to allow a cell differential count to be 
performed. This was expressed after exclusion of squamous epithelial cells that are taken to 
represent salivary contamination. The criterion for rejection of samples was if the viability 
was < 40% or squamous cell contamination was > 20%. (No samples were rejected on these 
criteria). Viability was typically >70% and squamous cell count usually <10%. The bronchial 
epithelial cell count was very low in all samples, typically <2%). The remaining sputum 
suspension was centrifuged at 4000 rpm for 5 minutes and the resulting supernatant stored at 
-70°C prior to mediator assays. Figure 3.7.2 describes this procedure graphically.
Normal values for the induced sputum cell counts in experiment 1 were based on reference 
values obtained from large cohorts of healthy individuals (81, 226) and confirmed to be 
similar to our laboratory values by measuring them in 50 healthy controls prior to this study. 
Cut-off values at the upper limits of normality were: total sputum cell count 8  xlO6, sputum 
eosinophils 2%, neutrophils 53% and lymphocytes 3%.
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Figure 3.7.2. Laboratory processing of samples of induced sputum
(adaptedfrom Pavord et al, 1997 (67)
1. Select viscid portion of sputum (using inverted microscope if necessary)
2. Weigh and incubate with 4x volume of 0.1% dithiothreitol (DTT)
3. Gently aspirate with pasteur pipette, vortex for 15 seconds
4. Rock on bench rocker for 15 minutes
5. Mix with equal volume (to DTT) of Dulbecco’s phosphate Buffered saline (D-PBS)
6 . Rock for 5 minutes
8 . Filter using 48pm nylon gauze
9. Centrifuge for 10 minutes
10. Store supernatant to measure fluid phase component
11. Total cell count and assess viability; discard if low viability (<40%)
12. Resuspend cell pellet in D-PBS
13. Adjust cell suspension to 1 x 106 cells per ml
14. Prepare cytospins for differential cell counts
3.8: MEASUREMENT OF INFLAMMATORY MEDIATORS
Inflammatory cytokines from the sputum supernatant were measured using commercially 
available kits. All tests were performed according to the manufacturer’s instructions.
Mediators measured using radio-immunoassay were ECP and MPO (Pharmacia UK Ltd, 
Milton Keynes, UK). The other mediators were measured by their immunoreactivity in 
sandwich enzyme immunoassay: IL- 8  and TNF-a (IDS, Boldon, Tyne and Wear, UK), PGE2 
and LTB4 (R&D Systems, Abingdon, UK)] and cysteinyl leukotrienes (LTC4 /D4/E4) 
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
Typical sensitivities of the assays were for IL- 8  (25pg/ml), TNF-a (lOpg/ml), PGE2 (36.2 
pg/ml), LTB4 (19.5 pg/ml), ECP (2 pg/ml), MPO (< 8  pg/ml) and Cys-LT (10 pg/ml). The 
precision of the assays was described by the within-plate and between-plate coefficients of 
variation, which across the concentration ranges of the study were, for TNF-a (< 1.0% and < 
3.1%), IL- 8  (< 2.1% and < 6.2%), Cys-LT (both < 8 .6 %), LTB4 (<6.9% and <16.7%), ECP (< 
11% and <9.2%), MPO (< 8.4% and 12.4%) and PGE2 (< 5.2% and < 17.6%) respectively. 
The cross-reactivity of the prostanoid assays was as follows. Cys-LT assay: for LTC4 (100%), 
LTD4 (115%), and for LTE4 62.7%; the cross-reactivity with the other main prostanoids was < 
1.2%. LTB4 assay: for 6 -trans-1 2 -epi-LTB4 [5.5%], and for 6 -trans-LBT4  [4.9%]; the cross­
reactivity with the other main prostanoids was <0.2%. PGE2 assay: for PGEi [70%], and for 
PGE3 [16.3%], the cross-reactivity with the other main prostanoids was <1.0%.
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Nerve growth factor (NGF) was measured with an enzyme immunoassay (Promega, UK). It 
was measured using an antibody sandwich ELISA. The mouse anti-human NGF antibody was 
used to coat flat-bottomed 96 well plates (Immunol 4). Any NGF present in the samples under 
analysis was captured during incubation on the immobilised anti human NGF. Following 
washing to remove any unbound NGF, the addition of biotinylated goat anti-human NGF 
bound the captured NGF. After washing, streptavidin conjugated to Horseradish peroxidase 
(HRP) bound the sandwich complex during incubation. A coloured substrate, TMB, was 
added and the amount of specifically bound NGF present in the samples under analysis was 
proportional to the resulting colour. This was quantified against a standard curve of known 
amounts of NGF. The reaction was stopped with IN HCL and the absorbance recorded at 450 
nm on a plate reader. The sensitivity of the kit was 15.6 pg/ml.
Neurotrophin-3 (NT-3) and brain derived neurotrophic factor (BDNF) were measured 
using a similar technique with an ELISA kit (Promega, UK). Sensitivity of the kit for NT3 
was 10 pg/ml and 15.6 pg/ml for BDNF.
For nerve growth factor the performance characteristics of the assay were: intra-assay co­
efficient of variation less than 4.3%, sensitivity 15.6 pg/ml, and less than 3% cross-reactivity 
with other neurotrophic factors. For BDNF the performance characteristics were: intra-assay 
CV less than 8.9%, sensitivity 15.6 pg/ml, and less than 3% cross-reactivity with other 
neurotrophic factors. For NT-3 the performance characteristics were: intra-assay CV less than 
5.3%, sensitivity 10 pg/ml, and less than 3% cross-reactivity with other neurotrophins.
67
3.9: BLOOD TESTS:
Serum IgE Levels:
Total serum IgE and IgE to common allergens (house dust mite, grass pollen and cat dander) 
were measured by enzyme immunoassay (Unicap System, Pharmacia UK Ltd, Milton Keynes, 
UK). Total IgE > 120 IU/L and specific IgE >0.35 IU/L were considered positive.
Cell counts:
The total and differential white blood cell counts were measured by an automated cell counter 
(SE9500, Sysmex UK Ltd, Milton Keynes, UK), with our standard laboratory values used as 
control values.
3.10: COUGH SEVERITY VISUAL ANALOGUE SCALE
Subjects were asked to enter the severity of cough on a 10 cm visual analogue scale, with 0 
being the best cough and 10 the most severe. This scale was incorporated in their daily diary 
card (appendix 2 ) for the 6  weeks of the cross-over study.
3.11: QUALITY OF LIFE QUESTIONNAIRES
All subjects were asked to complete 2 sets of questionnaires, the St. George’s Respiratory 
Questionnaire and the Hospital Anxiety and Depression Scale at baseline and after final 
treatment of cough.
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St. George’s Respiratory Questionnaire (SGRQ) [appendix 3]: has 76 weighted items divided 
into 3 sections: Symptoms (distress caused by respiratory symptoms), Activity (physical 
activities that cause or are limited by breathlessness) and Impact (aspects concerned with 
social functioning and psychological disturbances resulting from airway disease) (191). A 
score is calculated for each section as well as a total score derived from all items. The scoring 
uses a 0-100 scale, with the highest scores indicating the poorest level of health. It takes 
approximately ten minutes to complete. The SGRQ was designed so the scores would have an 
‘absolute’ property and be independent of patient and study (191).
Hospital Anxiety and Depression Scale (HADS) [appendix 4]: is a self-administered 
questionnaire consisting of 14 items, with 7 items each for the sub-scales of anxiety and 
depression, using a 0-3 scale for each question. The range of scores for each sub-scale is 0-21, 
with higher scores indicating greater emotional distress. Scores of 7 or less represent non­
cases, 8-10 indicate possible cases and scores of 11 or more definite cases (227).
3.12: FINAL DIAGNOSIS OF COUGH
On completion of the cross-over study, to achieve a final diagnosis for the cause of the cough, 
all subjects were offered sequential trials of specific therapy depending on the likely clinical 
diagnoses for their cough. Final diagnosis or diagnoses of the cause of the cough were based 
on defined pre-treatment criteria (5) and accepted only when the cough significantly improved 
or disappeared with specific therapy (8 ).
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Pre-treatment diagnostic criteria:
Certain pre-treatment criteria were set to aid the preliminary diagnoses of cough.
Asthma: History of cough with or without paroxysmal dyspnoea and wheeze or evidence of 
reversible airflow obstruction (15% improvement in FEVi following salbutamol) and/or >/= 
2 0 % lability on peak flow readings. The PC2 0  on methacholine challenge testing was < 8  
mg/ml.
Post nasal drip syndrome: Any one of the following on history or examination: sensation of 
something dripping down the throat, nasal discharge, need to clear the throat frequently, 
mucoid/mucopurulent nasal secretions on examination or cobblestone appearance of the oro­
pharyngeal mucosa.
Gastro-oesophageal reflux disease: History of heartburn and/or acid regurgitation. 
Bronchiectasis: History of cough with large volumes of sputum production.
Eosinophilic bronchitis was considered when sputum eosinophilia > 2%, normal PEF 
variability, spirometry and methacholine challenge test.
Final diagnosis
The final diagnosis was based on the above criteria and a response to appropriate treatment. 
When the cause of cough was unknown, it was termed ‘Idiopathic cough ’.
Treatment plan:
All patients were treated with medication for their cough, starting with the most likely 
diagnosis based on their history and baseline tests as above. As cough is known to be
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frequently due to multiple causes, for each patient a plan was drawn up with a list of potential 
diagnoses and the order in which to treat them.
Treatment trials were done sequentially, for two months each, with the clinical response noted 
to each treatment. This was based on the patient’s view of the effectiveness of the treatment in 
reducing their cough compared to their baseline level prior to that treatment trial.
The treatment responses were noted as
Very good response: if the improvement was between 75-100%
Good response: if the improvement was between 50-75%
Minimal response: if the improvement was between 25-50%
No response: if the improvement was <25%.
A final diagnosis was made when there was a ‘very good’ response to treatment.
If the response was ‘good’, then patients were asked to continue with further treatment trials, 
until the cough resolved. If subjects declined further treatment, then the final diagnosis of the 
cause of cough would be accepted based on a ‘good response’ to treatment. If a subject had 
good responses to two treatment lines, then a combined diagnosis was made with the primary 
diagnosis being the one for which there was a better therapeutic response.
If there was ‘minimal’ or ‘no response’ to treatment, patients were requested to continue with 
further treatment trials using alternative medication. If they declined further treatment at any 
stage, the cause of cough was considered idiopathic.
A high resolution CT scan was performed prior to confirming a diagnosis of bronchiectasis.
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Therapy used for the common causes of cough:
For each of the common conditions, a plan of treatment was made. First line therapy was used 
initially, if possible, in all subjects. Second line therapy was used when the first line treatment 
did not work or was not suitable for an individual patient based on adverse events or contra­
indications due to other medical conditions. Third line therapy was very occasionally used to 
tailor to the requirements of an individual patient and consisted of a combination of first and 
second line treatment.
a. Gastro-oesophageal reflux disease:
First line therapy for GORD (GORDi):Specific first line therapy used for GORD was oral 
omeprazole 2 0  mg bid for a month, followed by 2 0  mg od for a second month along with 
advice on life-style alterations to reduce acidity, including elevation of the head end of the bed 
and alterations in diet.
Second line therapy for GORD (GORD2):
This was a combination of metoclopramide and ranitidine for two months along with advice 
on life-style alterations to reduce acidity.
b. Cough variant asthma and eosinophilic bronchitis 
First line therapy for CVA and EB (CVAi and EBi):
Inhaled corticosteroid (budesonide turbohaler) was prescribed at a dose of 400 meg bid for 
two months along with a short acting beta2 agonist as required for asthma.
Second line therapy for CVA (CVA2 ):
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Inhaled corticosteroid dose was 800 meg bid for two months along with a short acting beta2 
agonist as required for asthma.
c. Post nasal drip syndrome
First line therapy for PNDS (PNDSi):
A combination of a local nasal decongestant (pseudo-ephedrine drops, 2-3 drops to each 
nostril, tid) for a week, along with two months of intra-nasal corticosteroid (mometasone, 50 
mcg/day, 2  sprays od) and an oral non-sedating anti-histamine (loratadine 1 0  mg od).
Second line therapy for PNDS (PNDS2):
This comprised of three weeks of an oral decongestant (pseudo-ephedrine, 60 mg tid) and a 
first generation antihistamine (brompheniramine maleate, 4 mg tid).
Subjects were treated with first and second line treatment for each of the common causes of 
cough. A high resolution CT scan of the chest, CT scan of the sinuses and an oesophageal pH 
monitoring test were performed if the patient was agreeable, to look for a specific diagnosis 
for the cough.
3.13: DATA HANDLING AND STATISTICAL ANALYSIS
The baseline characteristics of the cough patients were compared with either a normal 
comparator group or cut-off values, using appropriate tests. Correlation amongst the baseline 
factors was examined by Spearman-rank correlation coefficients. The response to inhaled 
steroids was calculated for each variable in turn by first removing the effect of baseline from
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the post treatment and post placebo periods. The differences of these differences were then 
calculated by subtracting the placebo effect from the treatment effect. The responses were 
analyzed by one-sample t-tests, and the corresponding 95% confidence intervals were 
calculated. This method was used because many of the underlying variables were not suitable 
for ANOVA analyses due to non-normality.
The study was adequately powered, as with a sample size of 6 8 , the study would have 90% 
power to detect a within-subject change of one unit on the VAS scale, assuming a standard 
deviation of 2.5, and using a two-tailed test at the five percent significance level.
The treatment difference for the cough VAS scale was modelled by regression analyses to see 
if any of the baseline factors could predict steroid responsiveness.
The analysis of the study was conducted with Dr. Alex McMahon of the Robertson Centre for 
Bio-statistics at the University of Glasgow, using a computerised statistical package, SAS 
version 8 .0 2 .
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CHAPTER 4
INDIVIDUAL EXPERIMENTS, RESULTS AND DISCUSSION
“ W h e n  y o u  c a n  m e a s u r e  w h a t  y o u  a r e  s p e a k i n g  a b o u t  a n d  e x p r e s s  i t  i n  
n u m b e r s , y o u  k n o w  s o m e t h in g  a b o u t  i t  B u t , w h e n  y o u  c a n n o t - y o u r  
k n o w l e d g e  i s  o f  a  m e a g r e  a n d  u n s a t i s fa c t o r y  k i n d ”
L o r d  K e l v in , B r i t i s h  p h y s i c i s t
Chapter 4.1
EFFECT OF INHALED CORTICOSTEROIDS ON SYMPTOM SEVERITY AND 
SPUTUM MEDIATOR LEVELS IN CHRONIC PERSISTENT COUGH
INTRODUCTION
Chronic cough has a reported prevalence of between 14-23%, and is associated with 
considerable morbidity including sleep loss, impaired performance of daily activities and 
considerable social disability (10, 184, 185). The diagnosis and management of chronic cough 
is often unsatisfactory. In non-smokers with a normal chest radiograph, the most frequent 
causes identified are postnasal drip syndrome (PNDS), gastro-oesophageal reflux disease 
(GORD) and cough variant asthma (CVA) (8 , 32, 34). Several algorithms have been 
developed for investigating the cause of chronic cough, involving a series of investigations 
and/or trials of empirical treatments (8 , 33, 34). However, despite these attempts, in a 
significant proportion of patients (12-40%), the specific cause of the cough is not established 
(32, 33, 35, 110). Patients presenting with chronic cough have often had symptoms for many 
years (33, 35, 110). In clinical practice, inhaled corticosteroids are often used empirically 
when patients first present with a chronic cough. The value of inhaled corticosteroids in 
patients with chronic cough that has persisted for over one year is not known.
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Airway inflammation is usually a common underlying feature of all the main causes of cough, 
such as asthma, rhino-sinusitis, gastro-oesophageal reflux disease or angiotensin-converting 
enzyme (ACE) inhibitor induced cough (40-42, 51). Eosinophil and/or neutrophil numbers in 
the airways can be elevated in patients with chronic cough (40, 41). The type of airway 
inflammatory cell present in an individual patient presenting with chronic cough, may help to 
predict the response to corticosteroids (60), as occurs in patients with asthma (65) and COPD 
(6 6 ). Inflammatory mediators within the airways are elevated in specific groups of patients 
with cough, such as IL- 8  and TNF-a in non-asthmatic patients with chronic dry cough (51), 
cys-LT and ECP in eosinophilic bronchitis (44). Recently, Birring et al demonstrated elevated 
levels of mast cell derived mediators in all causes of cough, where the main groups of subjects 
were cough variant asthma, eosinophilic bronchitis and idiopathic cough (45). The effect of 
inhaled corticosteroids on pro-inflammatory mediators in cough is unknown. Exhaled nitric 
oxide (eNO) and exhaled carbon monoxide (CO) have been used as markers of airway 
inflammation in various respiratory conditions, especially asthma, and have been shown to be 
responsive to corticosteroids (8 8 , 96). Their value as predictors of corticosteroid 
responsiveness in chronic cough has not been determined.
The aims of this study were to determine the efficacy of inhaled corticosteroids in patients 
with chronic cough that has persisted for over one year and to assess the effect of this 
treatment on induced sputum inflammatory mediators, cell counts, exhaled nitric oxide and 
carbon monoxide levels. The secondary aims were to assess the role of non-invasive tests, 
such as induced sputum cell counts and exhaled gases as predictors of a successful response to 
inhaled corticosteroid treatment in chronic persistent cough.
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METHODS
Study design
Adults with a cough persisting for longer than one year were recruited from hospital 
respiratory clinics and by advertisement in a local newspaper. No subject had evidence of any 
other lung disease based on history, clinical examination, chest radiography and spirometry. 
Details of study design are included in the general methods section, chapter 3.
This was a double-blind, randomised, placebo-controlled, crossover study where subjects 
were treated with inhaled fluticasone accuhaler 500 meg or matching placebo, twice daily, for 
14 days, with a 2-week washout phase in between. All other treatment for cough was omitted. 
A daily cough diary was maintained by the patient to chart the cough severity. A computer 
generated randomisation sequence was used with random numbers allocated consecutively. 
The randomisation code was withheld from the investigators until completion of the study. 
The study medication was packed by the central pharmacy according to the randomisation 
code and was identical in appearance and taste.
On completion of the cross-over study, to achieve a final diagnosis for the cause of the cough, 
all subjects were offered sequential trials of specific therapy depending on the likely clinical 
diagnoses for their cough. Final diagnosis or diagnoses of the cause of the cough (described in 
chapter 3) were based on defined pre-treatment criteria (5) and accepted only when the cough 
significantly improved or disappeared with specific therapy (8 ).
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Measurements
The primary outcome measure for improvement in the cough was a cough severity visual 
analogue scale (a linear scale with 0 cm = no cough to 10 cm = worst cough). Patients were 
asked to enter the number of puffs administered of the study inhalers into their daily diary 
card (as 1 or 0), morning and night. The number of inhalations left in the accuhaler device 
used for fluticasone and placebo were recorded as an indicator of adherence to medication.
Details of measurement techniques are included in the general methodology section, chapter
3. Investigations performed were:
■ Pre-and post inhaled salbutamol FEVi
■ Total serum IgE and IgE to common allergens
■ Total and differential white blood cell counts
■ Bronchial challenge testing with methacholine
■ Sputum induction with 3% hypertonic saline (at 4 visits). The supernatant was frozen 
at -70° C for subsequent mediator measurements. Normal values for the induced 
sputum cell counts and exhaled gases were based on reference values obtained from 
large cohorts of healthy individuals (81, 226) and confirmed to be similar to our 
laboratory values by measuring them in 50 healthy controls prior to this study. Cut-off 
values at the upper limits of normal were: total sputum cell count 8  xlO6, sputum 
eosinophils 2%, neutrophils 53% and lymphocytes 3%.
■ Exhaled nitric oxide (eNO) and exhaled carbon monoxide (CO) were measured at all 
visits. Exhaled NO was considered elevated above 9 ppb and CO above 4 ppm.
■ Mediators in induced sputum:
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■ ECP and MPO were measured using radio-immunoassay
■ IL-8 , TNF-a, PGE2 , LTB4 and cysteinyl leukotrienes (LTC4/D4/E4) were
measured by their immunoreactivity in sandwich enzyme immunoassay:
Healthy volunteers were recruited from hospital staff to perform induced sputum to obtain 
control levels for the mediator measurements.
Statistical Methods
The baseline characteristics of the cough patients were compared with either a normal 
comparator group or cut-off values, using appropriate tests. Correlation amongst the baseline 
factors was examined by Spearman-rank correlation coefficients. The response to inhaled 
steroids was calculated for each variable in turn by first removing the effect of baseline from 
the post treatment and post placebo periods. The differences of these differences were then 
calculated by subtracting the placebo effect from the treatment effect. The responses were
analysed by one-sample t-tests, and the corresponding 95% confidence intervals were
calculated. This method was used because many of the underlying variables were not suitable 
for ANOVA analyses due to non-normality. The study was adequately powered, as with a 
sample size of 6 8 , the study would have 90% power to detect a within-subject change of one 
unit on the VAS scale, assuming a standard deviation of 2.5, and using a two-tailed test at the 
five percent significance level. The treatment difference for the cough VAS scale was 
modelled by regression analyses to see if any of the baseline factors could predict steroid 
responsiveness. All analyses were carried out using SAS version 8.02.
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RESULTS
Baseline subject characteristics and investigations
We screened 120 subjects with cough, 93 of whom met all the inclusion criteria and were 
randomised; 8 8  completed all study visits. Of these, 52 were recruited from the community 
(GP referrals and advertisement in a newspaper) and 36 were referred from hospital clinics. 
Five subjects dropped out due to inability to attend for all study visits.
A final diagnosis for the cough was obtained in 78/88 (89%) of subjects; 74% had a single 
diagnosis, 24% had 2 diagnoses and 2% had 3 diagnoses. The pattern of primary diagnoses 
(figure 4.1.1) was PNDS (30), GORD (18), CVA (13), bronchiectasis (9), eosinophilic 
bronchitis (5), habitual cough (2) and bronchitis (1). In 10 subjects, the cough was termed 
idiopathic. Baseline characteristics of the patients are shown in table 4.1.1. Individual data for 
the smaller diagnostic sub-groups are not depicted because the numbers were too small for 
meaningful analysis.
An adequate sample of sputum for differential cell counts was obtained in 70 chronic cough 
subjects (80%). All were able to perform the eNO and CO tests adequately. The results of the 
non-invasive tests are depicted in Table 4.1.2. The total sputum cell count, sputum neutrophil 
proportion and eNO were elevated in subjects with chronic cough, compared to cut-off values. 
The sputum eosinophil proportion correlated significantly with the eNO levels (r=0.43, 
p<0.001) and the total cell count correlated with the neutrophil proportion in sputum (r=0.48, 
p<0.001). There was no significant correlation between neutrophils in induced sputum and
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age of the patient (r=0.249, p=0.225) or duration of cough (r = -0.013, p=0.916). The total and 
differential blood cell counts were within the normal range (table 4.1.3).
Mediators at baseline were measurable in 61/88 subjects and 12/17 controls (table 4.1.4). 
Mean age (SD) of controls was 41 (11) years. LTB4 , cys-LT and PGE2 were significantly 
elevated in all causes of cough. IL-8 , MPO and TNF-a were elevated only in bronchiectasis 
(Figures 4.1.2 -  4.1.8 ).
Response to inhaled corticosteroids
There was a significant difference in the cough VAS scales pre- and post- fluticasone 
compared to pre- and post- placebo [difference of differences (95%CI) 1.0 (0.4, 1.5), p<0.001] 
(Figure 4.1.9). The mean (95%CI) % change in VAS was 22.3% (-3.5, 48.2). There was no 
carry-over effect of active treatment. Compliance was >90% with fluticasone and placebo 
inhalers. Sputum ECP levels, eNO and CO showed a significant reduction following inhaled 
corticosteroids. The mean difference (Cl), p value was [-2.1 (-3.56,-0.64), p=0.005] for eNO, 
[-0.34 (-0.6, 0.04), p=0.025] for CO and [-396 (-753, 39), p=0.031] for ECP (figure 4.1.10). 
There was no significant difference in the other mediators following treatment (figures 4.1.11 
-4.1.16). For the individual causes of cough, there was no significant change in sputum cell 
counts, cys-LT, LTB4, PGE2 , IL-8 , TNF-a and MPO following treatment (tables 4.1.5, 4.1.6), 
except for a reduction in sputum eosinophils in CVA and IL- 8  levels in bronchiectasis.
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Predictors of inhaled corticosteroid responsiveness
Exhaled NO (R2 0.152, p < 0.001), sputum eosinophils (R2 0.08, p=0.019), sputum ECP (R2 
0.064, p=0.05), cys-LT (R2 0.07, p=0.039) and total IgE levels (R2 0.07, p=0.022) were 
significant predictors of corticosteroid responsiveness (table 4.1.7, figure 4.1.17) . The other 
mediators and cell counts had no predictive value for this response. Factors unrelated to 
corticosteroid responsiveness were age, gender, duration of cough, baseline cough VAS level, 
positive specific IgE levels, FEVi% predicted, previous smoking history and whether the 
patient entered the study through the community or hospital clinics. Only one subject had 
received a course of oral corticosteroids in the past. Forty-eight subjects had previously 
received inhaled corticosteroids in varying doses and durations of treatment. There was no 
significant difference in response to fluticasone in those who had received inhaled 
corticosteroids in the past compared to those who had never received this treatment earlier 
(R2= 4%, p = 0.069).
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Figure 4.1.1: Patterns of Primary Diagnosis in Chronic Cough
PNDS=post-nasal drip syndrome, GORD=gastro-oesophageal reflux disease, Bronch=bronchiectasis, 
Eos bronch =  eosinophilic bronchitis, Idio=idiopathic cough
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Figure 4.1.2: L T B 4 levels [mean (SD)] in induced sputum in different causes
of chronic cough
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Figure 4.1.3 : Cysteinyl leukotriene levels [mean (SD)J in induced sputum in different
causes of chronic cough
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Figure 4 .1.4 : Prostaglandin E2 levels [mean (SD)] in induced sputum in different causes
of chronic cough
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Figure 4.1.5 : Eosinophilic cationic protein levels [mean (SD)[ in induced sputum in
different causes of chronic cough
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Figure 4.1.6: Myeloperoxidase levels [mean (SD)[ in induced sputum in different causes of
chronic cough
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Figure 4.1.7: Tumour necrosis factor-a levels [mean (SD)J in induced sputum in different
causes of chronic cough
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Figure 4.1.8: Interleukin- 8  levels [mean (SD)] in induced sputum in different causes
of chronic cough
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Figure 4.1.9: Change in cough visual analogue scale following fluticasone compared to
placebo
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Mean visual analogue scale (VAS) for cough severity measured on a 10 cm scale, following 
inhaled fluticasone (hatched box) compared to placebo (clear box).
The boxes represent the inter-quartile range, with the extended lines representing the 
maximum and minimum values. The mean (+) and the median (-) values o f  the VAS are 
depicted in the figure, p  <0.001 is the difference o f differences fo r  treatment with placebo 
compared to fluticasone.
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Figure 4.1.10: Eosinophilic cationic protein in induced sputum following inhaled
fluticasone compared to placebo
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Figure 4.1.11: Cysteinyl leukotrienes in induced sputum following inhaled fluticasone
compared to placebo
p=0.319
p=0.127 p=0.9853500
3000 -
2500 -
>* 1500 -
1000  -
500 -
Before After
Inhaled placebo
Before After
Inhaled fluticasone
The box represents the interquartile range, the +  the mean value and -  the median value.
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Figure 4.1.12: Leukotriene B4  in induced sputum following inhaled fluticasone compared
to placebo
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Figure 4.1.13: Prostaglandin E2 in induced sputum following inhaled fluticasone
compared to placebo
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The box represents the interquartile range, the +  the mean value and  -  the median value.
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Figure 4.1.14: Myeloperoxidase in induced sputum following inhaled fluticasone
compared to placebo
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Figure 4.1.15: TNF-alpha in induced sputum following inhaled fluticasone compared to
placebo
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Figure 4.1.16: lnterleukin-8 in induced sputum following inhaled fluticasone compared
to placebo
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Table 4.1.7 Predictors of steroid responsiveness in chronic cough
a: Baseline demographic features as predictors of steroid responsiveness in chronic cough
R2 P value
Duration of cough, weeks 0 . 0 1 0.377
Age 0 . 0 1 0.510
IgE total 0.07 0 . 0 2 2
IgE specific 0 . 0 0 0.522
FEVi pre 0.04 0.080
FEVi%pred 0 . 0 0 0.674
Baseline VAS 0 . 0 1 0.454
Gender 0.04 0.071
Ex-smoker 0 . 0 0 1 . 0 0 0
Source of patient (community or hospital) 0 . 0 0 0.971
Table 4.1.7 b: Non-invasive tests as predictors of steroid responsiveness in chronic cough
Test R 2 P value
Exhaled NO 0.152 < 0 . 0 0 1
CO 0.018 0.209
Methacholine challenge test 0 . 0 1 0.403
Sputum total cell count 0 . 0 0 0.946
Sputum neutrophils % 0 . 0 0 0.604
Sputum eosinophils % 0.08 0.019
Sputum lymphocytes % 0 . 0 0 0.783
Sputum macrophages % 0 . 0 1 0.448
Combined exhaled NO and sputum 0.2527 < 0 . 0 0 1
eosinophils %
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Table 4.1.7c: Mediator levels in induced sputum as predictors of steroid responsiveness in 
chronic cough
M ediator in induced sputum R2 P value
ECP 0.064 0.050
p g e 2 0.045 0 . 1 1 1
IL - 8 0 . 0 0 0 0.940
l t b 4 0.004 0.625
Cys-LT 0.070 0.039
MPO 0.005 0.573
TNF-a 0.018 0.342
[II
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Figure 4.1.17: Predictors of steroid responsiveness
a. Correlation of exhaled nitric oxide and change in cough 
severity following inhaled fluticasone
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DISCUSSION
This is the first randomised, placebo-controlled study to demonstrate an improvement in 
cough severity following inhaled fluticasone compared to placebo in patients with chronic 
cough for over one year. The decrease in cough severity score was accompanied by a fall in 
sputum ECP, eNO and CO but there was no reduction in sputum mediator levels of LTB4 , 
cys-LT, PGE2 , IL-8 , MPO and TNF-a. Exhaled NO levels were the best predictor of 
corticosteroid responsiveness.
Although there was a statistically significant decrease in the cough VAS scale, this 
corresponded to a mean (95%CI) % improvement of 22.3 (-3.5, 48.2) in the cough. There are 
several possible explanations for the modest improvement in cough severity score for most 
subjects in this study. Firstly, the baseline sputum samples demonstrated a predominant 
airway neutrophilia rather than eosinophilia. Neutrophilic inflammation of the airways is 
relatively insensitive to corticosteroid therapy (228). The association between airway 
eosinophilia and corticosteroid responsiveness has been demonstrated in patients with chronic 
cough (76). Corticosteroids are very effective at reducing eosinophils in the airways (229) and 
sputum eosinophilia has been shown to predict a clinical benefit from corticosteroids in 
asthma and COPD (65, 230). A study by Pizzichini et al (52), which included subjects with 
chronic cough where asthma, PNDS and GORD were excluded as possible causes, found none 
of the subjects had elevated sputum eosinophils and there was no response to a trial o f inhaled 
corticosteroids. Secondly, we included subjects with a duration of cough greater than one 
year, as it represented the most problematic patients with cough in the community. It is
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possible that cough of a shorter duration may be more corticosteroid responsive. Thirdly, it is 
possible that a longer duration of treatment with inhaled corticosteroids could increase the 
number of responders. In some studies response to inhaled corticosteroids was seen within 
two weeks (60, 75) and in others, extending treatment to four weeks did not improve the 
response rate (43, 52, 231). We believe that two weeks of high dose inhaled corticosteroids 
should have identified a change in cough severity in the vast majority of subjects who are 
likely to respond to this treatment.
In this study, patients had a history of cough for a mean duration of 16.2 years. Most of the 
subjects had previously received some form of treatment for chronic cough, details of which 
they were unable to accurately recall. As we had no record of response to previous therapy, 
we included all subjects provided they had not been taking inhaled or oral corticosteroids in 
the previous 3 weeks. There was no significant difference in response to inhaled fluticasone 
in those who had received a prior course of inhaled corticosteroid compared to those who had 
never received this treatment. Hence there was no bias towards selecting subjects who were 
unlikely to respond to inhaled corticosteroids.
We have shown that in cough persistent for over a year, regardless of aetiology, there is 
airway inflammation, with an increase in induced sputum neutrophils, airway mediators and 
exhaled nitric oxide. Jatakanon and colleagues selected patients with non-asthmatic chronic 
cough and demonstrated a marked neutrophilia in induced sputum (51). We have shown that 
this neutrophilia extends across the spectrum of causes of chronic persistent cough, with the 
highest levels in bronchiectasis. Although the reasons for this are not known, speculation has
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included the effect of mediators such as TNF-alpha and IL- 8  promoting the neutrophil influx, 
which may be perpetuated by the act of coughing itself (51). In contrast, Birring and 
colleagues noted elevated sputum eosinophils in a sub-group of patients and normal 
neutrophil counts (45). They included subjects with a duration of cough greater than three 
weeks as opposed to one year in our study and the mean duration of cough was about three 
years compared to 16 years in ours. Hence, although the trend of inflammation in induced 
sputum in persistent cough appears to be neutrophilic, further work on this subject is required.
As the inflammatory pattern can vary in cough, we chose to measure seven mediators to 
assess activation of different inflammatory cells. ECP and MPO are indirect markers of 
eosinophil and neutrophil activity respectively. IL- 8  is a neutrophil chemo-attractant and 
activator and can also induce the release of histamine and cys-LTs from human blood 
basophils (232, 233). TNF-a is a pro-inflammatory cytokine produced by macrophages and 
mast cells and maybe an important mediator in initiating chronic inflammation by activating 
the secretion of cytokines from a variety of cells in the airways (234). Leukotrienes are 
produced by mast cells, eosinophils and neutrophils and are implicated in the inflammation of 
asthma and COPD. PGE2 can increase cough sensitivity (130).
In our study we noted elevated levels of cysteinyl-LT, LTB4 , ECP, PGE2 and IL-8 . Following 
two weeks of inhaled fluticasone, 1000 meg daily, exhaled NO, CO and ECP were 
significantly suppressed compared with placebo, with no change in sputum cell counts and 
other mediators. Responsiveness of ECP to corticosteroids has been noted in asthma (150, 
235) as well as in COPD (154). Leukotrienes and IL- 8  were elevated at baseline but did not
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respond to corticosteroids, similar to findings in asthma and COPD (152, 154). Choudry et al 
demonstrated that the cough reflex is increased in the presence of PGE2 in the airways (130) 
and Birring et al found elevated PGE2 in induced sputum of subjects with cough (45). We 
have demonstrated that induced sputum levels of PGE2 , cys-LT and LTB4 are significantly 
high in patients with all causes of chronic persistent cough and persist after inhaled 
corticosteriod treatment.
Exhaled NO has been shown to be increased in inflammatory lung conditions such as asthma 
and has been used as a predictor of oral corticosteroid responsiveness (73). In this study, eNO 
was mildly elevated in patients with chronic cough. We found a strong correlation between 
eNO and sputum eosinophils, similar to patients with asthma (84). Regression analysis 
revealed eNO to be the most useful predictor of corticosteroid responsiveness. Levels of 
exhaled CO are elevated in asthma, bronchiectasis, upper respiratory tract infections, lower 
respiratory tract infections, seasonal allergic rhinitis and cystic fibrosis (95-99, 104). 
Treatment with inhaled or oral corticosteroid has been shown to reduce exhaled CO in 
asthmatics (96, 100). The level of CO was not elevated at baseline in chronic persistent cough, 
but did reduce significantly after inhaled corticosteroid treatment.
In conclusion, chronic cough, persistent for over one year, partially responds to inhaled 
corticosteroids regardless of the aetiology of cough. Exhaled nitric oxide is the most useful 
predictor of this response. The inflammation is complex with sputum neutrophilia and 
elevated PGE2 , LTB4 and cys-LT in all causes of cough. ECP was the only mediator to reduce 
following corticosteroid treatment. This result raises the possibility that alternative drugs
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targeted to reduce the production/action of these pro-inflammatory mediators may be of 
therapeutic benefit in chronic cough.
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4.2: SERUM AND SPUTUM NEUROTROPHIN LEVELS IN CHRONIC
PERSISTENT COUGH
INTRODUCTION
Chronic cough is a common clinical problem with a reported prevalence of between 14-23%. 
It often persists for over a year (33, 35) and has adverse effects on quality of life. In non- 
smokers with a normal chest radiograph, the most frequent causes are post-nasal drip 
syndrome (PNDS), gastro-oesophageal reflux disease (GORD) and cough variant asthma 
(CVA) (6 , 8 , 32, 34). Although chronic cough can be caused by various different conditions, 
underlying airway inflammation appears to be a common factor (40-42, 51).
There is evidence that chronic cough is associated with neurogenic inflammation. The afferent 
sensory receptors and nerves (the myelinated rapidly adapting receptors and the unmyelinated 
C-fibres) are considered important components of the cough reflex (170). Up-regulation in 
sensory nerve function in the afferent portion of the cough reflex appears fundamental to the 
pathophysiology which underlies chronic cough (236). It is believed that activation of C-fibre 
receptors in the airway releases sensory neuropeptides, which cause neurogenic inflammation 
and may activate rapidly adapting receptors to cause cough (170). Inhaled substance P induces 
cough in humans with an upper respiratory tract infection or idiopathic pulmonary fibrosis and 
increased levels have been found in nasal lavage fluid from patients with chronic productive 
cough (237). The neuropeptide calcitonin gene-related peptide (CGRP) induces histamine 
release from broncho-alveolar lavage mast cells obtained from asthmatic and non-asthmatic 
subjects with chronic cough (236).
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Neurotrophins are a family of structurally related growth factors, which include nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and 
neurotrophin-4/5 (NT-4/5). The physiological role of neurotrophins includes regulating the 
development, differentiation, survival and function of distinct neurons. In addition, there is 
growing evidence for their involvement in inflammation. T-cells, B-cells, macrophages and 
mast cells may be sources of neurotrophic factors during the process of inflammation 
(167).Mast cells are able to produce, store and release NGF. In vitro stimulation with NGF 
leads to degranulation with the release of pre-formed and newly generated mediators such as 
histamine, leukotrienes and cytokines, all of which are known to be increased in cough (45, 
238). NGF is a known regulator of neuropeptide synthesis in sensory nerves, which triggers 
neurogenic inflammation (239). In a mouse model of allergic inflammation and in NGF 
transgenic mice, neurotrophins altered sensory innervation, enhanced neuropeptide production 
and induced airway hyper-responsiveness (162, 163). Elevated levels of NGF and BDNF have 
been demonstrated in plasma from patients with untreated asthma (164, 166), which were 
reduced by corticosteroid treatment (166) and in the sputum of patients with idiopathic 
pulmonary fibrosis (175).
The aim of the present study was to assess the role of neurotrophins in chronic persistent 
cough by measuring the levels of nerve growth factor, brain derived neurotrophic factor and 
neurotrophin-3 in serum/induced sputum of subjects with this condition.
I ll
METHODS
Subjects
Adult subjects with a cough persistent for at least one year were recruited from hospital 
respiratory clinics and by advertisement in a local newspaper. No subject had evidence of any 
other lung disease based on history, clinical examination, spirometry and chest radiography. 
Healthy volunteers with no history of recent upper or lower respiratory tract infection, were 
recruited as controls. Details are included in Chapter 3 (General Methods).
Measurements
Pre- and post- inhaled salbutamol FEVi and bronchial challenge testing with methacholine 
were performed as per techniques described in Chapter 3. Total serum IgE and IgE to 
common allergens (house dust mite, grass pollen and cat dander) were measured by enzyme 
immunoassay to assess atopic status. Patients recorded their cough severity on a 10 cm linear 
visual analogue scale (0 =no cough, 1 0 =maximum cough).
Sputum induction with 3% hypertonic saline was performed using a modification of the 
method described by Pin et al (71, 240). The sputum was processed according to the technique 
described by Popov et al (225). The supernatant was frozen at -70° C for NGF measurements.
Measurement of NGF, BDNF and NT-3
Serum NGF, BDNF and NT-3 immuno-reactivity was measured by enzyme immunoassay 
(EIA) according to the manufacturers’ instructions (Promega UK Ltd., Southampton, UK),
112
described in the Methods section, Chapter 3. As the reducing agent dithiothreitol (DTT) used 
to homogenize the specimens can affect measurements, we performed an extra test for assay 
performance and found full recovery of NGF immunoreactivity in normal serum samples 
spiked with exogenous NGF (Sigma Ltd, Poole, UK).
Final Diagnosis of the cough
To achieve a final diagnosis for the cause of the cough, all subjects were offered sequential 
trials of specific therapy depending on the likely clinical diagnoses for their cough. Final 
diagnosis or diagnoses of the cause of the cough were based on defined pre-treatment criteria 
(5) and accepted only when the cough significantly improved or disappeared with specific 
therapy (8 ).
Statistical Methods
Associations between demographic variables, sputum cell counts and neurotrophins were 
assessed by spearman rank correlations. Differences between groups of patients were 
examined by Wilcoxon tests. A p value of <0.05 was considered significant. All analyses were 
carried out with SAS version 8.02 software.
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RESULTS
Baseline subject characteristics
We screened 110 subjects with cough, 81 of whom met all the inclusion criteria. Of these, 49 
were recruited from the community and 32 were referred from hospital clinics. A final 
diagnosis for the cough was obtained in 73/81 (90%) of subjects; 73% had a single diagnosis, 
25% had 2 diagnoses and 3% had 3 diagnoses. The pattern of primary diagnoses was PNDS 
(29), GORD (16), CVA (12), bronchiectasis (9), eosinophilic bronchitis (5), habitual cough 
(1) and bronchitis (1). In 8  subjects, the cough was termed idiopathic. 31% of cough subjects 
were atopic (allergen specific IgE positive) and the median (IQR) total serum IgE levels were 
28.5 (16.5-72.5).
Cough subjects were significantly older than the control group; median (IQR) age 63 (51.3- 
68.4) compared to 31 (26-32) for controls, p<0.001. 30 cough subjects were male (51 female) 
and 16 controls were male (14 female). Median (IQR) FEVj % predicted was 96 (83-106) in 
cough subjects and 100 (89-105) in controls (p=0.314).
Neurotrophin levels
Serum NGF, BDNF and NT-3 were not elevated in persistent cough subjects (n=77) 
compared to healthy controls (n=30) (Table 4.2.1; figure 4.2.1). NGF was measured in 
induced sputum samples of 46 subjects with persistent cough and 17 healthy controls and 
there was no significant difference between the two groups (Table 4.2.1).
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Induced sputum cell counts showed a significantly higher total cell count and neutrophil 
proportion in cough subjects compared to controls (Table 4.2.1). Neutrophils in induced 
sputum did not correlate with the duration of cough or age of the patient.
There was no correlation between neurotrophin levels in serum/ sputum with age of the 
patient, gender, baseline VAS cough severity scale, FEVi, FEVj % predicted, total IgE level, 
atopy to common allergens, total and differential sputum cell counts, blood cell counts, 
presence of lower airway hyper-reactivity, previous smoking history or whether the patient 
was recruited from the community or hospital clinics.
There was no major difference in the neurotrophin levels based on the final diagnosis of the 
cough (Figure 4.2.1). Individual data for the smaller diagnostic sub-groups are not depicted 
because the numbers were too small for meaningful analysis. There was a significant inverse 
correlation between serum BDNF and serum NGF (r = -0.24, p = 0.032), but no correlation 
between the other neurotrophins. Serum NGF levels were related to the duration of cough (r = 
0.34, p = 0.002).
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Table 4.2.1: Baseline neurotrophin levels (pg/ml) and induced sputum cell counts in 
chronic cough subjects compared to controls
Controls Persistent cough
Induced sputum cell counts
(n=17) (n=46)
Total cell count 2.7 (2.0-3.4) 7.3 (4.5-15.9)**
Neutrophil % 32.1 (10.1-53.1) 67.3 (44.0-80.5)**
Eosinophil % 0.0 (0.0-0.2) 0.2 (0.0-1.0)
Lymphocyte % 0.35 (0.0-0.7) 0.0 (0.0-0.2) *
Macrophage % 67.1 (46.0-89.5) 30.8 (18.3-52.3)**
Neurotrophins
Sputum NGF 516 (296-772) 580 (312-880)
Serum (n=30) (n=77)
Serum BDNF 1157 (1068-1367) 1064 (838-1290)
Serum NGF 116.1 (0-547.4) 44.3 (1.7-541.2)
Serum NT-3 1464.5 (183-9562) 211 (129-1195)
Data entered as median (IQR) ; * p  = 0.005, **p  < 0.001
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Figure 4.2.1: Neurotrophins [median (IQR)Jin chronic cough compared to healthy controls.
The box represents the inter-quartile range; the line in the box is the median value.
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Figure 4.2.2: Neurotrophins [median (IQR)] in different causes of chronic cough
The box represents the inter-quartile range and the line in the box is the median value.
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DISCUSSION
Nerve growth factor, brain-derived growth factor and neurotrophin-3 are the common 
neurotrophins associated with airway inflammation and atopy. This is the first study 
measuring the levels o f these neurotrophins in serum/induced sputum in subjects with 
chronic cough. We found no increase in neurotrophin levels in cough patients 
compared to healthy controls, despite the presence o f airway inflammation.
There are various factors that could account for the normal neurotrophin levels in our 
subjects with chronic cough. Firstly, the technique o f separation o f sputum involves 
the addition o f dithiothreitol (DTT) which has been shown to reduce the levels o f 
certain mediators (241). This is unlikely to account for the normal levels of NGF in 
our study as the technique was similar in patients and controls and we found full 
recovery of immunoreactivity of exogenous NGF when added to normal serum. 
Furthermore, Hope-Gill and colleagues have demonstrated that NGF levels in sputum 
were unaffected by DTT (175). Secondly, inhaled corticosteroids can suppress levels 
o f NGF and BDNF in serum in subjects with asthma (166). This cannot explain the 
normal levels we observed, as cough subjects were excluded if  they had received 
inhaled corticosteroids for three weeks or oral corticosteroids for six weeks prior to 
inclusion. The third consideration was whether the study was adequately powered to 
demonstrate a difference between groups. We believe it was, as studies in asthma and 
pulmonary fibrosis have demonstrated differences with smaller group sizes (164, 166, 
175). Results could vary in cough o f a shorter duration, but we found a positive 
correlation with serum NGF and the duration o f cough. There was no correlation
between age/gender and the levels o f any of the neurotrophins therefore it was 
unlikely that any difference between the study groups were important.
We chose to measure only the NGF in sputum as it has been measurable in previous 
work (175) whereas NT-3 has not and levels of BDNF would have been affected by 
DTT used in our method o f sputum processing (175). Besides, NGF is the 
neurotrophin most expressed in pulmonary tissue, followed by BDNF and then NT-3 
as revealed by microdensitometric analysis o f bands o f immunoreactivity (176) and is 
usually representative o f the other neurotrophins.
Nerve growth factor increased eosinophilic airway inflammation and augmented IL-5 
production in an animal model of airway inflammation (242). The major 
inflammatory cell type in our cough subjects was the neutrophil, in keeping with the 
findings o f others (51). A significant increase in neurotrophins has been demonstrated 
in allergic conditions (164, 243). Only 31% of cough subjects were atopic and there 
was no difference in neurotrophin levels based on total or allergen-specific IgE levels. 
It is possible that neurotrophins are less involved in inflammation associated with 
neutrophils as compared to eosinophilic inflammation in asthma and allergic 
conditions.
The main causes of cough in our subjects were post nasal drip syndrome, gastro- 
oesophageal reflux disease, cough variant asthma, bronchiectasis and eosinophilic 
bronchitis; similar to other studies on chronic cough (8, 32, 34, 45). We found no 
significant difference in neurotrophins in any of the causes of cough, including cough 
variant asthma.
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It is possible that rather than absolute concentrations of neurotrophins in body fluids, 
it is their expression at receptor level that is important. It has been speculated that 
NGF affects airway nerves through the vanilloid receptor (VR1) in allergic asthma 
(183). This receptor, originally known as the capsaicin receptor, has been proposed as 
a receptor for cough (182). Further studies are indicated to determine the effect o f 
nerve growth factor at the receptor level in chronic cough.
In conclusion, we have demonstrated that nerve growth factor, brain-derived growth 
factor and neurotrophin-3 are not elevated in serum/sputum of subjects with chronic 
cough, regardless of the aetiology o f cough. This implies that these neurotrophins do 
not have a central role in perpetuating airway inflammation in chronic persistent 
cough.
4.3: QUALITY OF LIFE IN CHRONIC PERSISTENT COUGH
INTRODUCTION
Chronic cough is a common symptom in general medical practice with significant 
associated morbidity (10, 184, 185). It can persist for several years (33, 35, 110) and 
patients are often been told by their physician that they have no option but to learn to 
live with the cough (8).
Quality of life is an outcome which is a fundamental aim of health care (186). Health 
related quality of life measurement is a means o f quantifying, in a standardised and 
objective manner, the impact o f disease on a patient’s daily life, health and wellbeing. 
It is a process that is similar to a highly structured clinical history, leading to an 
objective measurement that can be used for scientific purposes (187).
In other respiratory conditions such as asthma and COPD, cough is one of the major 
symptoms affecting patients’ quality o f life. A study of patient weighting of the 
importance o f different symptoms o f asthma found cough to be the most troublesome 
o f all symptoms(244).
Until recently, the quality o f life o f people with chronic cough had never been studied. 
French and colleagues used the Sickness Impact Profile (SIP) and Adverse Cough 
Outcome Survey (ACOS) developed by themselves and demonstrated, in a 
prospective study, that chronic cough was associated with adverse psychosocial and 
physical effects on the quality of life (188). They then developed a cough specific
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quality o f life questionnaire (the CQLQ) in 2002 (189), followed by the Leicester 
Cough Questionnaire (LCQ) by Birring and colleagues in 2003 (190). Both are recent 
additions likely to be beneficial as an outcome measure in cough studies, but they do 
not allow comparison o f quality o f life across different respiratory conditions.
Successful treatment o f cough improved the QOL in a small study including subjects 
with cough for over 3 weeks (188). Birring and colleagues reported a similar 
improvement using the LCQ in 9 subjects (190). The change in quality of life 
following specific treatment o f chronic persistent cough has not been assessed in any 
large study.
Quality o f life is widely used in studies in asthma and COPD with respiratory disease 
specific questionnaires such as the St. George’s Respiratory Questionnaire (SGRQ) 
and in various medical disorders with the Hospital Anxiety and Depression scale. The 
SGRQ has been a useful strategy for monitoring the outcomes of clinical interventions 
(245-247). The SGRQ was designed so the scores would have an ‘absolute’ property 
and be independent o f patient and study (191). Despite the large numbers of sufferers, 
chronic cough is a relatively neglected condition in the medical world compared to 
asthma and COPD. A comparison o f the effect o f cough on quality o f life compared 
with other medical conditions has not been performed.
The aims o f this study were to assess the quality of life o f patients with cough 
persistent for over one year, using the St. George’s Respiratory Questionnaire and the 
Hospital Anxiety and Depression Scale. The secondary aims were to study the effect 
o f treatment of cough on these measures and to see if  the specific cause of cough 
affected these quality o f life measurements.
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M ETHODS
Subjects:
Adults with a cough persistent for over one year were recruited from hospital 
respiratory clinics and by advertisement in a local newspaper. No subject had 
evidence of any other lung disease based on history, clinical examination, chest 
radiography and spirometry. Details of study design are included in the general 
methods section, chapter 3.
Quality o f  Life assessments:
All subjects were requested to complete the St. George’s Respiratory Questionnaire 
and the Hospital Anxiety and Depression Scales.
The St. George’s Respiratory Questionnaire (SGRQ)
The SGRQ is a supervised self-administered measure designed for use in airway 
disease. [Details are included in the Methods section, Chapter 3]. A difference in the 
SGRQ total score o f four points would indicate clinically significant differences 
between populations (191, 248) and a large difference would be a change o f more 
than 7 points (191). The SGRQ has been shown to be responsive to therapeutic 
changes (247, 249).
In a study o f 307 normal individuals, the mean (SD) for SGRQ scores were 9.67 
(13.24) for symptoms, 13.4 (17.63) for activity, 4.73 (9.92) for impact and total score 
8.41 (11.33) (250). In a British study (251), Spencer and colleagues reported similar 
normal ranges [mean (SD)] for Symptoms 12 (15), Activity 11(13), Impact 3 (5) and 
total score 7 (7).
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The Hospital Anxiety and Depression Scale (HADS)
The HADS was specifically developed for the screening of clinically significant 
anxiety and depression in patients with somatic conditions as well as for changes in 
severity o f these conditions at subsequent visits (227). Scores o f 7 or less represent 
non-cases, 8-10 indicate possible cases and scores o f 11 or more definite cases (227).
Final Diagnosis o f  Cough
All subjects were offered sequential trials o f specific therapy depending on the likely 
clinical diagnoses for their cough. Final diagnosis or diagnoses o f the cause of the 
cough (described in chapter 3) were based on defined pre-treatment criteria (5) and 
accepted only when the cough significantly improved or disappeared with specific 
therapy (8).
Quality o f life questionnaires were posted to all participants after a final diagnosis had 
been achieved along with a stamped self-addressed envelope. If the questionnaire was 
not returned within ten days, a reminder phone call was made and a second set mailed 
out if  the questionnaires had been misplaced.
In the SGRQ, part 1 refers to symptom assessment over the past year and this had 
been validated for a symptom recall o f one year at the time this study commenced 
(191, 252). The time o f achieving a final diagnosis and repeating the score was 
expected to vary from two months to over a year, so the symptom domain and hence 
the total SGRQ score after treatment was not repeated after treatment in this study.
126
Statistical Analysis
Differences from baseline in the St. George’s Respiratory Questionnaire components 
and the Hospital Anxiety and Depression Scale were analysed by t-tests and the 
corresponding 95% confidence intervals for the mean changes. Quality o f life scores 
were compared between males and females with two-sample t-tests. Correlations 
between the quality o f life measures were analysed by Pearson correlations. The 
association between the quality o f life measures and other factors was assessed by 
Spearman rank correlations. The differences from baseline were compared between 
the diagnostic groups using ANOVA. A p value <0.05 was considered significant. All 
analyses were done using SAS version 8.02.
I
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RESULTS
Demography
88 subjects with cough persistent for over one year completed baseline quality o f life 
assessments and were included in this study. One HAD scale was incomplete at 
baseline and not utilised in the analysis. A final diagnosis for the cough was obtained 
in 78/88 (89%) o f subjects. The pattern o f primary diagnoses is as depicted in 
Experiment 1, figure 4.1.1. Baseline characteristics o f the patients are shown in table 
4.3.1. Individual data for the smaller diagnostic sub-groups are not depicted because 
the numbers were too small for meaningful analysis.
74 (84 %) subjects returned the final sets o f questionnaires. Fourteen subjects did not 
return the second set of questionnaires despite reminder telephone calls and letters. 
Analysis o f this sub-group revealed no major differences from the group who returned 
their questionnaires following treatment. The mean age was 55.04 (10.03) years, 9/14 
were female, 10/14 were recruited from the community compared to 4 from hospital 
clinics, 6 were ex-smokers compared to 8 never smokers and the mean (SD) duration 
o f cough was 14.5 (12.92) years. The primary diagnosis was PNDS (8), CVA (2), 
GORD (1), EB (1) and Idiopathic (2). There was no significant difference in any 
domain of the SGRQ score and the HADS in these subjects at baseline compared to 
those who completed the study.
There were a higher number o f females in the study; 56/88 subjects (64%). The 
differences in quality o f life scores based on gender are depicted in Table 4.3.3. 
Activity and Impact sections o f the SGRQ were significantly higher in females 
compared to males, but there was no difference in the anxiety or depression scores.
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The co-existence of another chronic illness was reported by 57/88 subjects. The 
commonest conditions were hypertension (23), angina (6), previous myocardial 
infarction (4), diabetes mellitus (4), previous stroke (30) and glaucoma (2). Chronic 
illnesses were associated with the depression score in the HAD Scale (p=0.022) but 
not with the other quality o f life assessments.
Factors unrelated to the quality o f life scores were age, previous smoking history and 
duration of cough. Baseline cough severity, marked on a 0-10 cm visual analogue 
scale, correlated with the impact domain o f the SGRQ (r=0.22, p=0.042). Quantity of 
sputum and cough during sleep correlated with the symptoms, impact and total 
SGRQ. Baseline FEVi, FVC and FEF25-75 significantly correlated with total, activity 
and impact scores of the SGRQ, but not with the symptom score or the HAD scale 
(table 4.3.4).
Quality o f  life scores in cough before and after treatment o f  cough 
The baseline HADS scores o f the 74 subjects who completed the study are depicted in 
Figure 4.3.1. Scores before and after treatment for the individual domains of the St. 
George’s Respiratory Questionnaire are depicted in table 4.3.2 (a) and figure 4.3.2 
The changes in the Hospital Depression and Anxiety Scales are depicted in Table 
4.3.2b and figure 4.3.3.
The most significant change in the SGRQ in all causes o f cough following treatment 
is in the Impacts Domain (figure 4.3.4) with a mean (SD) change o f [-9.82 (15.32), 
p<0.001]. The symptom score was not repeated following treatment and hence the 
total score could not be accurately calculated following treatment o f the cough.
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Keeping the symptom score unchanged, the change in the total score after treatment 
was a mean (SD) o f [-6.17 (11.45), pO.OOl]. A cut-off value o f 4 points has been 
considered the minimal clinically significant change by the developers of the SGRQ, 
and a value of 7 a very significant difference. For the activity section, 27 subjects 
(36%) had an improvement > 4 points of whom 20 had improved over 7 points. For 
the impact domain o f the SGRQ, a 4 point improvement was seen in 46 (62%) 
subjects of whom 43 had a change of 7 or greater points.
Although the anxiety and depression scores were not high at baseline, there was a 
significant reduction in both scores following treatment (Table 4.3.2.b).
Quality o f  life in different causes o f  cough
The quality o f life scores in the major causes o f cough are depicted in table 4.3.5 and 
changes with treatment in table 4.3.6. There was no statistical difference in the scores 
at baseline or the change with treatment, based on the final diagnosis o f cough.
Correlation between SGRQ and the HAD Scale and demographic features
These 2 scales measure different components of quality o f life. The anxiety scale 
correlated only with the total SGRQ, whereas the depression scale correlated 
significantly with the total as well as the individual domains o f the SGRQ. 
Correlations of SGRQ domains and HAD Scale before and after treatment of cough 
are depicted in table 4.3.7.
130
Ta
bl
e 
4.
3.
1:
 B
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
of 
ch
ro
ni
c 
co
ug
h 
su
bj
ec
ts
.
Table 4.3.2a: St. George’s Respiratory Questionnaire Scores before and after treatment of 
chronic persistent cough.
QOL score Before After Difference Statistical
treatm ent treatm ent significance
TOTAL SGRQ 34.66 - - -
(14.45
SGRQ SYMPTOMS 55.24 - - -
(18.74)
SGRQ ACTIVITY 29.33 26.82 -2.51 P=0.220
(22.97) (23.31) (17.45)
SGRQ IMPACT 30.35 20.53 -9.82 P<0.001
(14.64) (16.35) (15.32)
Table 4.3.2b: Hospital Anxiety and Depression Scale before and after treatment of chi
persistent cough.
QOL score Before After Difference Statistical
treatm ent treatm ent significance
ANXIETY SCORE 6.41 5.47 -0.96 P=0.008
(3.56) (3.28) (2.97)
DEPRESSION SCORE 3.72 2.96 -0.75 P=0.007
(2.70) {2A1) (2.32)
TOTAL HADS 10.12 8.43 -1.68 P=0.002
(5.15) (5.08) (4.31)
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Figure 4.3.1a : Baseline Anxiety score on the Hospital Anxiety and Depression Scale;
frequency of cough patients in different severity stages
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Figure 4.3.1 b : Baseline depression score on the Hospital Anxiety and Depression
Scale; frequency of cough patients in different severity stages
70
0-7 8 to 11 >11
Depression Score
134
Figure 4.3.2 : SGRQ scores before and after treatment of chronic persistent cough.
a. Change in the Activity Domain of SGRQ
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The box represents the interquartile range, the line within the median value, +  is the mean value 
and maximum and minimum values are depicted by the error bars.
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Figure 4.3.2 : SGRQ scores before and after treatment of chronic persistent cough.
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The box represents the interquartile range, the line within the median value, +  is the mean value 
and maximum and minimum values are depicted by the error bars.
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Figure 4.3.3. : HADS scores before and after treatment of chronic persistent cough.
a. Change in the Anxiety Score
The box represents the interquartile range, the line within the median value, +  is the mean value 
and maximum and minimum values are depicted by the error bars.
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Figure 4.3.3. : HADS scores before and after treatment of chronic persistent cough.
b. Change in the Depression Score
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The box represents the interquartile range, the line within the median value, +  is the mean value 
and maximum and minimum values are depicted by the error bars.
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Table 4.3.3. Quality of life scores in males versus females with chronic persistent cough.
Males Females Statistics
(n=32) (n=56)
Total SGRQ 29 (13) 3 8 (1 5 ) p=0.011
Symptom 53 (16) 57 (20) p=0.415
Activity 22  (20 ) 34 (23) p=0.019
Impacts 2 6 (1 1 ) 33 (16) p=0.027
Total HADS 9 (5 ) 1 1 (5 ) p=0.187
Anxiety 6 (3 ) 7 (4 ) p=0.264
Depression 3 (3 ) 4 (3 ) p=0.250
Data depicted as mean (SD) and statistical difference as t tests.
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Table 4.3.4 a: Correlation of St. George’s respiratory questionnaire with baseline demography in
chronic persistent cough
Duration of cough
Baseline cough severity 
VAS scale, cm
Sputum quantity, ml 
Cough during sleep 
FEVj pre salbutamol 
FVC pre-salbutamol 
FEF25-75 pre-salbutamol
TOTAL SGRQ
r =0.10 
P=0.349
r =-0.10 
P=0.348
r =0.12 
P=0.264
r = 0.33 
P=0.002
r =0.26  
P=0.017
r = - 0.40 
P=0.0001
r =- 0.40 
P=0.0001
r = - 0.38 
P=0.0003
SYMPTOMS
r = -0.02 
P=0.888
r =-0.08 
P=0.449
r =0.06 
P=0.593
r =0.48  
P<0.0001
r =0.26  
P=0.016
r = - 0.20 
P=0.064
r = - 0.21 
P=0.054
r = - 0.20 
P=0.058
ACTIVITY
r =0.11 
P=0.290
r =-0.14 
P=0.189
r =0.03 
P=0.784
r = 0.12 
P=0.266
r = 0.10 
P=0.377
r = - 0.38 
P=0.003
r = - 0.39 
P=0.0002
r = - 30 
P=0.005
IMPACT
r =0.01 
P=0.908
r =-0.02 
P=0.882
r =0 . 2 2  
P=0.042
r =0.35  
P=0.0008
r = 0.27 
P=0.012
r = -0.31 
P=0.004
r = - 0.29 
P=0.007
r = - 0.32 
P=0.002
Table 4.3. 4b : Correlation of the HAD scale with baseline demography in chronic persistent 
cough (using Spearman Rank Correlations)
Duration of cough
Baseline cough severity 
VAS scale, cm
Sputum quantity 
Cough during sleep 
FEVi pre salbutamol 
FVC pre-salbutamol 
FEF25-75 pre-salbutamol
TOTAL HADS
r =-0.15  
P=0.177
r =0.01 
P=0.897
r =0.09 
P=0.386
r = 0.09 
P=0.371
r =0.16 
P=0.154
r =0.00 
P=0.917
r = - 0.00 
P=0.971
r =0.00 
P=0.999
ANXIETY
r = - 0.25 
P=0.021
r =0.03 
P=0.817
r =- 0.00 
P=0.992
r = - 0.02 
P=0.843
r = - 0.14 
P=0.207
r =0.08 
P=0.436
r =0.05 
P=0.635
r =0.10 
P=0.338
DEPRESSION
r = 0.10 
P=0.339
r =-0.04 
P=0.735
r =0.16 
P=0.128
r =0.24 
P=0.030
r =0.04 
P=0.703
r =- 0.19 
P=0.085
r = - 0.19 
P=0.084
r = -0.14 
P=0.196
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Table 4.3.7: Correlation between the St. George’s Respiratory Questionnaire and the 
Hospital Anxiety and Depression Scale before and after treatment of chronic cough
a. Anxiety Scale
Before treatment 
Total SGRQ* r = 0.17
Symptoms
Activity
Impacts
P=0.107 
r = 0.18 
P=0.094 
r =0.12 
P=0.249 
r = 0.20 
P=0.067
After treatment 
r = 0.32 
P=0.007
r =0.34 
P=0.003 
r = 0.22 
P=0.058
difference with treatment 
r = 0.19 
P=0.117
r =0.20 
P=0.094 
r = 0.16 
P=0.175
b. Depression Scale
Before treatment After treatment difference with treatment
Total SGRQ*
Symptoms
Activity
Impacts
r  =0.49 
P0.0001 
r =0 . 2 2  
P=0.044 
r =0.49 
P<0.0001 
r =0.45 
PC0.0001
r =0.59 
P<0.0001
r =0.65 
PcO.OOOl 
r =0.47 
P<0.0001
r =0.40 
P=0.0005
r =0.31 
P=0.008 
r =0.39 
P=0.0007
*Total SGRQ calculated keeping symptom domain constant; Pearson correlations used.
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Figure 4.3.4: Mean change in SGRQ Impact Score in Different Causes of Cough.
A reduction o f  4 points is considered the minimally significant clinical difference.
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DISCUSSION
Chronic cough is a common condition with a prevalence of 14-23% in the general 
population (10, 184, 185). Successful treatment of all patients with chronic cough is 
difficult (32, 33, 35, 110). This is the first study of the quality of life in subjects with a 
cough persistent for over a year. We demonstrated that the impairment of quality of life 
parameters improves significantly following specific treatment of cough. Clinically 
significant levels of anxiety and depression are not present in cough, nevertheless, there is 
an improvement following treatment of cough.
The SGRQ score has been widely used in respiratory conditions such as asthma and 
COPD and has been validated in patients with bronchiectasis (253). It correlates 
moderately (r=0.54) with the Leicester Cough Questionnaire in patients with chronic 
cough lasting over 3 weeks (190). In our study, the total score and each individual 
domain were higher than reference values obtained from people with no respiratory 
symptoms (250, 251).
Following treatment of the cough, the Impact domain mean difference (SD) was - 9.8 
(15.3). A difference of 4 points is considered a minimal clinically significant difference in 
each of the sub-scales of the SGRQ (191, 248) and a large difference would be a change 
of more than 7 points (191). The symptom domain and hence the total score were not 
repeated after treatment in this study, as they had only been validated to record a 
symptom recall o f one year at the time the study commenced (191, 252). Barr et al have
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now modified the SGRQ into American English and validated it for a one month duration 
symptom recall (254) and Wilson and colleagues have validated it for a change in 
bronchiectasis after six months (253).
French and colleagues (188) studied 28 subjects before and after treatment of their cough 
using the Sickness Impact profile (SIPS) score and the adverse cough-specific outcome 
survey (ACOS) and found a resolution of the deterioration in quality of life following 
successful treatment of the cough. They modified the ACOS into the Cough-Specific 
Quality-of-Life Questionnaire (CQLQ) and found it responsive to changes with treatment 
in 24 subjects with cough persistent for over 3 weeks. Effect of treatment in modifying a 
cough persisting for over a year has not been studied to the best of our knowledge.
Our results show that both the anxiety and depression scales of the HADS and the impact 
domain of the SGRQ are highly responsive to treatment of cough persisting for over one 
year. The mean duration of cough in our subjects was 16 years but the duration of cough 
did not correlate with either the SGRQ or the HADS.
In COPD, both anxiety and depression correlated with SGRQ (255). In our cough 
patients, the depression score, but not the anxiety score of the HADS correlated with the 
individual domains of the SGRQ, similar to findings in bronchiectasis (253).
Cough reflex sensitivity has consistently been shown to be higher in females compared to 
males regardless of whether the stimulant was capsaicin (256, 257), inhaled citric acid
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(258) or inhaled tartaric acid (259). We found a significant increase in the total SGRQ 
score as well as the individual Activity and Impact domains in females compared to 
males but no difference in anxiety or depression scales. In asthma, anxiety but not 
depression has been shown to be higher in females compared to males using the HADS 
(260, 261). Using the CQLQ in chronic cough > 3 weeks, French et al have reported that 
HRQoL is adversely affected in women compared to men (189), with the speculation 
being that women were more likely to suffer from stress urinary incontinence due to 
coughing and became embarrassed by it. However, Thompson et al used a 5 point Likert 
scale to record the effect of cough on psychosocial and physical aspects of health and 
found an overall moderate affection of these parameters with no difference in male and 
female patients (262).
In smokers without COPD, abnormal SGRQ scores were due to cough and phlegm (263). 
The quality o f life measured by the SGRQ in our study showed a direct relation with 
sputum quantity and cough during sleep. Age, duration of cough and baseline cough 
severity were not factors affecting the quality of life.
The baseline quality of life as well as the improvement in the persistent cough was not 
related to the final diagnosis of the cough. This was similar to the findings of French and 
colleagues using the Adverse Cough Outcome Survey in their study of 28 subjects with 
cough persisting longer than three weeks (188). The fact that there was no difference in 
improvement in quality of life questionnaires in subjects with idiopathic cough compared 
to other groups who reported an improvement in their cough following treatment implies
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that the entire effort of being treated and investigated for the cause of the cough 
contributes to reported well being rather than elimination of the cough alone.
A double-blind placebo-controlled study would be an ideal study design to measure the 
effectiveness of treatment in any condition. Given the numerous different causes of cough 
and the variety of therapeutic strategies, this would not have been a feasible option for 
this study.
The SGRQ and HADS are not cough-specific questionnaires, but allow for certain 
comparisons with other medical conditions. Comparison of scores in this study with 
random studies in asthma and COPD (appendix 5) show that for subjects with chronic 
persistent cough, there is an impairment of quality of life similar to that with chronic 
asthma (table 4.3.8). In comparison with COPD, the Impact domain is similar, but 
patients with COPD have a higher activity and symptom score, as would be expected due 
to their persistent breathlessness.
Objective measures of cough such as portable cough counters of good quality along with 
randomised controlled treatment trials will eventually be the best method to assess the 
true effect of therapy on cough. Quality of life instruments are designed to quantify the 
overall benefit of health-care interventions to the patient and currently, these subjective 
measures are likely to be the ones that best reflect the frequency and intensity of cough as 
well as its effect on patients’ daily lives.
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Table 4.3.8: SGRQ in Chronic Cough compared with Asthma and COPD.
Mean values for normal and cough subjects, weighted means for asthma and COPD
Normals Cough Asthma COPD
Totals no o f studies 1 1 9 10
Total no o f subjects 307 88 1962 2234
Total SGRQ 8 34.6 34.23 40.92
Symptoms 10 55.6 48.95 57.08
Activity 13 29.6 37.94 57.74
Impacts 5 30.1 27.51 34.44
Anxiety Scale of HADS 6.6 7.09 4.27
Depression Scale of HADS 3.8 4.74 5.06
To calculate the mean value fo r  scores fo r  SGRQ, a total o f  9 asthma studies with 1962 
subjects were used. For COPD SGRQ scores, a total o f 10 studies with 2234 subjects 
were used. HADS Asthma and COPD means were calculated from 2 studies each, with 
data from 474 asthma subjects and 202 COPD subjects (Appendix 6)
For each study a total score was obtained by multiplying the mean score with number o f  
subjects. These totals fo r  each study were added to form a grand total; which was then 
divided by the total number o f subjects in all studies. This was to account fo r  the different 
weights the varying number o f participants would add to the average score.
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4.4: BRONCHIAL AND EXTRATHORACIC AIRWAY HYPERREACTIVITY IN 
CHRONIC PERSISTENT COUGH
INTRODUCTION
Airway hyperresponsiveness or hyperreactivity is an increased ability of the airways to 
narrow after exposure to constrictor agonists. Airway hyperresponsiveness is believed to 
be affected by genetic as well as environmental factors (192, 193). Acute allergen 
exposure causes an increase of airway hyperresponsiveness that is consistently associated 
with an influx of inflammatory cells in the airways (194), which suggests a possible 
causal relation between airway inflammation and hyperresponsiveness (84, 195-197). As 
upper and lower airway disease often co-exist there could be a continuum of 
inflammation along the airway (210, 264).
Chronic cough is a very common condition, with the main causes identified as post nasal 
drip syndrome, gastro-oesophageal reflux disease and asthma (265). Since cough can be 
initiated anatomically by conditions that are outside the lower airways, measuring lower 
airway hyper-reactivity alone may be inadequate in explaining airway responsiveness in 
cough.
Bucca and Rolla matched flow-volume loops with fibreoptic laryngoscopy during 
histamine challenge inhalation and found that the maximal mid-inspiratory flow (MIF5 0)
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best reflected changes in mid-inspiratory glottis area (204). They used this index to study 
patients with upper respiratory disorders and found evidence of hyperresponsiveness of 
the upper airways or extrathoracic airway hyperresponsiveness (EAHR) in subjects with 
sinusitis, laryngitis and pharyngitis (204, 205). This was associated with damage to the 
epithelium and proliferation of submucosal fibres (206).
Asthma like symptoms, especially cough, have been associated with extrathoracic airway 
dysfunction (208). In 7 patients with gastro-oesophageal reflux and cough, Rolla et al 
demonstrated a significantly lower PC2 5MIF5 0 , indicative of extrathoracic airway hyper­
reactivity compared to GORD without cough (207).
Carney and colleagues considered the possibility that upper airway hyperreactivity could 
be a unifying mechanism in cough, but found it present in only 12/30, 40% of subjects 
with chronic cough persistent for longer than 4 weeks (46).
The aim of this study was to record extrathoracic airway hyperreactivity in a large group 
of subjects with chronic cough persistent for over one year, to see if it was a common 
occurrence and whether EAHR was associated with increased airway inflammation, 
measured by induced sputum cell counts, exhaled gases and sputum inflammatory 
mediators.
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METHODS
Subjects:
Adults with a cough persistent for over one year were recruited for this study. No subject 
had evidence of any other lung disease based on history, clinical examination, chest 
radiography and spirometry. Details of study design are included in the general methods 
section, chapter 3.
Procedures:
Methacholine challenge test was performed as described in the methods section, chapter 
3. Extra thoracic airway threshold was expressed as the methacholine concentration 
causing a 25% drop in MIF50 (PC2 5MIF5 0) and the concentration of 8  mg/ml was 
expressed as the cut-off to define extrathoracic airway hyperresponsiveness (207, 224).
Other tests performed included:
■ Baseline flow volume loops with reversibility to nebulised salbutamol.
■ Induced sputum with the sample used for cell counts and supernatant for mediator 
measurements.
■ Exhaled nitric oxide (eNO)
■ Exhaled carbon monoxide (CO)
■ Nasal nitric oxide (Nasal NO)
Inhaled corticosteroid treatment: All subjects received inhaled fluticasone for 2 weeks 
compared with placebo as described in Chapter 3 and experiment 1.
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Statistical Analysis:
The variables were compared by chi-squared tests and Wilcoxon tests. A p value < 0.05
!
i
| was considered significant. All analyses were performed using a statistical package SAS
II
I Version 8.02.!
i
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RESULTS
8 8  patients were included in the study. Demography for the subjects is described in the 
results section of Experiment 1 and table 4.1.1.
Extrathoracic airway hyperreactivity (EAHR) alone was seen in 4 subjects, bronchial 
hyperreactivity (BHR) alone in 12, both EAHR and BHR in 8  and no hyperreactivity in 
64 subjects with chronic persistent cough. Demography, final diagnosis, exhaled gases, 
induced sputum cell counts and sputum mediator levels values are described for the four 
sub-groups individually in tables 4.4.1-4.4.4. The individual group sizes were not large 
enough for meaningful statistical comparisons. However, certain trends were noted. 
There were no major differences in demography except in gender where females 
accounted for 100% with EAHR alone, 92% with BHR alone, but 53% in the group 
where no hyperreactivity was present. Baseline lung functions, especially MIF5o, were 
lowest in the group with EAHR alone. Duration of cough and quantity of sputum were 
similar in all groups.
Final diagnosis o f  cough
EAHR alone was not specific to any single diagnosis of cough (one case each for PNDS, 
GORD, asthma and bronchiectasis). BHR was commonest in those with asthma.
Inflammatory Markers:
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Total cell count and neutrophil % in induced sputum were similar in all groups. 
Eosinophils were higher in those with BHR alone. Exhaled NO and CO were similar in 
all groups. Nasal NO values were highest in those with UAHR alone.
Mediators in sputum were similar in all groups. LTB4  levels were highest in those with 
EAHR alone. The numbers of subjects for whom sputum mediator measurement was 
possible in the EAHR group alone was very low [n=l- 4].
Mean (SD) difference of difference in the cough VAS scale (in cm) following inhaled 
fluticasone compared to placebo was 1.39 (2.85) for those with BHR alone, 0.11 (1.66) 
for those with EAHR alone and 0.89 (2.71) for subjects with no hyperreactivity.
Comparison o f  all subjects with EAHR compared to those without:
We analysed all subjects who had evidence of EAHR (n=12) compared to those who had 
no EAHR (n=76). 11/12 subjects with EAHR were female, compared with 45/76 in those 
without. Final diagnosis in the 12 subjects with EAHR was asthma in 6 , GORD in 3, 
PNDS in 2 and 1 was termed idiopathic. MIF5 0 , L was significantly lower at baseline in 
those with EAHR [3.4 (1.2) compared to 4.5 (1.8), p=0.050].
Wilcoxon tests were utilised and showed no significant differences in baseline cough 
severity, eNO, nasal NO, CO, sputum cell counts and fluticasone responsiveness. Levels 
of cys-LT, ECP, MPO, IL-8 , TNF-a and PGE2 were similar in both groups. LTB4 levels
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were higher in those with EAHR [mean (SD), ng/ml 37.1 (11) in the EAHR group, 28.2 
(13) in those without, p = 0.051].
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DISCUSSION
Hyperresponsiveness of the upper airways or extrathoracic airway hyperreactivity has 
been demonstrated in asthma and in a small number of subjects with rhinitis and gastro- 
oesophageal reflux disease (205, 207). In this study, we have demonstrated that in a large 
group of people with chronic persistent cough, EAHR is present in only 14% of subjects 
and is not associated with lower airway inflammation or sputum inflammatory mediator 
levels.
Irwin and colleagues selected 9 patients with cough and post-nasal drip and demonstrated 
upper airway obstruction which improved following specific treatment of the cough 
(266). Bucca et al also selected patients with sinusitis and found evidence of EAHR 
which improved following treatment (205). It is unknown whether the hyperreactivity is a 
cause or effect o f the nasal condition. It has been suggested that extrathoracic airway 
hyperresponsiveness in the absence of bronchial hyperresponsiveness may indicate upper 
airway disease as a cause of cough (46). Our findings are not in support of this hypothesis 
as only 2/30 subjects with PNDS had EAHR.
In our study where all subjects with chronic cough were grouped, EAHR was an 
uncommon finding. This is in keeping with the study by Carney and colleagues in 30 
subjects with cough persisting for over 4 weeks (46).
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The difference in our methodology compared to others was the use of methacholine as a 
broncho-provocative agent rather than histamine. Methacholine, a direct stimulus of 
bronchoconstriction, is currently the gold standard for the assessment of bronchial hyper­
reactivity (201, 202). As results for histamine and methacholine are similar for BHR and 
we were performing the methacholine challenge test for the lower airway hyperreactivity, 
we used methacholine for the upper airway test as well. This may account for some 
differences from other studies and further work on comparison of these agents in the 
upper airways is indicated.
Bronchial hyperreactivity has been suggested as an indirect method of assessing airway 
inflammation (2 0 1 , 2 0 2 ) and airway responsiveness can be associated with the severity of 
airway inflammation in asthma (267). We found no difference in induced sputum cell 
counts or exhaled nitric oxide levels in those subjects with EAHR compared to those 
without. Recently several studies have questioned the association of airway inflammation 
and hyperresponsiveness (198, 199). In chronic cough, Carney and colleagues found 
BHR in 23% subjects and sputum eosinophils in 50%, showing the dissociation between 
lower airway hyperreactivity and eosinophilic inflammation of the airways.
It has been suggested that upper airway hyperresponsiveness is possibly due to release of 
inflammatory mediators (46). We measured inflammatory mediators in induced sputum 
and found that levels of cys-LT, PGE2 , MPO, ECP, TNF-a and IL- 8  were similar in 
subjects with and without EAHR. It is possible that measurement of mediators in nasal 
secretions may yield different results. Leukotriene B4  was the only mediator marginally
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increased in the EAHR group. Nasal provocation in allergic rhinitis can increase levels of 
LTB4 and IL- 8  in nasal fluid, which respond to an anti-histamine, astemizole (268) 
Responsiveness to inhaled corticosteroids was unrelated to the presence of upper airway 
responsiveness.
We measured MIF50 and found baseline values lower in the group with EAHR. This must 
be interpreted with caution, as predicted values for MIF50 are not available for women of 
all ages. Age, gender and height would affect the predicted values as in all lung functions. 
Although age and height were not very dissimilar, there was a definite female 
preponderance in the EAHR group.
The female:male ratio was higher in the group with EAHR. This is identical to the 
findings of Bucca and colleagues (204). Airway hyperresponsiveness as well paroxysmal 
glottic closure are usually seen more commonly in women compared to men (269, 270) 
with reasons such as reduced airway calibre and hormonal changes considered.
The mechanism of EAHR is unknown. It could be triggered by stimulation of pharyngo- 
laryngeal receptors (208), or simply a reflex narrowing of the glottis (209). EAHR may 
represent an entity similar to vocal cord dysfunction (269, 271), a condition frequently 
associated with asthma.
In conclusion, we studied extrathoracic hyperreactivity in 8 8  subjects with chronic cough 
and found it present in only 14%. There was no association with lower airway 
inflammation other than an increase in leukotriene B4 levels in induced sputum of these
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subjects. There was a marked preponderance of women with EAHR. Currently the utility 
of EAHR measurements remains a research tool as it has no clinical utility in identifying
i
the aetiology of chronic cough.
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4.3.5: SENSITIVITY AND SPECIFICITY OF SYMPTOMS IN PREDICTING
THE CAUSE OF COUGH
INTRODUCTION
Chronic cough is a common condition with prevalence rates between 14-23% (10, 184, 
185). There are many known causes of chronic cough (tables 1.1.1 and 1.1.2, Introduction 
chapter) but several studies have demonstrated that in a non-smoker with normal chest 
radiography, chronic cough is usually caused by post nasal drip syndrome (PNDS), 
gastro-oesophageal reflux disease (GORD) or cough variant asthma (CVA), singly or in 
combination (8, 32, 34). Despite narrowing the commonest causes of cough to three, the 
actual diagnosis and control of cough remains a challenge. This is because patients can 
have symptoms suggestive of these conditions and yet treatment for them may not 
improve the cough. On the other hand, these conditions may be ‘silent’ with no obvious 
suggestive symptoms and the cough may improve with treatment for the condition (34, 
272). Specialist clinics have a higher success rate in treating cough than general clinics 
(7), as these issues are better appreciated.
The key to successful management of the cough is to establish a diagnosis and then treat 
the specific cause of cough (6). The final diagnosis is dependent on response to specific 
treatment. This is currently the most commonly utilised method of confirming a 
diagnosis, advocated by Irwin and colleagues (273), although it has been questioned
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recently (6, 274). The treatment trials are fairly long, lasting usually up to two months for 
each possible condition. GORD can take up to six months to resolve (8, 275, 276). When 
there are multiple causes of cough, time to response can be even longer. Evidence on 
response to treatment in cough in large, double-blind, placebo-controlled studies is 
lacking.
Investigations in chronic cough could reduce the overall treatment duration (213) and 
play a definite, but limited role. The positive predictive value for most tests is not high 
[88% for histamine challenge, 68% for 24 hours pH monitoring and 67% for CT scan 
sinuses] (33). Fibre-optic bronchoscopy does not contribute significantly to the diagnosis 
of cough (212). The tests commonly used in chronic cough subjects are expensive (213) 
and require special hospital set-ups to perform.
With cough being such a common clinical problem for a general practitioner, if a clinical 
solution like a ‘good history’ could predict a final diagnosis, it would be invaluable in 
saving time, inconvenience to the patient and expense. Mello and colleagues found that 
general features of character, timing and complications of cough could not predict a 
diagnosis (211). McGarvey and colleagues concluded that a specific clinical history was 
not helpful in diagnosing the cause of cough, as it was predictive of the final diagnosis in 
only 56% cases of asthma, 52% with PNDS and 40% with GOR (33). Simpson suggested 
that their choice of questions could have been a factor for their low success rate (277).
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The aim of our study was to evaluate the value of specifically selected clinical questions 
in making a final diagnosis of chronic persistent cough.
169
METHODS
Subjects
Adults with a cough persisting for longer than one year were recruited from hospital 
respiratory clinics and by advertisement in a local newspaper. No subject had evidence 
of any other lung disease based on history, clinical examination, chest radiography and 
spirometry. Details of study design are included in the general methods section, chapter 
3.
Clinical History
All subjects were asked a detailed clinical history at baseline, entered in our study 
proforma (appendix 6).
General Cough Questions:
These included duration of cough, approximate quantity of sputum production daily, 
positional and diurnal variation and whether the cough felt like a ‘tickle/itch in the 
throat’. Subjects were all asked if the cough occurred during sleep (either awakening 
them or being informed by family members).
Triggers for the cough were noted with specific questions about dust, pollen, pet dander, 
cold air, exercise, sprays and aerosols.
Disease specific questions:
For GORD: History of heartburn, acid regurgitation, waterbrash, dysphagia and 
odynophagia (278). For Asthma: History of associated wheeze or breathlessness
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(paroxysmal or exertional). For PNDS: Sensation of something dripping down the nose, 
need to frequently clear the throat and nasal discharge (8).
To assess the value of specific questions for rhino-sinusitis, a scoring system was used 
adapted from Osguthorpe and Hadley, where the presence of 2 major or 1 major and 2 
minor criteria represented the presence of rhino-sinusitis. The major criteria were facial 
pain/pressure, facial congestion/fullness, nasal obstruction/blockage, nasal 
discharge/purulence by history or examination and hyposmia. The minor criteria were 
headache, halitosis, fatigue, dental pain, cough, ear pain/pressure/fullness (265). For 
allergic rhinitis, history of frequent sneezing, itchy nose/eyes/ throat and profuse watery 
nasal discharge was recorded (279).
Final diagnosis o f cough
To achieve a final diagnosis for the cause of the cough, all subjects were offered 
sequential trials of specific therapy depending on the likely clinical diagnoses for their 
cough. Final diagnosis or diagnoses of the cause of the cough (described in chapter 3) 
were based on defined pre-treatment criteria (5) and accepted only when the cough 
significantly improved or disappeared with specific therapy (8).
Pre-treatment diagnostic criteria:
Certain pre-treatment criteria were set to aid the preliminary diagnoses of cough.
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Asthma: History of cough with or without paroxysmal dyspnoea and wheeze or evidence 
of reversible airflow obstruction (15% improvement in FEVi following salbutamol) 
and/or >/= 20% lability on peak flow readings. The PC2 0  on methacholine challenge 
testing was < 8 mg/ml.
Post nasal drip syndrome: Any one of the following on history or examination: sensation 
of something dripping down the throat, nasal discharge, need to clear the throat 
frequently, mucoid/mucopurulent nasal secretions on examination or cobblestone 
appearance of the oro-pharyngeal mucosa.
Gastro-oesophageal reflux disease: History of heartburn and/or acid regurgitation. 
Bronchiectasis: History of cough with large volumes of sputum production.
Eosinophilic bronchitis was considered when sputum eosinophilia > 2%, normal PEF 
variability, spirometry and methacholine challenge test.
Final diagnosis
The final diagnosis was based on the above criteria and a response to appropriate 
treatment. When the cause of cough was unknown, it was termed ‘Idiopathic cough ’.
Treatment plan:
All patients were treated with medication for their cough, starting with the most likely 
diagnosis based on their history and baseline tests as above. As cough is known to be 
frequently due to multiple causes, for each patient a plan was drawn up with a list of 
potential diagnoses and the order in which to treat them.
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Treatment trials were done sequentially, for two months each, with the clinical response 
noted to each treatment. This was based on the patient’s view of the effectiveness of the 
treatment in reducing their cough compared to their baseline level prior to that treatment 
trial.
The treatment responses were noted as
Very good response: if the improvement was between 75-100%
Good response: if the improvement was between 50-75%
Minimal response: if the improvement was between 25-50%
No response: if the improvement was < 25%.
A final diagnosis was made when there was a ‘very good’ response to treatment.
If the response was ‘good’, then patients were asked to continue with further treatment 
trials, until the cough resolved. If subjects declined further treatment, then the final 
diagnosis of the cause of cough would be accepted based on a ‘good response’ to 
treatment. If a subject had good responses to two treatment lines, then a combined 
diagnosis was made with the primary diagnosis being the one for which there was a better 
therapeutic response.
If there was ‘minimal’ or ‘no response’ to treatment, patients were requested to continue 
with further treatment trials using alternative medication. If they declined further 
treatment at any stage, the cause of cough was considered idiopathic.
A high resolution CT scan was performed prior to confirming a diagnosis of 
bronchiectasis.
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Therapy used for the common causes of cough:
For each of the common conditions, a plan of treatment was made. First line therapy was 
used initially, if possible, in all subjects. Second line therapy was used when the first line 
treatment did not work or was not suitable for an individual patient based on adverse 
events or contraindications due to other medical conditions. Third line therapy was very 
occasionally used to tailor to the requirements of an individual patient and consisted of a 
combination of first and second line treatment.
a. Gastro-oesophageal reflux disease:
First line therapy for GORD (GORDi):Specific first line therapy used for GORD was 
oral omeprazole 20 mg bid for a month, followed by 20 mg od for a second month along 
with advice on life-style alterations to reduce acidity, including elevation of the head end 
of the bed and alterations in diet.
Second line therapy for GORD (GORD2):
This was a combination of metoclopramide and ranitidine for two months along with 
advice on life-style alterations to reduce acidity.
b. Cough variant asthma and eosinophilic bronchitis 
First line therapy for CVA and EB (CVAi and EBi):
Inhaled corticosteroid (budesonide turbohaler) was prescribed at a dose of 400 meg bid 
for two months along with a short acting beta2 agonist as required for asthma.
Second line therapy for CVA (CVA2 ):
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Inhaled corticosteroid dose was 800 meg bid for two months along with a short acting 
beta2 agonist as required for asthma.
c. Post nasal drip syndrome
First line therapy for PNDS (PNDSi):
A combination of a local nasal decongestant (pseudo-ephedrine drops, 2-3 drops to each 
nostril, tid) for a week, along with two months of intra-nasal corticosteroid (mometasone, 
50 mcg/day, 2 sprays od) and an oral non-sedating anti-histamine (loratadine 10 mg od). 
Second line therapy for PNDS (PNDS2 ):
This comprised of three weeks of an oral decongestant (pseudo-ephedrine, 60 mg tid) and 
a first generation antihistamine (brompheniramine maleate, 4 mg tid).
Subjects were treated with first and second line treatment for each of the common causes 
of cough. A high resolution CT scan of the chest, CT scan of the sinuses and an 
oesophageal pH monitoring test were performed if the patient was agreeable, to look for a 
specific diagnosis for the cough.
Statistical Analysis
The association between each test and the diagnosis was tested by a Mantel-Haenszel 
Chi-squared test. The sensitivity, specificity, positive and negative predictive values were 
also calculated.
A p value < 0.05 was considered significant. SAS version 8.2 was used for all analyses.
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RESULTS
Patient demography
88 subjects with chronic persistent cough were recruited. Of these, 52 were recruited 
from the community (GP referrals and advertisement in a newspaper) and 36 were 
referred from hospital clinics.
The flow of patients through the different treatment trials is described in Figure 4.5.1. A 
final diagnosis for the cough was obtained in 78/88 (89%) of subjects; 74% had a single 
diagnosis, 24% had 2 diagnoses and 2% had 3 diagnoses. The pattern of primary 
diagnoses [figure 4.5.2] was PNDS (30), GORD (18), CVA (13), bronchiectasis (9), 
eosinophilic bronchitis (5), habitual cough (2) and bronchitis (1). In 10 subjects, the 
cough was termed idiopathic. Baseline characteristics of the patients are shown in 
experiment 1, table 4.1.1. Individual data for the smaller diagnostic sub-groups are not 
depicted because the numbers were too small for meaningful analysis.
Value o f general cough questions
The general cough questions were compared with each of the major final diagnoses (as 
primary or secondary cause of cough) and there was no significant association for cough 
during sleep, tickly cough, positional or diurnal variation in any condition other than 
bronchiectasis where cough during sleep had a 97% NPV, 23% PPV, p=0.039 (Tables 
4.5.1-4.5.4)
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Presence of sputum with the cough was strongly associated with bronchiectasis and had a 
100% negative predictive value for this condition although a low PPV of 37% (Table 
4.5.4).
Value o f symptoms in predicting final diagnosis o f  cough
For GORD, clinical history had a 100% NPV if the 5 questions were considered together. 
The PPV was low (35%). Heartburn alone had the highest sensitivity (87%, p=0.001). 
Odynophagia, dysphagia and waterbrash had a high specificity (80%-97%) but low 
sensitivity (Table 4.5.1).
For asthma, wheeze and dyspnoea had a high sensitivity but low specificity leading to a 
PPV of 20% and NPV of 86%; (table 4.5.3). Triggers for cough as a group were not 
specific for asthma, but cough triggered by cat/dog dander or grass pollen had a high 
specificity for a diagnosis of asthma (90-99%).
Questions for PNDS had the lowest sensitivity and specificity for a definitive diagnosis, 
individually and combined. The rhino-sinusitis specific questions or allergic rhinitis 
specific questions did not increase this significantly (table 4*5.2).
A summary of the results of the grouped questions for each diagnosis is depicted in table 
4.5.5 and figure 4.5.3.
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gure 4.5.1: Flow of patients through different treatm ent trials for a final diagnosis of cough
REATMENT 1 (n=88)
M D S 1 n = 3 2 G O R D 1 n = 1 6
V A 1 n = 3 2 E B n - 5
O R D 3 n = 1 P N D S 3 n =1
I r o n c h  n =1
REATMENT 2
N D S i  n = 1 8  
V A i  n =6 
N D S 2 n = 3  
» O R D 2 n =2
(n=57)
G O R D ,  n = 2 3  
B r o n c h  n = 3  
C V A 2 n =1
TREATMENT 3 (n=32)
* N D S 1 n = 5  G O R D t  n = 1 0
J V A i n = 7  B r o n c h  n = 2
) V A 2 n = 2  P N D S 2 n =6
REATMENT 4
I O R D 2 n = 3  
N D S 2 n = 7
(n=20)
C V A i  n = 4  
B r o n c h  n =6
REATMENT 5 (n=5) — ►
i O R D 2 n = 2  C V A 2 n =1
r o n c h  n =2
REATMENT 6 (n=1) — ►
l O R D 2 n = 1
L . . . . . . . . . . . . . . . . . . . — ►
Very good response n=25 (28%)
P N D S !  n = 7 ,  G O R D !  n = 6 , C V A i  n = 8 , E B  n = 2 ,  P N D S 3 
n = 1 ,  G O R D 3 n = 1
Declined further treatment trials n=6
U n k n o w n  c a u s e  n = 3 ,  s p o n t a n e o u s  i m p r o v e m e n t  
1 a v i a n  a n t i b o d y  p o s i t i v e ,  t e r m e d  p i g e o n  f a n c i e r ’s  
b r o n c h i t i s ,  2  g o o d  r e s p o n s e s  t o  P N D S i .
Very good response n= 17 (30%)
P N D S 1 n = 6 , C V A 1 n = 3 ,  G O R D 1 n = 4 ,  C V A 2 n = 1 ,  
P N D S 2 n = 1 ,  G O R D 2 n = 2 .
Declined further treatment trials n=8
( 2  g o o d  r e s p o n s e s  t o  P N D S i ,  3  g o o d  r e s p o n s e  t o  E B  
d u r i n g  t r e a t m e n t  1 ,  1 b r o n c h i e c t a s i s  +  G O R D i ,  1 
b r o n c h i e c t a s i s  a n d  1 u n k n o w n  c a u s e  o f  c o u g h )
Very good response n= 7 (22%)
P N D S ,  n = 3 ,  G O R D 1 n = 2 ,  P N D S 2 n = 1 ,  C V A 2 n = 1
Declined further treatment trials n=5
2  g o o d  r e s p o n s e s  t o  G O R D 1, 1 b r o n c h i e c t a s i s ,  2  
u n k n o w n  c a u s e s  o f  c o u g h
Very good response n= 4 (20%)
P N D S 2 n = 4
Declined further treatment n=11
2  g o o d  r e s p o n s e s  t o  c o m b i n e d  P N D S i ,  1 h a b i t  c o u g h ,  
5  b r o n c h i e c t a s i s  a n d  3  u n k n o w n  c a u s e s  o f  c o u g h
Very good response n= 1 (20%)
G O R D 2 n = 1
Declined further treatment trials n=3
1 g o o d  r e s p o n s e  t o  P 2 d u r i n g  R x 4 ,  1 b r o n c h i e c t a s i s ,  1 
u n k n o w n  c a u s e  o f  c o u g h
Very good response n=0
H a b i t  c o u g h  n = 1
Continued to further treatment n=0
Figure 4.5.2: Pattern of primary diagnoses in chronic cough
□ PNDS □  GORD OCVA □ Bronch
□ EB □ habit cough □ bronchitis □ idiopathic
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Table 4.5.1. Sensitivity and specificity of history in diagnosing GORD
Symptom Sensitivity % Specificity % p value
GORD SPECIFIC QUESTIONS
Heartburn 87 54 <0.001
Acid regurgitation 70 42 0.350
Waterbrash 09 82 0.274
Dysphagia 22 80 0.860
Odynophagia 13 97 0.078
Any one of the above 100% 22% 0.001
PPV 35 % NPV100%
GENERAL COUGH QUESTIONS
Cough during sleep 67 34 0.050
Tickly cough 65 40 0.661
Sputum with cough 83 35 0.119
Positional variation: 0.540
[Worst position (n=17): upright 5, stooping 4, supine 8]
Diurnal variation 0.353
[Worst time of day (n=15): morning 11, afternoon/evening 0, night 4]
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Table 4.5.2. Sensitivity and specificity of history in diagnosing PNDS
Symptom Sensitivity % Specificity % p value
PNDS SPECIFIC
Sensation of drip down 66 36 0.863
the back of the throat
Frequent throat clearing 74 26 0.974
Nasal discharge 76 32 0.657
Any one of the above 92 10 0.735
PPV 48% NPV 63%
ENT GROUPED QUESTIONS
Chronic rhinosinusitis 87 20 0.401
PPV 45% NPV 67%
Allergic rhinitis 28 19 0.251
PPV 48% NPV 66%
GENERAL COUGH QUESTIONS
Cough during sleep 68 26 0.515
Tickly cough 66 42 0.460
Sputum with cough 65 27 0.392
Positional variation 0.038
[Worst position (n=26): upright 10, stooping 2, supine 14]
Diurnal variation 0.819
[Worst time of day (n=21): morning 13, afternoon/evening 2, night 6]
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Table 4.5.3. Sensitivity and specificity of history in diagnosing CVA
Symptom Sensitivity % Specificity % p value
ASTHMA RELATED QUESTIONS
Wheeze 56 56 0.395
Exertional dyspnoea 62.5 56 0.193
Either of the above 75 24 0.520
PPV 20% NPV 86%
Triggered by dust 38 63 0.917
Triggered by pollen 25 90 0.097
Triggered by cat dander 0 99 0.637
Triggered by dog dander 13 96 0.195
Triggered by exercise 50 56 0.688
Triggered by cold air 63 47 0.482
Triggered by aerosols 56 47 0.802
Triggered by any one 81 21 0.853
PPV 19% NPV 83%
GENERAL COUGH QUESTIONS
Cough during sleep 76 30 0.716
Tickly cough 69 40 0.505
Sputum with cough 63 29 0.486
Positional variation 0.665
[Worst position (n=10): upright 2, stooping 1, supine 7]
Diurnal variation 0.050
[Worst time of day (n=13): morning 7, afternoon/evening 2, night 4]
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Table 4.5.4. Sensitivity and specificity of history in diagnosing Bronchiectasis
Symptom Sensitivity % Specificity % p value
Sputum with cough 100 37 0.005
PPV 25% NPV 100%
Quantity of sputum <0.001
0 ml 0% had bronchiectasis
1-29 ml 20% had bronchiectasis
> 30 mis 56% had bronchiectasis
GENERAL COUGH QUESTIONS
Cough during sleep 93 33 0.039
PPV 23% NPV 96%
Tickly cough 50 36 0.305
Positional variation 0.571
[Worst position (n=9): supine 6, stooping 2, upright 1]
Diurnal variation 0.873
[Worst time of day (n= ll): morning 8, afternoon/evening 1, night 2]
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Figure 4.5.3 : Positive and negative predictive value of symptoms in diagnosing he
cause of chronic cough
PPV=positive predictive value, NPV= negative predictive value
□  PPV
□  NPV
PNDS BronchGORD CVA
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DISCUSSION
Cough is one of the commonest symptoms presenting to a general practitioner. When the 
cough has persisted for several months it is quite difficult to achieve a clinical diagnosis 
of the cause of the cough. Even when all investigations are utilised, the success rate can 
be low (110). As there are a variety of causes of cough, the ability to reduce the 
differential diagnosis to a minimum would help to achieve a quicker therapeutic success. 
Various studies have shown that in a non-smoker with a normal chest X-ray, the three 
commonest causes of cough are PNDS, asthma and GORD (8, 32, 34). Bronchiectasis is 
another common cause of cough (14, 211). In this study we have shown that certain 
specific questions have a high negative predictive value for these common causes and 
could help to guide the choice of specific therapeutic trials.
The pattern of final diagnoses in our study was similar to others, with the commonest 
diagnoses being PNDS, GORD, CVA and bronchiectasis. 24% subjects had 2 diagnoses 
for the cough and 2% had 3 diagnoses; which is fairly typical of this condition (8, 14, 34). 
When assessing the value of symptoms in achieving a diagnosis, both the primary and 
secondary diagnoses were considered, as successful treatment would require resolution of 
both. As a tertiary diagnosis was uncommon in our study, this was not incorporated into 
the analysis.
Of the three commonest conditions for cough, our study showed that GORD can be 
eliminated in 100% cases and asthma in 86% if there is no suggestive history. However
186
the positive predictive value for all questions was low, implying a significant overlap of 
symptoms. Irwin and colleagues studied the key components of diagnostic evaluation in 
cough and the outcomes of specific therapy (8). For subjects with a diagnosis of GORD 
based on response to specific therapy, in 43% they found no suggestive symptoms and 
called them ‘silent reflux’. 24 hour oesophageal pH monitoring was positive in all. The 
two symptoms they utilised were ‘heartburn and sour taste in the mouth’. McGarvey and 
colleagues only comment on PPV of symptoms and found that when subjects were asked 
about ‘dyspepsia and cough worse after meals’ they could identify 8/20 subjects correctly 
with a PPV of 40% (33). It is possible that the choice of questions utilised may account 
for the difference.
Oesophageal pH monitoring has been shown to have a PPV of 84% an NPV of 100% 
(14), but is uncomfortable as well as expensive (213). We found that 5 symptoms related 
to GORD had an identical NPV, but lower PPV. Hence they would be very useful in 
eliminating GORD from the list of conditions to treat as a cause of cough.
For patients with a dry cough, bronchiectasis was eliminated in 100% cases. Sputum 
production is typical o f bronchiectasis, although present in all common causes of cough 
(31). Bronchiectasis sicca which is a ‘dry bronchiectasis’ is seen less commonly in the 
western world as it is bronchiectatic changes in the upper lobes following tuberculosis. In 
subjects with a dry cough and a normal chest X-ray, our data suggests that bronchiectasis 
as a potential cause can be eliminated.
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A cough at night was significantly associated with bronchiectasis, but the PPV for a night 
cough was low as it was present in all causes of cough. Previous studies suggest that in 
GORD cough diminishes during sleep as the lower oesophageal sphincter tone is 
maximal (6). In our study, night cough was similar in all sub-groups and did not help to 
differentiate the cause of cough.
It was difficult to utilise the history to make a definitive diagnosis of PNDS. In our study, 
although the sensitivity was 92%, the specificity for this diagnosis was only 10%. The 
PPV and NPV are similar to that noted by McGarvey et al (33).
The sensitivity for wheeze and dyspnoea for diagnosing asthma was 75%, but 
surprisingly the specificity was 24%, implying that these symptoms were present even 
when the cough did not respond to anti-asthma treatment.
Positional and diumal variation of cough did not help in achieving any particular 
diagnosis, as noted by Mello and colleagues (211). Description of the cough as a ‘tickle 
or itch was common to all diagnoses of cough.
Triggers for cough were common and did not have a high sensitivity for diagnosing 
cough due to asthma. McGarvey and colleagues used a history of nocturnal cough and 
cold air, exercise and aerosols as precipitating factors and found a PPV of 56% for 
asthma (33). We demonstrated that if  the trigger factor for cough was cat dander, dog
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dander or grass pollen, then the specificity for asthma was 99%, 96% and 90% 
respectively.
Other studies have examined the value of investigations (14, 34, 273) as well as their cost 
effectiveness (213) in the management of chronic cough. We did not perform routine 24 
hour oesophageal monitoring, CT scan of the sinuses, HRCT chest in this study as the 
purpose was not a comparison of investigations versus clinical history, but an evaluation 
of symptoms with response to therapeutic treatment trials.
The value of the choice of symptoms used in this study needs to be assessed in 
prospective studies on chronic cough.
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CHAPTER 5
CONCLUSIONS
5.1 PRINCIPAL FINDINGS
In this study, we included 88 subjects with chronic cough persistent for over one year, 
with normal chest radiographs and spirometry. The principal findings in the different 
experiments were:
a. Evidence of airway inflammation in chronic persistent cough, with increased induced 
sputum cell counts, exhaled nitric oxide and inflammatory mediators (LTB 4 , cys-LT, 
PGE2, ECP, IL-8 and TNF-a).
The predominant cellular pattern in induced sputum was neutrophilic, which differed 
from studies by Carney et al (46) and Birring et al (45) but was in agreement with the 
work from Jatakanon and colleagues (51). A difference in our study population was that 
we included subjects with cough persistent for over a year, unlike the 3-4 week cut-off in 
other studies as we felt this group represented a bigger therapeutic challenge in the 
community.
An interesting observation was the marked increase in inflammatory mediators, 
especially PGE2, LTB 4  and cys-LT in all causes of cough. This suggests a certain 
homology in all causes of cough and presents a therapeutic option that may benefit cough 
caused by different aetiologies. IL-8, MPO and TNF-a levels were elevated in 
bronchiectasis alone.
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A two-week trial of high dose inhaled fluticasone compared to placebo, lead to a 
statistically significant improvement in cough as recorded on a 10 cm visual analogue 
scale. In addition, this treatment was accompanied by a reduction in exhaled nitric oxide, 
carbon monoxide and sputum ECP levels.
The overall mean% improvement in cough was 22.3 [95%CI, -3.5 to 48.2] and sputum 
mediator levels, other than ECP, remained elevated, implying that two weeks of inhaled 
corticosteroids have only a partial effect on the inflammation in cough.
Non-invasive tests as predictors of corticosteroid responsiveness were evaluated. Exhaled 
nitric oxide levels correlated best with inhaled fluticasone response in cough. This was 
followed by sputum eosinophil%, total IgE levels, sputum ECP and sputum cys- 
leukotriene levels.
b. The second experiment measured neurotrophins in serum/ induced sputum of patients 
with chronic cough. Despite several theoretical reasons for these mediators to be involved 
in chronic cough, measured levels of neurotrophins in serum and NGF in induced sputum 
were not elevated compared to controls. This implies that either neurotrophins are not 
responsible for the neurogenic inflammation in cough or that different methods of 
evaluating them, possibly at receptor level are required.
c. The third experiment studied the effect of cough on quality of life utilising general 
questionnaires like the St. George’s Respiratory Questionnaire and the Hospital Anxiety
191
and Depression Scale. We found a marked impairment in all SGRQ domains and a 
significant improvement following specific treatment of cough. These findings were 
independent of the cause of cough. Clinical levels of anxiety and depression were not a 
feature of chronic cough, but there was a significant improvement in the scores after 
treatment.
d. In the fourth experiment we studied extrathoracic airway hyperreactivity in chronic 
cough and found that EAHR was present in only 14% of subjects and was unrelated to 
any particular aetiology of cough. Airway inflammatory cells in induced sputum and 
mediator levels were similar in the group with EAHR compared to the group without, 
other than an increase in sputum LTB4 levels. There was a marked predominance of 
females noted in the group with EAHR (11/12). This test does not seem to provide any 
clinically useful addition to the management of chronic cough.
e. In the fifth experiment, the value of symptoms in making a final diagnosis was 
assessed. The diagnostic pattern was similar to other cough studies with PNDS [n=30], 
GORD [18], asthma [13], bronchiectasis [9] and eosinophilic bronchitis [5] being the 
commonest causes. In 10 subjects the cough was termed idiopathic. General cough 
questions regarding the positional or diurnal variation in cough did not lead to any 
specific diagnosis, confirming the findings of Mello and colleagues (211). Positive 
predictive value of symptoms in diagnosing a specific cause of cough was low, similar to 
the values described by McGarvey et al (33). However, we found that specific history for 
GORD had a 100% negative predictive value, which could prove useful in a clinical
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situation, if evaluation in prospective studies confirms this. For bronchiectasis, history of 
a dry cough had a 100% NPV. For asthma, the NPV was 86% for history. Certain specific 
triggers like cat/dog dander and grass pollen had > 9 0 %  specificity for asthma. Questions 
for PNDS had the lowest positive or negative predictive value and improving the 
specificity of questions with scoring systems for rhino-sinusitis did not improve this 
outcome.
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5.2 STRENGTHS AND LIMITATIONS OF THE STUDY
With this project, we aimed to study five different aspects about subjects with chronic 
cough. There are certain strengths in the study design and in retrospect, several 
limitations as well. Identifying these might help in the design of future projects in chronic 
cough.
a. Crossover trial with inhaled corticosteroids.
To study the effect of inhaled fluticasone in cough, we utilised a randomised, double­
blind, placebo-controlled crossover design. There are relatively few randomised, 
placebo-controlled studies including large numbers of subjects in treatment of chronic 
cough. The cross-over design, however, could lead to a carry over effect of the first 
treatment. In our study, this did not happen and we were able to demonstrate that 
results were similar whether subjects received fluticasone or placebo first. However, 
in other cough studies, the cross-over design has been suggested to account for poor 
results and possibly parallel group studies are better suited for the treatment 
evaluation in chronic cough (280-282).
We used a high dose (500 meg bid) of inhaled fluticasone and a placebo inhaler for 
two weeks each with a two week washout phase in between. The duration of 
treatment could be considered too short to achieve any significant effect on cough. In 
a therapeutic trial, when attempting to resolve cough with inhaled corticosteroids, we 
would use two months as routine treatment, although we would expect a clinical
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improvement in a steroid responsive cough within that period. In some studies 
response to inhaled corticosteroids was seen within two weeks (60, 75). Since we 
were performing a cross-over trial and aiming for an improvement and not necessarily 
a resolution of cough we opted for a two-week trial. However, in a study attempting 
to show a resolution of cough, longer treatment trials should be incorporated.
b. Use o f  a visual analogue scale as an outcome measure:
For monitoring the effect of treatment we relied on a visual analogue scale where 
patients recorded their perceived cough severity on a 10 cm scale in a daily diary 
card. They have been used in several other studies and appear to be responsive to 
therapeutic interventions (283, 284). Some studies have compared visual analogue 
scales with capsaicin cough sensitivity (35, 285, 286). However, it requires further 
comparisons with other measures of cough (287). Of late, portable cough monitors 
are getting more robust and easier to use, although their value in cough studies with a 
long duration of treatment is to be developed. Future studies should incorporate an 
additional objective measure of cough improvement such as this along with daily 
visual scales.
c. Measurement o f  inflammatory mediators in induced sputum:
In this study we measured a wide variety of mediators allowing an evaluation of 
possible activation of different inflammatory cells. This opened up a wider picture 
than studies demonstrating selective mediator elevation in specific sub-groups of 
cough (44, 51). A technical problem with measuring induced sputum mediators is that
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adequate samples were not available in all subjects at each visit. We were able to 
measure cell counts in 80% of samples at baseline, similar to results in other studies 
(72, 288). Higher success rates have been reported using increasing concentrations of 
hypertonic saline (284) but this runs the potential risk of increased side effects.
d. Quality o f  life measurements:
In this study we used the St. George’s Respiratory Questionnaire and the Hospital 
Anxiety and Depression Scale to assess the effect of cough on quality of life. These 
are not cough specific scales, which has the advantage of allowing for comparison 
with other medical conditions. As they are not disease specific, they are probably less 
sensitive at identifying all the issues associated with cough as a specific symptom. 
Birring and colleagues found a good correlation of their cough specific questionnaire 
and the SGRQ (190). We started our study when no cough specific questionnaires 
were available, but in future studies, we would like to combine a general with a cough 
specific questionnaire to allow for a more specific assessment of the effect of 
treatment in patients with cough.
When we repeated the quality of life questionnaires after specific treatment of cough, 
we noted a significant improvement in the scores, implying that the questionnaires 
were sensitive enough to record a response. However, this improvement in quality of 
life scores occurred in all groups of cough and the effect of participating in a trial 
with intensive treatment attempts to improve the cough account for some of this 
improved sense o f well being. Ideally, a quality of life questionnaire should be
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applied to groups of people treated with medication versus placebo in a double­
blinded fashion to truly judge the effect of the medication itself. In this study, by the 
nature of treatment trials for a variety of causes of cough that would not have been an 
option.
e. Comparison o f lower airway inflammation and upper airway hyperreactivity 
Lower airway inflammation could lead to hyperresponsiveness all along the airway 
and cough. When we compared inflammatory markers of the lower airway in a group 
of subjects with chronic cough and extrathoracic airway hyperreactivity, we found no 
correlation other than elevated LTB4 levels. It is possible that upper airway 
inflammation may occur independently and future studies of upper airway sensitivity 
should incorporate nasal fluid inflammatory cell count and mediator levels.
f  Use o f non-invasive tests to identify corticosteroid responsiveness:
We identified exhaled nitric oxide and induced sputum eosinophils as the most useful 
non-invasive tests to identify corticosteroid responders in chronic cough. The 
practical utility of this is currently limited as these are tests that can only be 
performed at specialised centres. Portable exhaled nitric oxide machines are now 
available, but are expensive. A study from Finland (289) looking into the possibility 
of performing induced sputum in primary health care centres in cough subjects found 
a high success rate, but as smears of samples were made in the clinic itself, this would 
be too time consuming out-with a research study.
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g. Final diagnosis o f cough
Most of our subjects had received some form of treatment in the past from their general 
practitioners, but it was probably inadequate in dose or duration and no systematic 
approach to treating all potential causes of cough had been made. This study confirms the 
finding of other studies in chronic cough subjects, that cough can be significantly 
improved in the majority of subjects with persistence and accurate utilisation of 
medication.
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5.3: UNANSWERED QUESTIONS AND IMPLICATIONS FOR FUTURE 
RESEARCH
“E v e r y  i m p o r ta n t  s c ie n t i f ic  a d v a n c e  th a t  h a s  c o m e  in  lo o k in g  l i k e  a n  
a n s w e r  h a s  tu r n e d , s o o n e r  o r  la te r , in to  a  q u e s t io n  -  a n d  th e  g a m e  is  j u s t
b e g in n i n g . . .”
Lewis Thomas
In: Late Night Thoughts on Listening to Mahler’s Ninth Symphony
Use o f specific treatment trials to make a final diagnosis in cough
The results of our study show that inhaled corticosteroids can be beneficial in a mixed 
group of subjects with chronic persistent cough. Although the clinical effect was not 
large, the fact that there was some response in subjects with causes other than asthma and 
eosinophilic bronchitis suggests that there could be some benefit with an agent powerful 
enough to suppress inflammation in all subjects with cough. It also highlights the need for 
large randomised, double-blind, placebo controlled studies to study the effectiveness and 
specificity of all medication used in cough.
Neurogenic inflammation in cough
Studies to find a common pathway in all causes o f cough would be very crucial in 
improving understanding of the pathophysiology as well as finding appropriate new 
medications. Interesting work on a possible cough receptor has begun (182) and the role 
of neurotrophins as possible signalling molecules remains an unanswered question.
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Quality o f life in chronic cough
We have shown that quality of life in chronic cough can improve with treatment. Further 
studies utilising double-blind, placebo controlled treatment would answer the question of 
whether people improve because of the care given to them during intensive treatment 
trials in a research project or whether the actual change in their cough is the major factor 
in improving their quality of life. Comparisons with other medical conditions in large 
meta-analyses will allow the distress faced by cough sufferers to be viewed in 
comparison with other medical conditions and possibly serve to focus medical attention 
and research towards this difficult problem.
Inflammation in chronic cough and potential new medications:
Novel therapies can be developed through better understanding of the disease process. 
Several potential targets for antitussive drugs have been identified recently (6 ). In this 
study, we found airway inflammation is an important feature in all causes of cough. This 
can open up further new avenues for potential suppressants of chronic cough. As the 
highest levels of mediators in all causes of cough were noted for LTB4 , PGE2 and cys-LT, 
these would be the first targets to suppress. It would still be important to pursue efforts to 
find the cause of the cough and use specific therapy, but suppressing inflammation may 
provide some respite for patients during this process.
Leukotriene inhibition:
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Anti-leukotrienes include leukotriene receptor antagonists and 5-lipoxygenase inhibitors. 
The currently available receptor anatagonists (montelukast, zafirlukast and pranlukast) 
are widely used in asthma and are effective in reducing cys-LT levels. Montelukast 
reduced cough in infants with reactive airway disease following respiratory syncytial 
virus (RSV) bronchiolitis (126). In patients with cough due to chronic bronchitis, 
pranlukast, had no significant effect (125). Recently, a randomised controlled trial in 8  
patients with CVA demonstrated that zafirlukast 20mg bid for 14 days, reduced cough 
scores and capsaicin-induced cough compared to placebo (290). Their role in chronic 
cough in general requires evaluation.
5-lipoxygenase (5-LOX) inhibitors like zileuton may be more effective as they block the 
effect of LTB4 (291), which we found at higher levels in all causes of cough compared to 
cys-LT. Other LTB4 receptor antagonists being studied for COPD, such as LY293111, 
may be useful in cough as they reduce neutrophil influx (292).
PGE2 inhibition:
In asthmatics, indomethacin increased the cough threshold compared to placebo (293) but 
celecoxib had no effect on cough challenge testing (294).
A combined cycloxygenase and lipoxygenase inhibitor, BW755C, was studied in dogs 
several years ago, and prevented the development of airway resistance following ozone 
exposure (295). Liclofelone, a new inhibitor of 5-LOX and COX pathways (296) may 
have a potential benefit in chronic cough
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Neutrophil suppression:
The efficacy of selective phosphodiesterase 4 inhibitors such as cilomilast and roflumilast 
in the treatment of COPD (297) and their inhibitory effect on neutrophil function suggests 
that these compounds might be effective in chronic cough. In addition, cilomilast has 
been shown to reduce levels of TNF-a and IL- 8  in patients with COPD (298).
Other mediator suppression:
■ IL-8 production can be downregulated by macrolide antibiotics (299).
■ TNF-a can be inhibited by etanercept [a TNF-a receptor fusion protein](300)and 
infliximab [a monoclonal anti-TNF-a antibody] (301). Their role in cough has not 
been evaluated.
Since the inflammation in cough is complex, with involvement of several different 
mediators, an ideal anti-inflammatory would be one with the potential to suppress several 
different pathways simultaneously.
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APPENDICES
7.1 Peak flow diary card
7.2 Cough visual analogue scale diary card
7.3 St. George’s Respiratory Questionnaire
7.4 Hospital Anxiety and Depression Scale
7.5 Quality of Life in asthma and COPD
7.6 Proforma for recording clinical history
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It George's Hospital Respiratory Questionnaire
Random No Initials Date of Visit
D D
V U J / \
l u e s t i o n n a i r e  i s  d e s i g n e d  t o  h e l p  u s  l e a r n  m u c h  m o r e  a b o u t  h o w  y o u r  b r e a t h i n g  i s  t r o u b l i n g  y o u  a n d  h o w  it a f f e c t s  
fe .  W e  a r e  u s i n g  it t o  f i n d  o u t  w h i c h  a s p e c t s  o f  y o u r  i l l n e s s  c a u s e  y o u  m o s t  p r o b l e m ,  r a t h e r  t h a n  w h a t  t h e  d o c t o r s  
i r s e s  t h i n k  y o u r  p r o b l e m s  a r e .
e  r e a d  t h e  i n s t r u c t i o n s  c a r e f u l l y  a n d  a s k  if y o u  d o  n o t  u n d e r s t a n d  a n y t h i n g .  D o  n o t  s p e n d  t o o  l o n g  d e c i d i n g  a b o u t
A n s w e r s .
[
5TIONS ABOUT HOW MUCH CHEST TROUBLE YOU HAVE HAD OVER THE LAST YEAR. 
iSE TICK IN ONE BOX FOR EACH QUESTION.
ter the last year, I have coughed:
ter the last year, I have brought 
>phlegm (sputum):
ter the last year, I have had 
tortness of breath:
ter the last year, I have had 
acks of wheezing:
iring the last year, how many severe or very unpleasant 
acks of chest trouble have you had:
Most Several A few Only with
days days days chest Not
a week a week a month infections at all
□ □ □ □ □-
□ □ □ □ □ -
□ □ □ □ □-
□ □ □ □
>w long did the worst attack of chest trouble last: 
to to Question 7 if you had no severe attacks)
irer the last year, in an average week, how many good 
lys (with little chest trouble) have you had:
m o r e  t h a n  3  a t t a c k s n
3  a t t a c k s n
2  a t t a c k s n
1 a t t a c k n
n o  a t t a c k s n
a  w e e k  o r  m o r e - n
3  o r  m o r e  d a y s n
1 o r  2  d a y s n
l e s s  t h a n  a  d a y R
n o  g o o d  d a y s n
1 o r  2  g o o d  d a y s n
3  o r  4  g o o d  d a y s n
n e a r l y  e v e r y  d a y  i s  g o o d n
e v e r y  d a y  i s  g o o d n-
you have a wheeze, is it worse in the morning: N o
Y e s
□□
The St George's Hospital Respiratory Questionnaire
Draft 03
R a n d o m  N o  I n i t i a l s  D a t e  o f  V i s i t
K T K
M M
SECTION 1
HOW WOULD YOU DESCRIBE YOUR CHEST CONDITION? 
(PLEASE TICK IN ONE BOX ONLY)
T h e  m o s t  i m p o r t a n t  p r o b l e m  I h a v e
C a u s e s  m e  q u i t e  a  l o t  o f  p r o b l e m s  
C a u s e s  m e  a  f e w  p r o b l e m s  
C a u s e s  n o  p r o b l e m
IF YOU HAVE EVER HAD PAID EMPLOYMENT, PLEASE TICK ONE OF THESE:
M y  c h e s t  t r o u b l e  m a d e  m e  s t o p  w o r k
M y  c h e s t  t r o u b l e  i n t e r f e r e s  w i t h  m y  w o r k  o r  m a d e  m e  c h a n g e  m y  w o r k  
M y  c h e s t  t r o u b l e  d o e s  n o t  a f f e c t  m y  w o r k  
SECTION 2
QUESTIONS ABOUT WHAT ACTIVITIES USUALLY MAKE YOU FEEL BREATHLESS THESE DAYS.
FOR EACH ITEM, PLEASE TICK EITHER TRUE OR FALSE AS IT APPLIES TO YOU.
TRUE FI
S i t t i n g  o r  ly in g  s t i l l  
G e t t i n g  w a s h e d  o r  d r e s s e d
W a l k i n g  a r o u n d  t h e  h o m e  Q
W a l k i n g  o u t s i d e  o n  t h e  l e v e l
W a l k i n g  u p  a  f l i g h t  o f  s t a i r s  ________  Q
W a l k i n g  h i l l s  \^ _
P l a y i n g  s p o r t s  o r  g a m e s
SECTION 3
SOME MORE QUESTIONS ABOUT YOUR COUGH AND BREATHLESSNESS THESE DAYS.
FOR EACH ITEM, PLEASE TICK EITHER TRUE OR FALSE AS IT APPLIES TO YOU.
TRUE F
M y  c o u g h  h u r t s  
M y  c o u g h  m a k e s  m e  t i r e d  
I a m  b r e a t h l e s s  w h e n  I t a l k  
I a m  b r e a t h l e s s  w h e n  I b e n d  o v e r  
M y  c o u g h  o r  b r e a t h i n g  d i s t u r b s  m y  s l e e p  
I g e t  e x h a u s t e d  e a s i l y
St George's Hospital Respiratory Questionnaire
R a n d o m  N o I n i t i a l s D a t e  o f  V i s i t
/ /
01 02 D D M M Y Y 03
) N  4
I O N S  A B O U T  O T H E R  E F F E C T S  T H A T  Y O U R  C H E S T  T R O U B L E  M A Y  H A V E  O N  Y O U  T H E S E  D A Y S .
A C H  I T E M ,  P L E A S E  T I C K  E I T H E R  T R U E  O R  F A L S E  A S  IT  A P P L I E S  T O  Y O U . T R U E F A L S E
M y  c o u g h  o r  b r e a t h i n g  i s  e m b a r r a s s i n g  in  p u b l i c □ 1_I-
M y  c h e s t  t r o u b l e  i s  a  n u i s a n c e  t o  m y  f a m i l y ,  f r i e n d s  o r  n e i g h b o u r s □ □»
1 g e t  a f r a i d  o r  p a n i c  w h e n  1 c a n n o t  g e t  m y  b r e a t h _ □ tu­
1 1 f e e l  t h a t  1 a m  n o t  in  c o n t r o l  o f  m y  c h e s t  p r o b l e m . □ r n .
1 d o  n o t  e x p e c t  m y  c h e s t  t o  g e t  a n y  b e t t e r □ □»
1 h a v e  b e c o m e  f r a i l  o r  a n  i n v a l i d  b e c a u s e  o f  m y  c h e s t □
E x e r c i s e  i s  n o t  s a f e  f o r  m e □ □-
E v e r y t h i n g  s e e m s  t o o  m u c h  o f  a n  e f f o r t □ 11..
O N  5
T I O N S  A B O U T  Y O U R  M E D I C A T I O N .  I F  Y O U  A R E  R E C E I V I N G  N O  M E D I C A T I O N  G O  S T R A I G H T  T O  
ION 6.
) M P L E T E  T H I S  S E C T I O N  P L E A S E  T I C K  E I T H E R  T R U E  O R  F A L S E  A S  IT  A P P L I E S  T O  Y O U .
T R U E  F A L S E
M y  m e d i c a t i o n  d o e s  n o t  h e l p  m e  v e r y  m u c h  Q  | | M
I g e t  e m b a r r a s s e d  u s i n g  m y  m e d i c a t i o n  in  p u b l i c   j_ ~ ]  | |,5
I h a v e  u n p l e a s a n t  s i d e  e f f e c t s  f r o m  m y  m e d i c a t i o n   ( ^ ]  | |,6
M y  m e d i c a t i o n  i n t e r f e r e s  w i t h  m y  l i f e  a  l o t  Q  | |17
O N  6
E A R E  Q U E S T I O N S  A B O U T  H O W  Y O U R  A C T I V I T I E S  M I G H T  B E  A F F E C T E D  BY YOUR BREATHING. 
E A C H  Q U E S T I O N ,  P L E A S E  T I C K  T R U E  I F  O N E  O R  M O R E  P A R T S  A P P L I E S  T O  Y O U  B E C A U S E  O F  Y O U R
T H I N G .  O T H E R W I S E  T I C K  F A L S E T R U E F A L S E
1 t a k e  a  l o n g  t i m e  t o  g e t  w a s h e d  o r  d r e s s e d n □»
1 c a n n o t  t a k e  a  b a t h  o r  s h o w e r ,  o r  1 t a k e  a  l o n g  t i m e n □„
1 w a l k  s l o w e r  t h a n  o t h e r  p e o p l e ,  o r  1 s t o p  f o r  r e s t s n □»
J o b s  s u c h  a s  h o u s e w o r k  t a k e  a  l o n g  t i m e ,  o r  1 h a v e  t o  s t o p  f o r  r e s t s n D
If  1 w a l k  u p  o n e  f l i g h t  o f  s t a i r s ,  1 h a v e  t o  g o  s l o w l y  o r  s t o p n Q
If 1 h u r r y  o r  w a l k  f a s t ,  1 h a v e  t o  s t o p  o r  s l o w  d o w n n □-
M y  b r e a t h i n g  m a k e s  it  d i f f i c u l t  t o  d o  t h i n g s  s u c h  a s  w a l k  u p  h i l l s ,  c a r r y i n g  t h i n g s  u p  s t a i r s ,  
l i g h t  g a r d e n i n g  s u c h  a s  w e e d i n g ,  d a n c e ,  p l a y  b o w l s  o r  p l a y  g o l f n Q
M y  b r e a t h i n g  m a k e s  it  d i f f i c u l t  t o  d o  t h i n g s  s u c h  a s  c a r r y  h e a v y  l o a d s ,  d i g  t h e  g a r d e n  
o r  s h o v e l  s n o w ,  j o g  o r  w a l k  a t  5  m i l e s  p e r  h o u r ,  p l a y  t e n n i s  o r  s w i m n
M y  b r e a t h i n g  m a k e s  it  d i f f i c u l t  t o  d o  t h i n g s  s u c h  a s  v e r y  h e a v y  m a n u a l  w o r k ,  r u n ,  c y c l e ,  
s w i m  f a s t  o r  p l a y  c o m p e t i t i v e  s p o r t s n □»
The St George's Hospital Respiratory Questionnaire
Draft 03
R a n d o m  N o  I n i t i a l s  D a t e  o f  V i s i t
r a : Y03
S E C T I O N  7
W E  W O U L D  L I K E  T O  K N O W  H O W  Y O U R  C H E S T  T R O U B L E  U S U A L L Y  A F F E C T S  Y O U R  D A I L Y  L I F E .  
P L E A S E  T I C K  E I T H E R  T R U E  O R  F A L S E  A S  I T  A P P L I E S  T O  Y O U  B E C A U S E  O F  Y O U R  C H E S T  T R O U B L E
( R E M E M B E R  T H A T  T R U E  O N L Y  A P P L I E S  T O  Y O U  I F  Y O U  C A N  N O T  D O  S O M E T H I N G  BECAUSE OF YO 
BREATHING). TRUE Fi
I c a n n o t  p l a y  s p o r t s  o r  g a m e s  _ _ _ _ _ _ _ _ _ _ _ _  Q
I c a n n o t  g o  o u t  f o r  e n t e r t a i n m e n t  o r  r e c r e a t i o n  Q
I c a n n o t  g o  o u t  o f  t h e  h o u s e  t o  d o  t h e  s h o p p i n g
I c a n n o t  d o  h o u s e w o r k
I c a n n o t  m o v e  f a r  f r o m  m y  b e d  o r  c h a i r
H E R E  I S  A  L I S T  O F  O T H E R  A C T I V I T I E S  T H A T  Y O U R  C H E S T  T R O U B L E  M A Y  P R E V E N T  Y O U  D O I N G .  ( Y O U  
H A V E  T O  T I C K  T H E S E ,  T H E Y  A R E  J U S T  T O  R E M I N D  Y O U  O F  W A Y S  IN  W H I C H  Y O U R  B R E A T H L E S S N E S S  
A F F E C T  Y O U ) :
G O I N G  F O R  W A L K S  O R  W A L K I N G  T H E  D O G  
D O I N G  T H I N G S  A T  H O M E  O R  IN  T H E  G A R D E N  
S E X U A L  I N T E R C O U R S E
G O I N G  O U T  T O  C H U R C H ,  O R  P L A C E  O F  E N T E R T A I N M E N T  
G O I N G  O U T  IN  B A D  W E A T H E R  O R  I N T O  S M O K Y  R O O M S  
V I S I T I N G  F A M I L Y  O R  F R I E N D S  O R  P L A Y I N G  W I T H  C H I L D R E N
P L E A S E  W R I T E  IN  A N Y  O T H E R  I M P O R T A N T  A C T I V I T I E S  T H A T  Y O U R  C H E S T  T R O U B L E  M A Y  S T O P  Y O U
N O W ,  W O U L D  Y O U  T I C K  IN  T H E  B O X  ( O N E  O N L Y )  W H I C H  Y O U  T H I N K  B E S T  D E S C R I B E S  H O W  Y O U R  C H  
A F F E C T S  Y O U :
It d o e s  n o t  s t o p  m e  d o i n g  a n y t h i n g  I w o u l d  l i k e  t o  d o _____________________________________________________________________
It s t o p s  m e  d o i n g  o n e  o r  t w o  t h i n g s  I w o u l d  l i k e  t o  d o  
I t s t o p s  m e  d o i n g  m o s t  o f  t h e  t h i n g s  I w o u l d  l i k e  t o  d o  
I t s t o p s  m e  d o i n g  e v e r y t h i n g  I w o u l d  l i k e  t o  d o
T H A N K  Y O U  F O R  F I L L I N G  IN  T H I S  Q U E S T I O N N A I R E .  B E F O R E  Y O U  F I N I S H  W O U L D  Y O U  C H E C K  T O  S E E  
Y O U  H A V E  A N S W E R E D  A L L  T H E  Q U E S T I O N S .
/? ^ \  P . n n x / r i n h t  P a u l  W  I m p ?  1 Q R Q -A-
irsion 1.0
Random No Initials D a t e  o f  V i s i t
m e
) r s  a r e  a w a r e  t h a t  e m o t i o n s  p l a y  a n  i m p o r t a n t  p a r t  in  m o s t  i l l n e s s e s .  If y o u r  d o c t o r  k n o w s  a b o u t  t h e s e  f e e l i n g s  h e  w  
>le t o  h e l p  y o u  m o r e .
q u e s t i o n n a i r e  i s  d e s i g n e d  t o  h e l p  y o u r  d o c t o r  t o  k n o w  h o w  y o u  f e e l .  R e a d  e a c h  i t e m  a n d  p l a c e  a  f i r m  t i c k  in  t h e  b o x  
i s i t e  t h e  r e p l y  w h i c h  c o m e s  c l o s e s t  t o  h o w  y o u  h a v e  b e e n  f e e l i n g  in  t h e  p a s t  w e e k .
t t a k e  t o o  l o n g  o v e r  y o u r  r e p l i e s :  y o u r  i m m e d i a t e  r e a c t i o n  t o  e a c h  i t e m  w il l  p r o b a b l y  b e  m o r e  a c c u r a t e  t h a n  a  l o n g  
g h t - o u t  r e s p o n s e .
Tick only one box in each section.
I tense or 'wound up':
t o s t  o f  t h e  t i m e  Q
V l o t  o f  t h e  t i m e
r i m e  t o  t i m e ,  o c c a s i o n a l l y
Nlot a t  a l l ____
04
II enjoy the things I used to enjoy:
D e f in i t e ly  a s  m u c h
t a t  q u i t e  s o  m u c h  
D n ly  a  l i t t l e  
- l a r d l y  a t  a l l
06
I  a sort of frightened feeling as if something 
ul is about to happen:
S/ery d e f i n i t e l y  a n d  q u i t e  b a d l y
Yes, b u t  n o t  t o o  b a d l y ________________________________ Q
\  l i t t l e ,  b u t  it  d o e s n ' t  w o r r y  m e  [ _
N o t  a t  a l l __________________________________________________ [ ~ ]
n laugh and see the funny side of things:
<Vs m u c h  a s  I a l w a y s  c o u l d  
N o t  q u i t e  s o  m u c h  n o w  
D e f i n i t e l y  n o t  s o  m u c h  n o w  
N o t  a t  a l l
07
rrying thoughts go through my mind:
^  g r e a t  d e a l  o f  t h e  t i m e  
\  l o t  o f  t h e  t i m e
F r o m  t i m e  t o  t i m e  b u t  n o t  t o o  o f t e n  
D n ly  o c c a s i o n a l l y
06
5l cheerful:
N o t  a t  a l l  Q
N o t  o f t e n
S o m e t i m e s ________________  £
I t o s t  o f  t h e  t i m e
09
n sit at ease and feel relaxed:
D e f in i te ly  
J s u a l l y  
s lo t  o f t e n  
N o t a t  a l l
I feel as if I am slowed down:
N e a r l y  a l l  t h e  t i m e _____________________________________ [_
V e r y  o f t e n  
S o m e t i m e s  
N o t  a t  a l l
11
I get a sort of frightened feeling like 'butterflies' 
in the stomach:
N o t  a t  a l l  
O c c a s i o n a l l y  
Q u i t e  o f t e n
V e r y  o f t e n   *L
12
I have lost interest in my appearance:
D e f i n i t e l y
I d o n ’t  t a k e  s o  m u c h  c a r e  a s  I s h o u l d  
I m a y  n o t  t a k e  q u i t e  a s  m u c h  c a r e  Q
I t a k e  j u s t  a s  m u c h  c a r e  a s  e v e r
13
I feel restless as if I have to be on the move:
V e r y  m u c h  i n d e e d
Q u i t e  a  l o t  ________________  Q
N o t  v e r y  m u c h  
N o t  a t  a l l
14
I look forward with enjoyment to things:
A s  m u c h  a s  I e v e r  d i d
R a t h e r  l e s s  t h a n  I u s e d  t o ___________________________ Q
D e f i n i t e l y  l e s s  t h a n  I u s e d  t o  
H a r d l y  a t  a i l
15
I get sudden feelings of panic:
V e r y  o f t e n  i n d e e d □
Q u i t e  o f t e n 1U
N o t  v e r y  o f t e n 1□
N o t  a t  a l l • 1□
I can enjoy a good book or radio or TV programme:
O f t e n     ' ____ Q
S o m e t i m e s  y
N o t  o f t e n  Q ]
V e r v  s e l d o m
Appendix 5: Quality of life in asthma and COPD using the SGRQ and HADS.
a. Asthma studies using SGRQ
No Reference No of subjects Total SGRQ 
Mean (SD)
Symptom score 
Mean (SD)
Activity 
Mean (SD)
Impacts score 
Mean (SD)
1 Sanjuas (1) 116 39.5(18.7) 46.2 (20.9 49.2 (24.7) 31.7(19.9)
2 Bumbacea (2) 29 51.7
(SEM 3.39)
75.65
(SEM 3.22)
60.63
(SEM 5.31)
40.07
(SEM 3.28)
3 37
(severe)
59.57 
(SEM 3.2)
79.03
(SEM 2.26)
67.66 
(SEM 4.3)
49.37
(SEM 3.55)
4a Vollmer (3) 347
(controlled)
30 42 41 19
4b 175 (mild) 40 51 53 29
4c 109 (less well 
controlled)
46 59 57 36
5 Osman (4) 
Scottish study
396 stable 
asthmatics
21.5(12.9) 40.3 (20.9) 15 (11.3) 22.7(17.2)
6 Jones (5) 368 39 55.2 34.1 39
7 Nishiyama (6) 68 28.6(18.4) 43.7 (23.4) 32.1 (25.4) 21.8(17.4)
8 Incalzi (7) 198 36.1 (20.53) 40.4 (20.79) 50.3 (25.11) 14.1
9a Meszaros (8) 64 education 
given
35.97 39.44 41.82 31.87
9b 55 control 39.88 49.4 38.87 37.48
b. COPD studies using SGRQ
No Reference No of 
subjects
Total 
SGRQ 
Mean (SD)
Symptom 
Mean (SD)
Activity 
Mean (SD)
Impacts 
Mean (SD)
1 Doll H (Quality of Life 
Research, 2003
230 41.6
(20.4)
61.8
(19.4)
48.8
(27.4)
30.7
(20.9)
2 Vincken W, Eur Resp J 
2002
356 40.9
(SEM 0.69)
47.32 
(SEM 1.07)
55.07
(SEM0.84)
30.95
(SEM0.81)
3 Spencer S etal (9) >350 48 (18) 66 (21) 61 (22) 35 (19)
4 Miravitles M etal. (10) 336 47.6(17.2 48.3 (20.2) 62.8 (20.9) 38.7(17.8)
5 Okubadejo et al. (11) 41
Severe
55.3(18.2) 64(21.9) 65.2(19.8) 46.5 (23.5)
6 Tinkelman D etal (12) 349 53.4(19.1) 62.2 (17.4) 70.1 (24.4) 40.8 (21.3)
7 Hajiro T etal (13) 161 stable 52.5 (19.9) 47.5(21.9) 25.7 (16.9)
8 Alemayehu etal (14) 181 stable 58.3 (21.5) 63.6 (28.2) 42.9 (26.6) 50.7 (23.1)
10 Incalzi (7) 230 43.8 (20.4) 53.78
(23.38)
57.2 (24.13) 17.6(11.52)
c. HAD scale in other studies
No Reference No of 
subjects
Condition Anxiety 
mean (SD)
Depression 
mean (SD)
1 Jones PW (5) 360 Asthma stable 6.7 (3.9) 4.6 (3.3)
2 Rimington et al (15) 4 0  suburban 
74 inner c ity
Asthma stable 6.2 (3.9) 
9.5 (4.1)
3.7 (2.7) 
6(4.3)
3 Okubadejo AA etal. (11) 41 Severe COPD 
with hypoxemia
5.7 (4.3) 5.3 (3.4)
4 Hajiro T etal (13) 161 stable COPD 3.9 (3.3) 5.0 (3.7)
5 McGarvey LPA (16) 33 Cough > 3 weeks 6.5 (3.75) 3.84 (3.2)
It Interview: Cough Details
rsion 1.0
Random No Initials
JGH HISTORY 
ation of cough years m onths
itum production
hich position is the cough worst?
U p r i g h t
I
S t o o p i n g
S u p i n e
inrhat time is the cough worst?
M o r n i n g
A f t e r n o o n / E v e n i n g
N i g h t
lich of the following are 
iqer factors?
3) D u s t
) )  P o l l e n
;)  C a t  d a n d e r
i )  D o g  d a n d e r
3) E x e r c i s e
)  C o l d  a i r
3) A e r o s o l s / s p r a y s
i )  O t h e r
If Yes, s p e c i f y _________________
w eeks
IS
Jm l/day
0
0
0
07
0
0
0
Y e s □ N o 2
Y e s 0 N o 2
Y e s 0 N o 2
Y e s 0 N o 2
Y e s 0 N o 0
Y e s 0 N o 0
Y e s 0 N o 0
Y e s 0 N o 2
the cough described as a 
kle/itch in the throat? Y e s  [ T ]  N o
| the cough originate after an
per respiratory tract infection? Y e s  [T] N o  2
es the cough occur during 
ep?
sociated wheeze?
Bociated exertional 
tathlessness?
C Grade
Y e s  [T] N o  |~2 
Y e s  [T] N o
Y e s  [ T ]  N o
0 0
B. ATOPY/ALLERGIES 
1. Does the patient have 
(a) Any known allergies
If Yes, s p e c i f y _______
Y e s  [7] N o
(b) Hay fever Y e s 0 N o
(c) Eczema Y e s 0 N o
(d) Family history of atopy Y e s 0 N o
C. PATIENT’S VIEW ON THE CAUSE OF COUGH
1. " I think my cough is caused b y  "
2. Physician's translation of the patient term above:
( a )  R h i n o s i n u s i t i s 0
( b )  A l l e r g i c  r h i n i t i s 0
( c )  G a s t r o - o e s o p h a g e a l  r e f l u x  d i s e a s e 0
( d )  C o u g h  v a r i a n t  a s t h m a 0
( e )  E o s i n o p h i l i c  b r o n c h i t i s 0
( f )  A t o p i c  c o u g h 0
( g )  P o s t - i n f e c t i v e  c o u g h 0
( h )  C h r o n i c  b r o n c h i t i s 0
( i)  O c c u p a t i o n a l  c o u g h 0
( j)  H a b i t u a l  c o u g h 0
( k )  O t h e r  c a u s e 0
If Yes, s p e c i f y
(I) U n k n o w n 12
Visual Analogue Scale
Version 1.0
R a n d o m  N o  I n i t i a l s
A. COUGH SEVERITY: VISUAL ANALOGUE SCALE
1. Ask the patient to complete the Visual Analogue Scale below.
0
N O
C O U G H
2. Result:
10
M A X I M A L
C O U G H
It Interview: Signs and Symptoms
rsion 1.0
Random No Initials
»ER RESPIRATORY TRACT 
t Nasal Drip
isation of something dripping 
ivn the throat Y e s  [T]
e d  to frequently clear the throat Y e s  [TJ
sal discharge:
N o n e
M u c o i d
M u c o p u r u l e n t
ronic Rhinosinusitis 
Major Factors
( i )  F a c i a l  p a i n / p r e s s u r e
( ii )  F a c i a l  c o n g e s t i o n / f u l l n e s s  
( in )  N a s a l  o b s t r u c t i o n / b l o c k a g e
( iv )  N a s a l  d i s c h a r g e / p u r u l e n c e  
I ( b y  h i s t o r y  o r  e x a m i n a t i o n )
( v )  H y p o s m i a / A n o s m i a
) Minor Factors
( i )  H e a d a c h e s
(ii)  D e n t a l  p a i n
(ii i)  E a r  p a i n / p r e s s u r e / f u l l n e s s
( iv )  F e v e r
( v )  C o u g h
( v i )  H a l i t o s i s
(v i i )  F a t i g u e  
lergic Rhinitis
( i )  F r e q u e n t  s n e e z i n g
( ii )  I t c h y  n o s e
(iii)  I t c h y  e y e s
( iv )  I t c h y  t h r o a t
( v )  P r o f u s e  w a t e r y  d i s c h a r g e
N o  2
N o  2
m
0
GE)
Y e s 0 N o 2
Y e s h N o 2
Y e s mN o 2
Y e s 0 N o 2
09
Y e s 0 N o 2
10
Y e s 0 N o 2
Y e s 0 N o 2
Y e s 0 N o 2
Y e s 0 N o 2
Y e s 0 N o 2
Y e s 0 N o 2
Y e s 0 N o 2
17
Y e s 0 N o 0
Y e s 0 N o 0
Y e s 0 N o 2
Y e s 0 N o 2
Y e s 0 N o 2
B. GASTRO-OESOPHAGEAL REFLUX
1. Heartburn
2. Acid regurgitation
3. Waterbrash
4. Dysphagia
5. Odynophagia
C .  OTHER RELEVANT HISTORY 
1. Any other relevant history?
If Yes, s p e c i f y _______________________
Y e s  \T \  N o  [2
2.
Y e s  [T| N o  [2~
2
Y e s  [Tj N o  jT
2
Y e s  f~Tj N o  [2~
2
Y e s  [Tj N o  \2_
Y e s  [Tj N o
I "
t Interview: Severity of Associated Symptoms
■sion 1.0
Random No Initials
>TOM SEVERITY: VISUAL ANALOGUE SCALE
the patient to complete the Visual Analogue Scales below to indicate the severity of associated symptoms.
Y e s  [T] N o  [Tt Nasal Drip?
0
N O
S Y M P T O M S
M O D E R A T E
S Y M P T O M S
10
M A X I M A L
S Y M P T O M S
tesult:
ro-Oesophageal Reflux Disease? Y e s  [T] N o
0
N O
S Y M P T O M S
 1--------
5
M O D E R A T E
S Y M P T O M S
10
M A X I M A L
S Y M P T O M S
gh Variant Asthma?
Result:
Result:
0
N O
S Y M P T O M S
er?
Yes, s p e c i f y
0
N O
S Y M P T O M S
Result:
Y e s  [ T ]  N o
M O D E R A T E
S Y M P T O M S
Y e s  [7] N o  \2_
M O D E R A T E
S Y M P T O M S
-7  -
10
M A X I M A L
S Y M P T O M S
10
M A X I M A L
S Y M P T O M S
Airway Inflammation in Chronic Dry Cough Visit 1, Page 8
Patient Interview: Medication Record
Version 1.0
R a n d o m  N o
01
I n i t i a l s
02
A.MEDICATION FOR CURRENT COUGH ILLNESS
1. Inhaled Steroids Y e s  [T] N o
s p e c i f y ________________
2. Inhaled P2 Agonist Y e s  |~T| N o
3. Other inhaler Y e s  [T] N o  2
s p e c i f y
4. Hz Antagonist
s p e c i f y
Y e s  [T| N o  |T
5. Proton pump 
inhibitor
s p e c i f y ________
Y e s  |~T| N o  [2~
6. Rhinitis treatment Y e s  [T] N o  [2]
If Yes,
a ) N a s a l  S t e r o i d s  Y e s  [T| N o  |~2j
s p e c i f y
b ) A n t i h i s t a m i n e Y e s B N o
34
2
39
s p e c i f y
c )  D e c o n g e s t a n t  ( u n i t s ) Y e s B N o
40
2
45
s p e c i f y ( ) „
d ) O t h e r  ( u n i t s ) Y e s B
17
N o 2
52
s p e c i f y (
>4
)S3
7. Non-specific cough
suppressant (units) Y e s  [T] N o
If Yes,
a )____
b  )_______
c)
(  )a
( )«
Date Started
]/[
M M  Y
]/[
M M  Y
M M  Y
]/[
M M  Y
]/[
M M  Y
M M  Y
] / [
M M  Y
M M  Y
M
M M  Y
M M  Y
Y10
Y16
Y 22
Y36
Y«n
M M  Y Y7<
f i S S
1 11 . IBRARV f I
Date stopped
o
M M  Y Y 06
]/[
M M  Y Yu
M M '  Y Yi7
M M  Y Yzj
y[
M M  Y Y 29
n
M M  Y Y*
]/[
M M  Y Y 42
M M  Y Y«
K
M M  Y Y«
y [
M M  Y Yes
M M  Y Yts
Total Daily 
Dose
Effect on 
cough
£ c 
I  I  $
pg m f e f e
oe
pg m s s
13
pg Emm
19
m9 m m m
mg E E S
pg B E E
38
m9 m m m44
B E E
51
B E E
B E E
B E E
71
B E E
